<SEC-DOCUMENT>0001193125-22-125555.txt : 20220428
<SEC-HEADER>0001193125-22-125555.hdr.sgml : 20220428
<ACCEPTANCE-DATETIME>20220428083058
ACCESSION NUMBER:		0001193125-22-125555
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20220614
FILED AS OF DATE:		20220428
DATE AS OF CHANGE:		20220428

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vor Biopharma Inc.
		CENTRAL INDEX KEY:			0001817229
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39979
		FILM NUMBER:		22862429

	BUSINESS ADDRESS:	
		STREET 1:		215 FIRST STREET
		STREET 2:		SUITE 430
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-655-6580

	MAIL ADDRESS:	
		STREET 1:		215 FIRST STREET
		STREET 2:		SUITE 430
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>d268305ddef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML><HEAD>
<TITLE>DEF 14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A
INFORMATION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy Statement Pursuant to Section&nbsp;14(a) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Amendment No. ) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the
Registrant&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by a Party other than the Registrant&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidential, for Use of the Commission Only (as permitted by Rule
<FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT></B> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Additional Materials </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting Material under <FONT STYLE="white-space:nowrap">&#167;240.14a-12</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>VOR BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified in its Charter) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check all boxes that apply): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No fee required </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee paid previously with preliminary materials </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules
<FONT STYLE="white-space:nowrap">14a-6(i)(1)</FONT> and <FONT STYLE="white-space:nowrap">0-11</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g268305g02a02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VOR BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 Cambridgepark Drive, Suite 101 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cambridge, Massachusetts 02140 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF ANNUAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD ON JUNE&nbsp;14, 2022 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear
Stockholder: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You are cordially invited to attend the 2022 Annual Meeting of Stockholders (the &#147;Annual Meeting&#148;) of Vor
Biopharma Inc., a Delaware corporation (&#147;Vor Bio&#148; or the &#147;Company&#148;). The Annual Meeting will be held solely virtually, via live webcast at<I> </I>www.virtualshareholdermeeting.com/VOR2022 originating from Cambridge,
Massachusetts, on Tuesday, June&nbsp;14, 2022 at 12:00 p.m. Eastern Time. You will not be able to attend the Annual Meeting in person. The logistics of the virtual meeting are discussed more fully in the attached Proxy Statement. The Annual Meeting
will be held for the following purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To elect each of the three Class&nbsp;I director nominees set forth in the Proxy Statement to our board of
directors, each to serve a three-year term expiring at the 2025 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation or removal. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To ratify the selection by the audit committee of the Board of Directors of Ernst&nbsp;&amp; Young LLP as our
independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2022. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To conduct any other business properly brought before the meeting or any adjournment or postponement thereof.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These items of business are more fully described in the Proxy Statement accompanying this Notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Instead of mailing a paper copy of our proxy materials to all of our stockholders, we are providing access to our proxy materials over the
internet under the U.S. Securities and Exchange Commission&#146;s &#147;notice and access&#148; rules. As a result, we are mailing to our stockholders a Notice of Internet Availability of Proxy Materials (the &#147;Notice&#148;) instead of a paper
copy of this Proxy Statement and our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021 (the &#147;2021 Annual Report&#148;). We are mailing the Notice on or about April&nbsp;28, 2022 to all
stockholders of record on our books at the close of business on April&nbsp;18, 2022, the record date for the Annual Meeting, and it contains instructions on how to access our proxy materials over the internet. The Notice also contains instructions
on how each of our stockholders can receive a paper copy of our proxy materials, including this Proxy Statement, our 2021 Annual Report, and a form of proxy card or voting instruction card. In addition, the Notice and website provide information
regarding how you may request to receive proxy materials in printed form by mail, or electronically by email, on an ongoing basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether or not you plan to attend the Annual Meeting online, we encourage you to read this Proxy Statement and submit your proxy or voting
instructions as soon as possible by using the internet as described in the instructions included on your Notice, by calling the toll-free telephone number included on your Notice, or, if you received a paper copy of the proxy materials, by
completing, signing, dating and returning your proxy card or voting instruction form. Further information about how to attend the Annual Meeting online, vote your shares and submit questions for consideration at the meeting is included in the
accompanying Proxy Statement. If your shares are held in &#147;street name,&#148; that is, held for your account by a bank, broker or other nominee, you will receive instructions from the holder of record that you must follow for your shares to be
voted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Thank you for your ongoing support and continued interest in&nbsp;Vor Bio. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By Order of the Board of Directors,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g268305g01a04.jpg" ALT="LOGO">
</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Ang</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>President and Chief Executive Officer</I></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cambridge, Massachusetts </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;28, 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Important Notice
Regarding the Availability of Proxy Materials for the</B> <B>Annual Meeting of Stockholders to be held on June</B><B></B><B>&nbsp;14, 2022</B>: This Proxy Statement and our 2021 Annual Report are available at www.proxyvote.com. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc268305_1">General Information about the Annual Meeting and Voting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc268305_2">Proposal No.&nbsp;1 &#150; Election of Three Class&nbsp;I
Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc268305_3">Class&nbsp;I Nominees For Election</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc268305_4">Information Regarding Directors </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc268305_5">Board Diversity Matrix</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc268305_6">Corporate Governance</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc268305_7">Proposal No.&nbsp;
2 &#150; Ratification of Selection of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc268305_8">Independent Registered Public Accountants&#146; Fees</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc268305_9"><FONT STYLE="white-space:nowrap">Pre-Approval</FONT> Policies and Procedures
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc268305_10">Executive Officers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc268305_11">Security Ownership of Certain Beneficial Owners and
Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc268305_12">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc268305_13">Director Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc268305_14">Delinquent Section&nbsp;16(A) Reports</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc268305_15">Equity Compensation Plans at December&nbsp;31, 2021</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc268305_16">Certain Relationships and Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc268305_17">Householding of Proxy Materials</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc268305_18">Other Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VOR BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>100 Cambridgepark Drive, Suite 101 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cambridge, Massachusetts 02140 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROXY STATEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE
2022 ANNUAL MEETING OF STOCKHOLDERS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD ON JUNE&nbsp;14, 2022 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This proxy statement (the &#147;Proxy Statement&#148;) contains information about our 2022 Annual Meeting of Stockholders of Vor Biopharma
Inc. (the &#147;Annual Meeting&#148;). The Annual Meeting will be held on Tuesday, June&nbsp;14, 2022, beginning at 12:00&nbsp;p.m. Eastern Time. To support the health and well-being of our stockholders, employees and directors in light of the
ongoing COVID pandemic, the Annual Meeting will be a virtual meeting held via the internet at a virtual web conference at www.virtualshareholdermeeting.com/VOR2022. There will not be a physical meeting location, and stockholders will not be able to
attend the Annual Meeting in person. The logistics of the virtual meeting are discussed more fully in this Proxy Statement. This means that you can attend the Annual Meeting online, vote your shares during the online meeting and submit questions
during the online meeting by visiting the above-mentioned Internet site. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except where the context otherwise requires, references to
&#147;Vor Bio,&#148; &#147;Vor,&#148; &#147;we,&#148; &#147;us,&#148; &#147;our&#148; and similar terms refer to Vor Biopharma Inc. and its consolidated subsidiary. References to our website are inactive textual references only and the contents of
our website are not incorporated by reference into this Proxy Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Proxy Statement and the enclosed proxy card are being
furnished in connection with the solicitation of proxies by our board of directors (the &#147;Board&#148;) for use at the Annual Meeting and at any adjournment of that meeting. All proxies will be voted in accordance with the instructions they
contain. If you do not specify your voting instructions on your proxy, it will be voted in accordance with the recommendations of the Board. We are making this Proxy Statement, the related proxy card and our 2021 Annual Report available to
stockholders for the first time on or about April&nbsp;28, 2022. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc268305_1"></A>GENERAL INFORMATION ABOUT THE ANNUAL MEETING
AND VOTING </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Why did I receive a notice regarding the availability of proxy materials on the internet instead of a full set of proxy materials?
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to rules adopted by the Securities and Exchange Commission (the &#147;SEC&#148;), we have elected to provide access to our
proxy materials over the internet. Accordingly, we have sent you a Notice of Internet Availability of Proxy Materials (the &#147;Notice&#148;) because the Board is soliciting your proxy to vote at the Annual Meeting, including at any adjournments or
postponements of the Annual Meeting. All stockholders will have the ability to access the proxy materials on the website referred to in the Notice or request to receive a printed set of the proxy materials. Instructions on how to access the proxy
materials over the internet or to request a printed copy may be found in the Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to mail the Notice on or about
April&nbsp;28, 2022 to all stockholders who are entitled to vote at the Annual Meeting. The proxy materials will be made available to stockholders on the internet on the same date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Will I receive any other proxy materials by mail? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No, you will not receive any other proxy materials by mail unless you request a paper copy of proxy materials. To request that a full set of
the proxy materials be sent to your specified postal address, please go to www.proxyvote.com or call <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-579-1639.</FONT></FONT></FONT> Please have
your proxy card in hand when you access the website or call and follow the instructions provided. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>When is the record date for the Annual Meeting? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board has fixed the record date for the Annual Meeting as of the close of business on April&nbsp;18, 2022 (the &#147;Record Date&#148;).
Our virtual meeting will be governed by our Rules of Conduct and Procedures which will be posted at www.virtualshareholdermeeting.com/VOR2022 in advance of the meeting.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Why is Vor Bio conducting a virtual Annual Meeting? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the ongoing public health crisis relating to the COVID pandemic, we believe that adopting the<B> </B>virtual meeting format will help
protect the health and well-being of our directors, members of management and<B> </B>stockholders who wish to attend the Annual Meeting. Stockholders attending the virtual meeting will be afforded the<B> </B>same rights and opportunities to
participate as they would at an <FONT STYLE="white-space:nowrap">in-person</FONT> meeting, including the ability to submit<B> </B>questions in advance and to vote. We believe that hosting a virtual meeting is in the best interest of our
stockholders<B> </B>and enables increased stockholder attendance in light of the current circumstances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How do I attend, participate in, and ask
questions during the Annual Meeting? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will be hosting the Annual Meeting via live webcast only. Any stockholder can attend the
Annual Meeting live online at www.virtualshareholdermeeting.com/VOR2022. The meeting will start at 12:00 p.m., Eastern Time, on Tuesday, June&nbsp;14, 2022. Stockholders attending the Annual Meeting will be afforded the same rights and opportunities
to participate as they would at an <FONT STYLE="white-space:nowrap">in-person</FONT> meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to enter the Annual Meeting, you
will need the control number, which is included in the Notice or on your proxy card if you are a stockholder of record of shares of the Company&#146;s common stock, $0.0001 par value per share (&#147;Common Stock&#148;), or included with your voting
instruction card and voting instructions received from your broker, bank or other agent if you hold your shares of Common Stock in a &#147;street name.&#148; Instructions on how to attend and participate are also available at<I>
</I>www.virtualshareholdermeeting.com/VOR2022. We recommend that you log in a few minutes before 12:00 p.m., Eastern Time to ensure you are logged in when the Annual Meeting starts. The webcast will open 15 minutes before the start of the Annual
Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you would like to submit a question during the Annual Meeting, you may log into, and ask a question on, the virtual meeting
platform at www.virtualshareholdermeeting.com/VOR2022 using your control number, type your question into the &#147;Ask a Question&#148; field, and click &#147;Submit.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To help ensure that we have a productive and efficient meeting, and in fairness to all stockholders in attendance, you will also find posted
our rules of conduct for the Annual Meeting when you log in prior to its start. Our Annual Meeting will be governed by our Rules of Conduct which will be posted in advance of the meeting at www.virtualshareholdermeeting.com/VOR2022. These Rules of
Conduct will address the ability of stockholders to ask questions during the meeting, including rules on permissible topics, and rules for how questions and comments will be recognized and disclosed to meeting participants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What if I have technical difficulties or trouble accessing the Annual Meeting? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will have technicians ready to assist you with any technical difficulties you may have accessing the Annual Meeting. If you encounter any
difficulties accessing the Annual Meeting during the <FONT STYLE="white-space:nowrap">check-in</FONT> or meeting time, please call the technical support number that will be posted at www.virtualshareholdermeeting.com/VOR2022. Technical support will
be available starting at 11:45 a.m., Eastern Time on June&nbsp;14, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Who can vote at the Annual Meeting? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only stockholders of record at the close of business on the Record Date will be entitled to vote online at the Annual Meeting. On the Record
Date, there were 37,511,434 shares of Common Stock outstanding and entitled </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to vote. Holders of our shares of Common Stock as of the Record Date are entitled to one vote for each share held on all matters to be voted on by stockholders at the Annual Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, a list of stockholders of record will be available during the Annual Meeting for inspection by stockholders of record for any
legally valid purpose related to the Annual Meeting at www.virtualshareholdermeeting.com/VOR2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholder of Record: Shares Registered in Your
Name </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, on the Record Date, your shares were registered directly in your name with our transfer agent, Computershare Trust Company,
N.A., then you are a stockholder of record. As a stockholder of record, you may vote online during the Annual Meeting or by proxy in advance. Whether or not you plan to attend the Annual Meeting, we urge you to vote your shares by proxy in advance
of the Annual Meeting through the internet, by telephone or by completing and returning a printed proxy card that you may request or that we may elect to deliver at a later time to ensure your vote is counted. Whether or not you plan to attend the
Annual Meeting, we urge you to fill out and return the enclosed proxy card to ensure your vote is counted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Beneficial Owner: Shares Registered in the
Name of a Broker, Bank or Other Agent </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, on the Record Date, your shares were held, not in your name, but rather in an account at a
broker, bank or other agent, then you are the beneficial owner of shares held in &#147;street name&#148; and the Notice is being forwarded to you by that organization. The organization holding your account is considered to be the stockholder of
record for purposes of voting at the Annual Meeting. As a beneficial owner, you have the right to direct your broker, bank or other agent regarding how to vote the shares in your account. You are also invited to attend the Annual Meeting. You should
follow the instructions in the Notice or the voting instructions provided by your broker, bank or other agent in order to instruct your broker, bank or other agent on how to vote your shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What am I voting on? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are two
matters scheduled for a vote: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Proposal No. 1 - To elect each of the three Class&nbsp;I director nominees to the Board, each to serve a
three-year term expiring at the 2025 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation or removal; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Proposal No. 2 - To ratify the selection by the audit committee of the Board of Ernst&nbsp;&amp; Young LLP as our
independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2022. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What if another matter is properly
brought before the meeting? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board knows of no other matters that will be presented for consideration at the Annual Meeting. If any
other matters are properly brought before the meeting, it is the intention of the persons named in the accompanying proxy to vote on those matters in accordance with his or her best judgment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How do I vote? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may either vote
&#147;For&#148; the nominees to the Board or you may &#147;Withhold&#148; your vote for any nominee you specify. For the proposal to ratify the selection of Ernst&nbsp;&amp; Young LLP, you may vote &#147;For&#148; or &#147;Against&#148; or abstain
from voting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The procedures for voting are fairly simple: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholder of Record: Shares Registered in Your Name </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a stockholder of record, you may vote (1)&nbsp;online during the Annual Meeting or (2)&nbsp;in advance of the Annual Meeting by
proxy through the internet, by telephone or by using a proxy card that you may request or that we may elect to deliver at a later time. Whether or not you plan to attend the Annual Meeting, we urge you to vote by proxy to ensure your vote is
counted. You may still attend the Annual Meeting and vote online even if you have already voted by proxy. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To vote online during the Annual Meeting, follow the provided instructions to join the Annual Meeting at
www.virtualshareholdermeeting.com/VOR2022., starting at 12:00 p.m., Eastern Time on Tuesday, June&nbsp;14, 2022. The webcast will open 15 minutes before the start of the Annual Meeting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To vote in advance of the Annual Meeting through the internet, go to www.proxyvote.com to complete an electronic
proxy card. You will be asked to provide the control number from the Notice or the printed proxy card. Your internet vote must be received by 11:59 p.m., Eastern Time on Monday, June&nbsp;13, 2022 to be counted. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To vote in advance of the Annual Meeting by telephone, dial <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-690-6903</FONT></FONT></FONT> using a touch-tone phone and follow the recorded instructions. You will be asked to provide the control number from the Notice or the printed proxy card.
Your telephone vote must be received by 11:59 p.m., Eastern Time on Monday, June&nbsp;13, 2022 to be counted. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To vote in advance of the Annual Meeting using a printed proxy card that may be delivered to you, simply
complete, sign and date the proxy card and return it promptly in the envelope provided. If you return your signed proxy card to us before the Annual Meeting, we will vote your shares as you direct. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Beneficial Owner: Shares Registered in the Name of Broker, Bank or Other Agent </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a beneficial owner of shares registered in the name of your broker, bank, or other agent, you should have received a notice
containing voting instructions from that organization rather than from us. Simply follow the voting instructions in the instructions received from your broker, bank or other agent to ensure that your vote is counted. To vote online at the Annual
Meeting, you should follow the instructions in the Notice or the voting instructions provided by your broker, bank or other agent in order to instruct your broker, bank or other agent on how to vote your shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How many votes do I have? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On each matter
to be voted upon, you have one vote for each share of Common Stock you own as of the Record Date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What happens if I do not vote? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholder of Record: Shares Registered in Your Name </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a stockholder of record and do not vote by completing your proxy card, through the internet, by telephone or online at the Annual
Meeting, your shares will not be voted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Beneficial Owner: Shares Registered in the Name of Broker, Bank or Other Agent </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a beneficial owner and do not instruct your broker, bank or other agent how to vote your shares, the question of whether your
broker, bank or other agent will still be able to vote your shares depends on whether the particular proposal is deemed to be a &#147;routine&#148; matter. Brokers, banks and other agents can use their
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
discretion to vote &#147;uninstructed&#148; shares with respect to matters that are considered to be &#147;routine,&#148; but not with respect to
<FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matters. Under applicable rules and interpretations, <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matters are matters that may substantially affect the rights or
privileges of stockholders, such as mergers, stockholder proposals, elections of directors (even if not contested), executive compensation (including any advisory stockholder votes on executive compensation and on the frequency of stockholder votes
on executive compensation), and certain corporate governance proposals, even if management-supported. Accordingly, your broker, bank or other agent may not vote your shares on Proposal No.&nbsp;1 without your instructions, but may vote your shares
on Proposal No.&nbsp;2 even in the absence of your instruction. We encourage you to provide voting instructions to your broker, bank or other agent. This ensures that your shares will be voted at the Annual Meeting according to your instructions.
You should receive directions from your broker, bank or other agent about how to submit your proxy to them at the time you receive this proxy statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a beneficial owner of shares held in street name, in order to ensure your shares are voted in the way you would prefer, you must
provide voting instructions to your broker, bank or other agent by the deadline provided in the materials you receive from your broker, bank or other agent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What if I return a proxy card or otherwise vote but do not make specific choices? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you return a signed and dated proxy card or otherwise vote without marking voting selections, your shares will be voted, as applicable,
&#147;For&#148; the election of the nominees for director and &#147;For&#148; the ratification of selection of Ernst&nbsp;&amp; Young LLP as our independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2022. If any
other matter is properly presented at the meeting, your proxyholder (one of the individuals named on your proxy card) will vote your shares using his best judgment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Who is paying for this proxy solicitation? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay for the entire cost of soliciting proxies. In addition to these proxy materials, our directors and employees may also solicit
proxies in person, or by other means of communication. Directors and employees will not be paid any additional compensation for soliciting proxies. We may also reimburse brokers, banks and other agents for the cost of forwarding proxy materials to
beneficial owners. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What does it mean if I receive more than one Notice? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you receive more than one Notice, your shares may be registered in more than one name or in different accounts. Please follow the voting
instructions on each of the Notices you receive to ensure that all of your shares are voted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Can I revoke my vote after submitting my proxy? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholder of Record: Shares Registered in Your Name </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Yes. You can revoke your proxy at any time before the final vote at the meeting. If you are the record holder of your shares, you may revoke
your proxy at any time before the final vote at the Annual Meeting in any one of the following ways: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You may submit another properly completed proxy card with a later date. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You may grant a subsequent proxy by telephone or through the internet. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You may send a timely written notice that you are revoking your proxy to our Secretary at Vor Biopharma Inc., 100
Cambridgepark Drive, Suite 101, Cambridge, Massachusetts 02140. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You may attend the Annual Meeting and vote online. Simply attending the meeting will not, by itself, revoke your
proxy. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Your most current proxy card or telephone or internet proxy is the one that is counted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Beneficial Owner: Shares Registered in the Name of Broker, Bank or Other Agent </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If your shares are held by your broker, bank or other agent, you should follow the instructions provided by your broker, bank or other agent.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How are votes counted? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Votes will
be counted by the inspector of election appointed for the meeting, who will separately count, (a)&nbsp;for Proposal No.&nbsp;1 to elect directors, votes &#147;For,&#148; &#147;Withhold&#148; and broker
<FONT STYLE="white-space:nowrap">non-votes</FONT> and (b)&nbsp;for Proposal No.&nbsp;2, votes &#147;For&#148; and &#147;Against,&#148; as well as abstentions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Abstentions will be counted towards the vote total for Proposal No.&nbsp;2 and will have the same effect as &#147;Against&#148; votes. Broker <FONT
STYLE="white-space:nowrap">non-votes</FONT> have no effect and will not be counted towards Proposal No.&nbsp;1. We do not expect broker <FONT STYLE="white-space:nowrap">non-votes</FONT> to exist in connection with Proposal No.&nbsp;2. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What are &#147;broker <FONT STYLE="white-space:nowrap">non-votes&#148;?</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed above, when a beneficial owner of shares held in &#147;street name&#148; does not give voting instructions to his or her broker,
bank or other agent holding his or her shares as to how to vote on matters deemed to be <FONT STYLE="white-space:nowrap">&#147;non-routine,&#148;</FONT> the broker, bank or other such agent cannot vote the shares. These unvoted shares are counted as
&#147;broker <FONT STYLE="white-space:nowrap">non-votes.&#148;</FONT> Since Proposal No.&nbsp;1 is considered to be <FONT STYLE="white-space:nowrap">&#147;non-routine,&#148;</FONT> we expect broker <FONT STYLE="white-space:nowrap">non-votes</FONT>
to exist in connection with Proposal No.&nbsp;1. Proposal No.&nbsp;2 is considered to be &#147;routine,&#148; and therefore we do not expect broker <FONT STYLE="white-space:nowrap">non-votes</FONT> to exist in connection with Proposal No.&nbsp;2.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>As a reminder, if you are a beneficial owner of shares held in street name, in order to ensure your shares are voted in the way you
would prefer, you <U>must</U> provide voting instructions to your broker, bank or other agent by the deadline provided in the materials you receive from your broker, bank or other agent. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How many votes are needed to approve each proposal? </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Proposal No. 1 - For the election of Class&nbsp;I directors, the three nominees receiving the most
&#147;For&#148; votes from the holders of shares present by virtual attendance or represented by proxy and entitled to vote on the election of directors will be elected, which is referred to as a plurality. Accordingly, only votes &#147;For&#148;
will affect the outcome. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Proposal No. 2 - To ratify the selection of Ernst&nbsp;&amp; Young LLP as our independent registered public
accounting firm for the fiscal year ending December&nbsp;31, 2022, the proposal must receive &#147;For&#148; votes from the holders of a majority of shares present by virtual attendance or represented by proxy and entitled to vote on the matter. If
you &#147;Abstain&#148; from voting, it will have the same effect as an &#147;Against&#148; vote. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What is the quorum requirement?
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A quorum of stockholders is necessary to hold a valid meeting. A quorum will be present if stockholders holding at least a majority of
the outstanding shares of stock entitled to vote are present at the meeting online or represented by proxy. On the Record Date, there were 37,511,434 shares outstanding and entitled to vote. Thus, the holders of 18,755,718 shares must be present at
the Annual Meeting by virtual attendance or represented by proxy at the meeting to have a quorum. The inspector(s) of election appointed for the Annual Meeting will determine whether or not a quorum is present. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Your shares will be counted towards the quorum only if you submit a valid proxy (or one is submitted on your behalf by your broker, bank or
other agent) or if you vote online at the meeting. Abstentions and broker </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">non-votes</FONT> will be counted towards the quorum requirement. If there is no quorum, the holders of a majority of shares present at the meeting by virtual
attendance or represented by proxy may adjourn the meeting to another date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How can I find out the results of the voting at the Annual Meeting?
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preliminary voting results will be announced at the Annual Meeting. In addition, final voting results will be disclosed in a current
report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> that we expect to file with the SEC within four business days after the Annual Meeting. If final voting results are not available to us in time to file a Form
<FONT STYLE="white-space:nowrap">8-K</FONT> within four business days after the meeting, we intend to file a Form <FONT STYLE="white-space:nowrap">8-K</FONT> to disclose preliminary results and, within four business days after the final results are
known to us, file an amended Form <FONT STYLE="white-space:nowrap">8-K</FONT> to disclose the final voting results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>When are stockholder proposals and
director nominations due for next year&#146;s Annual Meeting? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Requirements for stockholder proposals to be brought before an annual meeting.
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated bylaws (&#147;Bylaws&#148;) provide that, for stockholder director nominations or other proposals to be
considered at an annual meeting, the stockholder must give timely notice thereof in writing to our Secretary at Vor Biopharma Inc., 100 Cambridgepark Drive, Suite 101, Cambridge, Massachusetts 02140. To be timely for the 2023 Annual Meeting of
Stockholders, a stockholder&#146;s notice must be delivered to or mailed and received by our Secretary at our principal executive offices between February&nbsp;14, 2023 and March&nbsp;16, 2023; provided that if the date of that annual meeting of
stockholders is earlier than May&nbsp;15, 2023, or later than July&nbsp;14, 2023, you must give the required notice not earlier than the 120th day prior to the meeting date and not later than the 90th day prior to the meeting date or, the 10th day
following the day on which public announcement of that meeting date is first made. A stockholder&#146;s notice to the Secretary must also set forth the information required by our Bylaws. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Requirements for stockholder proposals to be considered for inclusion in our proxy materials. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholder proposals submitted pursuant to Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the Securities Exchange Act of 1934, as
amended (the &#147;Exchange Act&#148;), and intended to be presented at the 2023 Annual Meeting of Stockholders must be received by us not later than December&nbsp;29, 2022 in order to be considered for inclusion in our proxy materials for that
meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to satisfying the foregoing requirements under our Bylaws, to comply with the universal proxy rules (once
effective), stockholders who intend to solicit proxies in support of director nominees other than our nominees must provide notice that sets forth the information required by Rule <FONT STYLE="white-space:nowrap">14a-19</FONT> under the Exchange Act
no later than April&nbsp;15, 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc268305_2"></A>PROPOSAL NO. 1 &#150; ELECTION OF THREE CLASS I DIRECTORS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business and affairs are managed under the direction of the Board. The Board presently has seven members, six of whom are deemed
&#147;independent&#148; under SEC and rules of The Nasdaq Stock Market LLC (&#147;Nasdaq&#148;). Vacancies on the Board may be filled only by persons elected by a majority of the remaining directors. Our Board is divided into three classes with only
one class of directors being elected in each year and each class serving a three-year term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are three Class&nbsp;I directors whose
term expires in 2022. They are Matthew Patterson, the chairman of our Board, Daniella Beckman and Kush Parmar, M.D., Ph.D. The Board has nominated Mr.&nbsp;Patterson, Ms.&nbsp;Beckman and Dr.&nbsp;Parmar for election as Class&nbsp;I directors to
serve until our 2025 annual meeting of stockholders or until their successors have been duly elected and qualified, or, if sooner, until the director&#146;s death, resignation or removal. Although we do not have a formal policy regarding attendance
by members of our Board at our annual meeting of stockholders, we encourage all of our directors to attend the Annual Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Directors
are elected by a plurality of the votes of the holders of shares of Common Stock present by virtual attendance or represented by proxy and entitled to vote on the election of directors. Accordingly, the three nominees receiving the highest number of
affirmative votes will be elected. Shares represented by executed proxies will be voted, if authority to do so is not withheld, for the election of each of the nominees named below. If the nominee becomes unavailable for election as a result of an
unexpected occurrence, shares that would have been voted for that nominee will instead be voted for the election of a substitute nominee proposed by us. Each person nominated for election has consented to being named as a nominee in this proxy
statement and has agreed to serve if elected. We have no reason to believe that any nominee will be unable to serve. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a
brief biography of (i)&nbsp;the nominees for election at the Annual Meeting and (ii)&nbsp;the other members of our Board whose term will continue after the Annual Meeting, including their respective ages, as of the Record Date. Each biography
includes information regarding the specific experience, qualifications, attributes or skills that led the Board to determine that the applicable nominee or other current director should serve as a member of the Board. There are no family
relationships between or among any of our directors or executive officers.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc268305_3"></A>CLASS I NOMINEES FOR ELECTION FOR A THREE-YEAR
TERM EXPIRING AT THE 2025 ANNUAL MEETING </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Matthew Patterson</I></B>, age 50, has served as a member of our Board since October
2020 and as chairman since June 2021. Mr.&nbsp;Patterson is the <FONT STYLE="white-space:nowrap">co-founder</FONT> of Audentes Therapeutics, Inc. (&#147;Audentes&#148;) and he served as Chief Executive Officer of Audentes from 2012 until its
acquisition by Astellas Pharma, Inc. in January 2020. Mr.&nbsp;Patterson is the Executive Chairman at Remix Therapeutics, Inc. and Iris Medicine, Inc., each a private biotechnology company. He also serves on the board of directors of Homology
Medicines, Inc., a public gene therapy company (&#147;Homology Medicines&#148;), and 5:01 Acquisition Corp, a public special purpose acquisition company (&#147;5:01&#148;), since January 2018 and October 2020, respectively, and as the executive
chairman of the board of directors of Remix Therapeutics, Inc., a private biotechnology company, since March 2021. Mr.&nbsp;Patterson was a member of the board of directors of ARM since 2015 until 2020, including as a chair in 2019 and 2020.
Mr.&nbsp;Patterson received a B.A. in Biochemistry from Bowdoin College. We believe that Mr.&nbsp;Patterson is qualified to serve on our Board due to his expertise in the fields of business, biotechnology and drug development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Daniella Beckman</I></B>, age 43, has served as a member of our Board since July 2020. Since September 2019, she has served as the Chief
Financial Officer of Tango Therapeutics, Inc., a public targeted oncology biotechnology company. From November 2015 to September 2019, she provided consulting services and served as the Interim Chief Financial Officer for several early-stage
biotechnology companies. Ms.&nbsp;Beckman has served on the board of directors and is a member of the audit committee of Translate Bio, Inc., a clinical-stage mRNA </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
therapeutics company, since October 2017, on the board of directors of 5:01 since October 2020 and on the board of directors of Blueprint Medicines Corp, a public, global precision therapy
company, since December 2021. Ms.&nbsp;Beckman received a B.S. in business administration-accounting from Boston University. We believe that Ms.&nbsp;Beckman is qualified to serve on our Board due to her financial expertise and her experience in
public accounting in the life sciences industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Kush Parmar, M.D., Ph.D.</I></B>, age 41,<B><I> </I></B>has served as a member of
our Board since February 2019, the chairman of our Board from January 2021 until June 2021 and served as our interim President and Chief Executive Officer from February 2019 until August 2019. Dr.&nbsp;Parmar is currently a Member of 5AM Venture
Management, LLC, where he has worked since 2010, and is <FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officer and member of the board of directors of 5:01, positions he has held since its inception in August 2020. Dr.&nbsp;Parmar has
served on the boards of directors of Homology Medicines, Akouos, Inc., Rallybio Corporation, a public biotechnology company, and Entrada Therapeutics, Inc., a public biotechnology company, since December 2015, October 2017, April 2018 and December
2020, respectively, and previously served on the board of directors of Arvinas, Inc. from 2013 to November 2019, Audentes from 2013 to November 2018 and scPharmaceuticals, Inc. from March 2014 to July 2018. Dr.&nbsp;Parmar received an A.B. in
molecular biology and medieval studies from Princeton University, a Ph.D. in experimental pathology from Harvard University and an M.D. from Harvard Medical School. We believe that Dr.&nbsp;Parmar is qualified to serve on our Board due to his
extensive experience in the venture capital industry, medical and scientific background and training, and service on the boards of other public and private biopharmaceutical and biotechnology companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VOTING &#147;FOR&#148; THE ELECTION OF EACH OF MR. PATTERSON, MS. BECKMAN AND DR. PARMAR AS CLASS I DIRECTORS, FOR A THREE-YEAR TERM ENDING
AT THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD IN 2025 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc268305_4"></A>CLASS II DIRECTORS CONTINUING IN OFFICE UNTIL THE 2023 ANNUAL
MEETING </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>David C. Lubner</I></B>, age 58,<B><I> </I></B>has served as a member of our Board since July 2020. From January 2016 to
June 2020, Mr.&nbsp;Lubner served as the Executive Vice President and Chief Financial Officer of Ra Pharmaceuticals, Inc., a biotechnology company acquired by UCB S.A. in April 2020. Mr.&nbsp;Lubner has served on the boards of directors of Dyne
Therapeutics, Inc., a public biotechnology company, since March 2020, Gemini Therapeutics, Inc., a public precision medicine company, since April 2020, Arcellx Inc., a public biotechnology company, since August 2020, Point Biopharma, Inc., a public
late-stage clinical precision oncology (&#147;Point Biopharma&#148;), since June 2021 and several private companies. Mr.&nbsp;Lubner previously served on the board of directors of Nightstar Therapeutics plc, a gene therapy company, from July 2017
until it was acquired by Biogen Inc in June 2019 and Therapeutics Acquisition Corp., a special purpose acquisition company, from May 2020 until June 2021 when it merged with Point Biopharma. Mr.&nbsp;Lubner received a B.S. in business administration
from Northeastern University and an M.S. in taxation from Bentley University. Mr.&nbsp;Lubner is also a member of the American Institute of Certified Public Accountants and is a certified public accountant in Massachusetts. We believe
Mr.&nbsp;Lubner is qualified to serve on our Board due to his financial and accounting experience and his service as a director and executive officer of other biotechnology companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Joshua Resnick, M.D.</I></B>, age 47,<B><I> </I></B>has served as a member of our Board since February 2019. Dr.&nbsp;Resnick currently
serves as a Managing Director at RA Capital Management, a life sciences investment advisor, since October 2018. Dr.&nbsp;Resnick previously served as a Partner at SV Health Investors from January 2016 to September 2018 and as President and Managing
Partner at MRL Ventures Fund, an early-stage therapeutics-focused corporate venture fund that he built and managed within Merck&nbsp;&amp; Co., from 2014 to January 2016. Dr.&nbsp;Resnick also has served on the board of directors of Aerovate
Therapeutics, Inc., a public clinical stage biopharmaceutical company, since October 2018. Dr.&nbsp;Resnick is on staff in the Department of Emergency Medicine at Massachusetts General Hospital. Dr.&nbsp;Resnick has previously served on the boards
of directors of Kalvista Pharmaceuticals, Inc. and Avrobio, Inc. from November 2016 to September 2018 and July 2016 to September 2018, respectively. Dr.&nbsp;Resnick received a B.A. in chemistry from Williams College, an M.D. from
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the University of Pennsylvania School of Medicine and an M.B.A. from The Wharton School of Business. We believe that Dr.&nbsp;Resnick is qualified to serve on our Board due to his experience as a
biopharmaceutical and biotechnology public and private company investor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CLASS III DIRECTORS CONTINUING IN OFFICE UNTIL THE 2024 ANNUAL MEETING
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Robert Ang, M.B.B.S., M.B.A.</I></B>, age 48,<B><I> </I></B>has served as our Chief Executive Officer, President and a member of
our Board since August 2019. Prior to that, Dr.&nbsp;Ang served as Chief Business Officer at Neon Therapeutics Inc., a biopharmaceutical company, from October 2015 until August 2019, and as Senior Vice President, Business Development at Bavarian
Nordic A/S, an immuno-oncology and infectious disease vaccine company, from 2013 to 2015. Dr.&nbsp;Ang has served on the board of directors of Enara Bio Limited, a private biotechnology company, since September 2021 and the Alliance for Regenerative
Medicine (&#147;ARM&#148;), an international advocacy organization representing the gene and cell therapy and broader regenerative medicine sector, since January 2022. Dr.&nbsp;Ang received an M.B.B.S. medical degree from the University of Western
Australia and an M.B.A. from Columbia University. We believe that Dr.&nbsp;Ang is qualified to serve on our Board due to his service as our President and Chief Executive Officer and his experience in the field of medicine and biotechnology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Sven (Bill) Ante Lundberg, M.D.</I></B>, age 58, has served as a member of our Board since March 2019. Since December 2019, he has
served as President, Chief Executive Officer and Principal Financial Officer, and Executive Director of Merus N.V., a clinical-stage immune-oncology company. From 2015 to February 2018, Dr.&nbsp;Lundberg was Chief Scientific Officer of CRISPR
Therapeutics AG. Dr.&nbsp;Lundberg received an M.D. from Stanford University, an M.B.A. from the University of Massachusetts and a B.S. in Biology from the Massachusetts Institute of Technology. He completed post-doctoral training at the Whitehead
Institute/MIT and clinical training in Medicine and Medical Oncology from Harvard and the Dana-Farber Cancer Institute. We believe that Dr.&nbsp;Lundberg is qualified to serve on our Board due to his experience in the field of medicine and clinical
drug development as well as his leadership and business experience. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc268305_5"></A>BOARD DIVERSITY MATRIX AS OF
APRIL&nbsp;18, 2022 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total Number of Directors: 7 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Female</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Male</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Non-</B><br><B>Binary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Did Not</B><br><B>Disclose</B><br><B>Gender</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Part I: Gender Identity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Part II: Demographic Background</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">African American or Black</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alaskan Native or Native American</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Asian</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hispanic or Latinx</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Native Hawaiian or Pacific Islander</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">White</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Two or More Races or Ethnicities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LGBTQ+</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="13" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Did Not Disclose Demographic Background</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="13" NOWRAP ALIGN="center">1</TD>
<TD VALIGN="bottom" NOWRAP>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors who are Military Veterans</B>: None.<B> </B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors with Disabilities</B>: None.<B> </B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc268305_6"></A>CORPORATE GOVERNANCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that good corporate
governance is important to ensure that Vor Bio is managed for the long-term benefit of our stockholders. This section describes key corporate governance practices that we have adopted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also adopted a code of business conduct and ethics (the &#147;Code of Conduct&#148;), which applies to all of our officers, directors
and employees. This includes our principal executive officer, principal financial officer and principal accounting officer or controller, or persons performing similar functions. We have also adopted corporate governance guidelines and charters for
our Board&#146;s audit committee (the &#147;Audit Committee&#148;), compensation committee (the &#147;Compensation Committee&#148;) and nominating and corporate governance committee (the &#147;Nominating and Corporate Governance Committee&#148;). We
have posted copies of our Code of Conduct and corporate governance guidelines, as well as each of our committee charters, on the Corporate Governance page of the Investors section of our website,&nbsp;www.vorbio.com, which you can access free of
charge. Information contained on the website is not incorporated by reference in, or considered part of, this Proxy Statement. We intend to disclose on our website any amendments to, or waivers from, our Code of Conduct that are required to be
disclosed by law or applicable Nasdaq rules (the &#147;Nasdaq Listing Rules&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Nasdaq Listing Rules require a majority of a listed company&#146;s board of directors to be comprised of independent directors, as
affirmatively determined by the board of directors. In addition, the Nasdaq Listing Rules require that, subject to specified exceptions, each member of a listed company&#146;s audit, compensation and nominating and corporate governance committees be
independent and that audit committee members also satisfy independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act. The Nasdaq independence definition includes a series of objective tests, such as
that the director is not, and has not been for at least three years, one of our employees, and that neither the director nor any of his or her family members has engaged in various types of business dealings with us. In addition, under applicable
Nasdaq rules, a director will only qualify as an &#147;independent director&#148; if, in the opinion of the listed company&#146;s board of directors, that person does not have a relationship that would interfere with the exercise of independent
judgment in carrying out the responsibilities of a director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board has determined that all of our directors other than Robert Ang, by
virtue of his employment with us, are &#147;independent directors&#148; as defined under applicable Nasdaq rules. In making such determination, our Board considered the current and prior relationships that each such director has with our company and
all other facts and circumstances that our Board deemed relevant in determining his or her independence, including the beneficial ownership of our capital stock by each director and the transactions described below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Leadership Structure </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board has
an independent chairperson, Mr.&nbsp;Patterson, who has authority, among other things, to call and preside over Board meetings, including meetings of the independent directors, to set meeting agendas and to determine materials to be distributed to
the Board. Accordingly, the chairperson has substantial ability to shape the work of the Board. We believe that separation of the positions of the chairperson and the chief executive officer reinforces the independence of the Board in its oversight
of the business and affairs of our Company. In addition, we believe that having an independent chairperson creates an environment that is more conducive to objective evaluation and oversight of management&#146;s performance, increasing management
accountability and improving the ability of the Board to monitor whether management&#146;s actions are in the best interests of our company and our stockholders. As a result, we believe that having an independent chairperson can enhance the
effectiveness of the Board as a whole. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Role of the Board in Risk Oversight </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the key functions of our Board is informed oversight of our risk management process. Our Board does not have a standing risk management
committee, but rather administers this oversight function directly through the Board as a whole, as well as through various standing committees of our Board that address risks inherent in their respective areas of oversight. In particular, our Board
is responsible for monitoring and assessing strategic risk exposure. The Audit Committee has the responsibility to consider and discuss our major financial risk exposures and the steps our management has taken to monitor and control these exposures,
including guidelines and policies to govern the process by which risk assessment and management is undertaken. The Audit Committee will also monitor compliance with legal and regulatory requirements. Audit Committee responsibilities also include
oversight of data privacy, technology information security risk management, including cybersecurity. Our Nominating and Corporate Governance Committee monitors the effectiveness of our corporate governance guidelines, including whether they are
successful in preventing illegal or improper liability-creating conduct. Our Compensation Committee assesses and monitors whether any of our compensation policies and programs has the potential to encourage excessive risk-taking. In addition, the
entire Board receives reports from time to time regarding various enterprise risks facing the Company, and the applicable Board committees receive related reports with respect to the committees&#146; respective areas of oversight. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Governance Guidelines </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
Board has adopted corporate governance guidelines to assist in the exercise of its duties and responsibilities and to serve the best interests of our Company and our stockholders. The guidelines provide that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Board&#146;s responsibilities are to review, approve, and monitor fundamental financial and business
strategies, assess our major risks, and consider ways to address those risks, select and oversee management, and establish and oversee processes to maintain our integrity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">except as required by Nasdaq Listing Rules, a majority of the members of our Board must be independent directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the independent directors meet in executive session at least twice a year; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">directors have access to management and, as necessary, independent advisors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Nominating and Corporate Governance Committee will oversee periodic self-evaluations of the Board to
determine whether it and its committees are functioning effectively. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A copy of the corporate governance guidelines is
posted under the heading &#147;Corporate Governance&#148; on the Investors&nbsp;&amp; Media section of our website, which is located at&nbsp;http://www.vorbio.com. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Meetings of The Board and Its Committees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board met ten times during the year ended December&nbsp;31, 2021. The Audit Committee, the Compensation Committee and the Nominating and
Corporate Governance Committee met four, four and one times, respectively during the year ended December&nbsp;31, 2021. Each director attended 75% or more of the aggregate number of meetings of the Board and of the committees on which he or she
served, held during the portion of the year ended December&nbsp;31, 2021 for which he or she was a director or committee member. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Regarding Committees of the Board </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board has an Audit Committee, Compensation Committee and a Nominating and Corporate Governance Committee. The following table provides
current membership information for each of these Board committees: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Audit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Compensation</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nominating<BR>and&nbsp;Corporate<BR>Governance</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew Patterson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniella Beckman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Lubner</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sven (Bill) Ante Lundberg, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kush Parmar, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joshua Resnick, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Ang, M.B.B.S., M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Committee Chairperson </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Below is a description of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee of the Board. Pursuant to our Bylaws,
the Board may establish such other committees as may be permitted by law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Audit Committee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of the Audit Committee are Daniella Beckman, David Lubner and Matthew Patterson. Ms.&nbsp;Beckman is the chair of the Audit
Committee. Our Board has determined that each of these individuals meets the independence requirements of Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act, and the Nasdaq Listing Rules. Each member of our Audit Committee can
read and understand fundamental financial statements in accordance with Nasdaq audit committee requirements. Our Board has also determined that Daniella Beckman qualifies as an audit committee financial expert within the meaning of SEC regulations
and meets the financial sophistication requirements of the Nasdaq Listing Rules. In arriving at these determinations, the Board has examined each Audit Committee member&#146;s scope of experience and the nature of their prior and/or current
employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The functions of our Audit Committee include, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">helping our Board oversee our corporate accounting and financial reporting processes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">managing the selection, engagement, qualifications, independence and performance of a qualified firm to serve as
the independent registered public accounting firm to audit our financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discussing the scope and results of the audit with the independent registered public accounting firm, and
reviewing, with management and the independent accountants, our interim and <FONT STYLE="white-space:nowrap">year-end</FONT> operating results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing procedures for employees to submit concerns anonymously about questionable accounting or auditing
matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving related person transactions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving or, as permitted, <FONT STYLE="white-space:nowrap">pre-approving,</FONT> audit and permissible <FONT
STYLE="white-space:nowrap">non-audit</FONT> services to be performed by the independent registered public accounting firm. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of
the Compensation Committee are Daniella Beckman, Bill Lundberg, M.D., and Joshua Resnick, M.D. Dr.&nbsp;Resnick is the chair of the Compensation Committee. Each of these individuals is a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">non-employee</FONT> director, as defined in Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act. Our Board has determined that
each of these individuals is &#147;independent&#148; as defined under the applicable listing standards of Nasdaq, including the standards specific to members of a Compensation Committee. The functions of this committee include, among other things:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, modifying and approving (or if it deems appropriate, making recommendations to the full Board
regarding) our overall compensation strategy and policies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, approving and making recommendations to the full Board regarding the compensation and other terms of
employment of our Chief Executive Officer and reviewing and approving (or if it deems appropriate, making recommendations to the full Board regarding) the compensation and other terms of employment of our other executive officers and senior
management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving (or if it deems appropriate, making recommendations to the full Board regarding)
performance goals and objectives relevant to the compensation of our executive officers and assessing their performance against these goals and objectives; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating and approving (or if it deems it appropriate, making recommendations to the full Board regarding) the
equity incentive plans, compensation plans and similar programs advisable for us, as well as modifying, amending or terminating existing plans and programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing risks associated with our compensation policies and practices and determining whether risks arising
from our employee compensation policies and practices are reasonably likely to have a material adverse effect on us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and making recommendations to the full Board regarding the type and amount of compensation to be paid
or awarded to our <FONT STYLE="white-space:nowrap">non-employee</FONT> board members; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and considering votes by our stockholders to approve executive compensation to the extent required by
Section&nbsp;14A of the Exchange Act and, if applicable, making recommendations to the Board regarding the frequency of advisory votes on executive compensation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and assessing the independence of compensation consultants, legal counsel and other advisors as
required by Nasdaq Listing Rules; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">administering our equity incentive plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing policies with respect to equity compensation arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the competitiveness of our executive compensation programs and evaluating the effectiveness of our
compensation policy and strategy in achieving expected benefits to us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving the terms of any employment agreements, severance arrangements, change of control
protections and any other compensatory arrangements for our executive officers and senior management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing with management our disclosures under the caption &#147;Compensation Discussion and Analysis&#148; in
our periodic reports or proxy statements to be filed with the SEC, to the extent such caption is required to be included in any such report or proxy statement, and determine whether to recommend to the full Board that such disclosures be approved
for inclusion in SEC filings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparing the report that the SEC requires in our annual proxy statement to the extent required; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and assessing on an annual basis the adequacy of the Compensation Committee charter.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Compensation Committee Processes and Procedures </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Typically, the Compensation Committee meets quarterly<B></B>&nbsp;and with greater frequency if necessary. The agenda for each meeting is
usually developed by the Chair of the Compensation Committee, in consultation with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our Chief Executive Officer, our Chief People Officer or Radford, a compensation consultant which is part of the Rewards Solutions practice at Aon plc (&#147;Radford&#148;). The Compensation
Committee meets regularly in executive session. In addition, various members of management and other employees as well as outside advisors or consultants<B></B>&nbsp;are frequently invited by the Compensation Committee to
make<B></B>&nbsp;presentations, to provide financial or other<B></B>&nbsp;background information or advice or to otherwise participate in Compensation Committee meetings. The Chief Executive Officer may not participate in, or be present during, any
deliberations or determinations of the Compensation Committee regarding his compensation or individual performance objectives. The charter of the Compensation Committee grants the Compensation Committee full access to all of our books, records,
facilities and personnel. In addition, under its charter, the Compensation Committee has the authority to obtain, at our expense, advice and assistance from compensation consultants and internal and external legal, accounting or other advisors and
other external resources that the Compensation Committee considers necessary or appropriate in the performance of its duties. The Compensation Committee has direct responsibility for the oversight of the work of any consultants or advisors engaged
for the purpose of advising the Compensation Committee. In particular, the Compensation Committee has the sole authority to retain, in its sole discretion, compensation consultants to assist in its evaluation of<B></B>&nbsp;executive<B></B>&nbsp;and
director compensation, including the authority to approve the consultant&#146;s reasonable fees and other retention terms. Under the charter, the Compensation Committee may select, or receive advice from, a compensation consultant, legal counsel or
other advisor to the Compensation Committee, other <FONT STYLE="white-space:nowrap">than&nbsp;in-house&nbsp;legal</FONT> counsel and certain other types of advisors, only after taking into consideration six factors, prescribed by the SEC and Nasdaq,
that bear upon the advisor&#146;s independence; however, there is no requirement that any advisor be independent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During
2022,<B></B>&nbsp;after taking into consideration the six factors prescribed by the SEC and Nasdaq referenced above, the Compensation Committee determined to continue engaging Radford<B></B>&nbsp;as its compensation consultant.<B></B>&nbsp;Our
Compensation Committee identified Radford based on Radford&#146;s general reputation in the industry. The Compensation Committee requested that Radford: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluate the efficacy of the Company&#146;s existing compensation strategy and practices in supporting and
reinforcing the Company&#146;s long-term strategic goals; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assist the Compensation Committee in refining the Company&#146;s compensation strategy and in developing and
implementing an executive compensation program to execute that strategy.</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of its ongoing engagement, Radford has
assisted the Compensation Committee with developing and revising a comparative group of companies and to perform analyses of competitive performance and compensation levels for that group. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under its charter, the Compensation Committee may form, and delegate authority to, subcommittees as appropriate. The Compensation Committee
has delegated authority to our Chief Executive Officer, to grant, without any further action required by the Compensation Committee, stock options to employees who are not officers of the Company. The purpose of this delegation of authority is to
enhance the flexibility of option administration within the Company and to facilitate the timely grant of options <FONT STYLE="white-space:nowrap">to&nbsp;non-management&nbsp;employees,</FONT> particularly new employees, within specified limits
approved by the Compensation Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, the Compensation Committee has reviewed and determined annual compensation for our
executive officers other than our Chief Executive Officer during the last quarter of the year for any adjustments to annual base salaries and annual performance-based cash bonus target percentages for the subsequent year and during the first quarter
of the year for performance-based cash bonuses for the prior year and the approval of awards of annual performance bonuses and equity awards, as well as approval of new annual performance objectives for the current year. The Compensation Committee
has historically reviewed the compensation components of our Chief Executive Officer&#146;s salary, including base salary, bonus, benefits, equity incentives and other perquisites, in the first quarter of the year and makes a recommendation to our
Board regarding such components. Our Board then determines any adjustments or changes to our Chief Executive Officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, at various meetings throughout the year the Compensation Committee also
considers matters related to individual compensation, such as compensation for new executive hires and other strategic compensation issues, such as the efficacy of the Company&#146;s compensation strategy, potential modifications to that strategy
and new trends, plans or approaches to compensation. For executives other than the Chief Executive Officer, the Compensation Committee solicits and considers evaluations and recommendations submitted by the Chief Executive Officer when determining
the compensation of the other executive officers. In the case of the Chief Executive Officer, the Compensation Committee evaluates his performance, which influences any adjustments the Compensation Committee determines to recommend to our Board
regarding his<B></B>&nbsp;compensation<B></B>&nbsp;as well as awards to be granted. As part of its deliberations, the Compensation Committee may review and consider, as appropriate,<B></B>&nbsp;materials that it deems appropriate, including
financial reports and projections, tax and accounting information, executive and director stock ownership information, company stock performance data, analyses of historical executive compensation levels and current company-wide compensation levels
and recommendations of the Compensation Committee&#146;s compensation consultant, including analyses of executive and director compensation paid at other companies identified by the consultant. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nominating and Corporate Governance Committee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of the Nominating and Corporate Governance Committee are Kush Parmar, M.D., Ph.D., Matthew Patterson and Joshua Resnick, M.D.
Dr.&nbsp;Parmar is the chair of the Nominating and Corporate Governance Committee. Our Board has determined that each of these individuals is &#147;independent&#148; as defined under the applicable listing standards of Nasdaq and SEC rules and
regulations. The functions of this committee include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, reviewing, evaluating and recommending candidates to serve on our Board, consistent with the
criteria approved by our Board; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating performance on the Board and applicable committees of the Board, including directors, and determining
whether continued service on our Board is appropriate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating nominations by stockholders of candidates for election to our Board, and to recommend to our Board
appropriate action on any such proposal or recommendation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">considering and assessing the independence of members of our Board; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing a set of corporate governance guidelines and principles and recommending to our Board any changes to
such policies and principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and making recommendations to the Board with respect to executive officer succession planning;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and making recommendations to the Board to consider changes to our insider trading policy;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">considering questions of possible conflicts of interest of directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and assessing on an annual basis the Nominating and Corporate Governance Committee charter and the
performance of the Nominating and Corporate Governance Committee. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee
believes that candidates for director should have certain minimum qualifications, including the ability to read and understand basic financial statements, being over 21 years of age and having the highest personal integrity and ethics. The
Nominating and Corporate Governance Committee also considers other factors when considering potential candidates, including expertise relevant to the Company&#146;s current and planned operations, having sufficient time to devote to the affairs of
the Company, demonstrated excellence in his or her field, having the ability to exercise sound business judgment and having commitment to support the long-term interests of the Company&#146;s stockholders. The Nominating and Corporate Governance
Committee retains the right to modify these qualifications from time to time as the Company&#146;s needs change and evolve. Board diversity and inclusion is critical to the Company&#146;s success. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Candidates for director nominees are also reviewed in the context of the current composition of the Board, the operating requirements of the Company and the long-term interests of stockholders.
In conducting this assessment, the Nominating and Corporate Governance Committee may also consider diversity, age, skills and such other factors as it deems appropriate, given the current needs of the Board and the Company. As presently constituted,
the Board represents a deliberate mix of members who have a deep understanding of the Company&#146;s business, as well as members who have different skill sets and points of view on substantive matters pertaining to our business. Our nomination
process and our Board&#146;s approach to assessment and evaluation of our nominees support our commitment to diversity and inclusion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Nominating and Corporate Governance Committee appreciates the value of thoughtful changes to the Board&#146;s membership and identifies and considers qualities, skills and other director attributes that might enhance the composition of the Board. In
the case of incumbent directors whose terms of office are set to expire, the Nominating and Corporate Governance Committee reviews these directors&#146; overall service to the Company during their terms, including the number of meetings attended,
level of participation, quality of performance and any other relationships and transactions that could impair the directors&#146; independence. In the case of new director candidates, the Nominating and Corporate Governance Committee also determines
whether the nominee is independent, which determination is based upon applicable Nasdaq listing standards, applicable SEC rules and regulations, and other factors. The Nominating and Corporate Governance Committee then uses its network to compile a
list of potential candidates, which may include recommendations from a professional search firm when deemed appropriate. The Nominating and Corporate Governance Committee conducts any appropriate and necessary inquiries into the backgrounds and
qualifications of possible candidates after considering the needs of the Board. The Nominating and Corporate Governance Committee then meets to discuss and consider the candidates&#146; qualifications and then selects a nominee for recommendation to
the Board. all current directors and nominees for director were identified and nominated by members of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Nominating and
Corporate Governance Committee will consider director candidates recommended by stockholders. The Nominating and Corporate Governance Committee does not intend to alter the manner in which it evaluates candidates, including the minimum criteria set
forth above, based on whether or not the candidate was recommended by a stockholder. Stockholders who wish to recommend individuals for consideration by the Nominating and Corporate Governance Committee to become nominees for election to the Board
may do so by delivering a written recommendation to the Nominating and Corporate Governance Committee at the following address: Secretary at c/o Vor Biopharma Inc., 100 Cambridgepark Drive, Suite 101, Cambridge, Massachusetts 02140, at least 90
days, but not more than 120 days prior to the anniversary date of the mailing of our proxy statement for the preceding year&#146;s Annual Meeting of Stockholders. Submissions must include the information required by our Bylaws, including the full
name of the proposed nominee, a description of the proposed nominee&#146;s business experience for at least the previous five years, complete biographical information, a description of the proposed nominee&#146;s qualifications as a director and a
representation that the nominating stockholder is a beneficial or record holder of our stock and has been a holder for at least one year. Any submission must be accompanied by the written consent of the proposed nominee to be named as a nominee and
to serve as a director if elected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of our directors who serve as a member of our Compensation Committee is, or has at any time during the past year been, one of our officers
or employees. None of our executive officers currently serves, or in the past year has served, as a member of the board of directors or compensation committee of any other entity that has one or more executive officers serving on our Board or
Compensation Committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policy Regarding Hedging of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our employees, executive officers and directors are prohibited from engaging in short sales, transactions in put options, call options or other
derivative securities, hedging transactions or other inherently speculative </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transactions with respect to our stock at any time. In addition, our employees, executive officers, directors and designated consultants are prohibited from holding our securities in a margin
account or otherwise pledging our securities as collateral for a loan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stockholder Communications with the Board </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our stockholders wishing to communicate with our Board or an individual director may send a written communication to the Board or such director
c/o Vor Biopharma Inc., 100 Cambridgepark Dr., Suite 101, Cambridge, MA 02140, Attn: Corporate Secretary. Each communication must set forth: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name and address of the stockholder on whose behalf the communication is sent; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and class of our shares that are owned beneficially by such stockholder as of the date of the
communication. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The corporate secretary will review each communication. The corporate secretary will forward such
communication to the Board or to any individual director to whom the communication is addressed unless the communication contains advertisements or solicitations or is unduly hostile, threatening or similarly inappropriate, in which case the
corporate secretary shall discard the communication. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Report of the Audit Committee of the Board </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Audit Committee has reviewed our audited financial statements for the year ended December&nbsp;31, 2021 and discussed them with our
management and our independent registered public accounting firm, Ernst&nbsp;&amp;&nbsp;Young&nbsp;LLP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Audit Committee has also
received from, and discussed with, Ernst&nbsp;&amp;&nbsp;Young&nbsp;LLP various communications that Ernst&nbsp;&amp;&nbsp;Young&nbsp;LLP is required to provide to our Audit Committee, including the matters required to be discussed by the applicable
requirements of Public Company Accounting Oversight Board (&#147;PCAOB&#148;) and the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Ernst&nbsp;&amp; Young&nbsp;LLP
provided our Audit Committee with the written disclosures and the letter required by applicable requirements of the PCAOB regarding the independent registered public accounting firm&#146;s communications with the Audit Committee concerning
independence, and the Audit Committee has discussed with the company&#146;s independent registered public accounting firm their independence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the review and discussions referred to above, our Audit Committee recommended to our Board that our financial statements audited by
Ernst&nbsp;&amp; Young&nbsp;LLP be included in our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December&nbsp;31, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">By the Audit Committee of the Board of Directors of Vor Biopharma Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Daniella Beckman, Chairperson </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">David
Lubner </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Matthew Patterson </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The material in this report is not &#147;soliciting material,&#148; is not deemed &#147;filed&#148; with the SEC and is not to be
incorporated by reference in any of our filing under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;) or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in
any such filing. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc268305_7"></A>PROPOSAL NO. 2 &#150; RATIFICATION OF SELECTION OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee has selected Ernst&nbsp;&amp; Young LLP as our independent registered public
accounting firm for the fiscal year ending December&nbsp;31, 2022 and has further directed that management submit the selection of the independent registered public accounting firm for ratification by the stockholders at the Annual Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A representative of Ernst&nbsp;&amp; Young LLP is expected to attend the virtual Annual Meeting and will have an opportunity to make a
statement if he or she desires to do so and to respond to appropriate questions from our stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither our Bylaws nor other
governing documents or law require stockholder ratification of the selection of Ernst&nbsp;&amp; Young LLP as our independent registered public accounting firm. However, the Audit Committee is submitting the selection of Ernst&nbsp;&amp; Young LLP
to the stockholders for ratification as a matter of good corporate practice. If the stockholders fail to ratify the selection, the Audit Committee will reconsider whether or not to retain that Ernst&nbsp;&amp; Young LLP. Even if the selection is
ratified, the Audit Committee in its discretion may direct the appointment of different independent auditors at any time during the year if they determine that such a change would be in our best interests and the best interests of our stockholders.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc268305_8"></A>Independent Registered Public Accountants&#146; Fees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the fees of Ernst&nbsp;&amp; Young LLP billed us for each of the last two fiscal years. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Fees <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">815,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">870,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit-Related Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax Fees <SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All Other Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">878,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">870,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Audit fees consist of fees billed for professional services by Ernst&nbsp;&amp; Young LLP for audit and
quarterly review of our consolidated financial statements and review of the registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> for our initial public offering, and related services that are normally provided in connection
with statutory and regulatory filings or engagements. The aggregate fees included in the Audit Fees are those fees billed for the fiscal year. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tax fees consist of fees billed or accrued for professional services by Ernst&nbsp;&amp; Young LLP for tax
consulting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All fees described above were <FONT STYLE="white-space:nowrap">pre-approved</FONT> by the Audit Committee. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc268305_9"></A><FONT STYLE="white-space:nowrap">Pre-Approval</FONT> Policies and Procedures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee has adopted policies and procedures for the <FONT STYLE="white-space:nowrap">pre-approval</FONT> of audit and <FONT
STYLE="white-space:nowrap">non-audit</FONT> services for the purpose of maintaining the independence of our independent auditor. We may not engage our independent auditor to render any audit or <FONT STYLE="white-space:nowrap">non-audit</FONT>
service unless either the service is approved in advance by the Audit Committee, or the engagement to render the service is entered into pursuant to the Audit Committee&#146;s <FONT STYLE="white-space:nowrap">pre-approval</FONT> policies and
procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, our Audit Committee may <FONT STYLE="white-space:nowrap">pre-approve</FONT> services that are expected to
be provided to us by the independent auditor during the following 12 months. At the time such <FONT STYLE="white-space:nowrap">pre-approval</FONT> is granted, the Audit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Committee must identify the particular <FONT STYLE="white-space:nowrap">pre-approved</FONT> services in a sufficient level of detail so that our management will not be called upon to make a
judgment as to whether a proposed service fits within the <FONT STYLE="white-space:nowrap">pre-approved</FONT> services and, at each regularly scheduled meeting of the Audit Committee following such approval, management or the independent auditor
shall report to the Audit Committee regarding each service actually provided to us pursuant to such <FONT STYLE="white-space:nowrap">pre-approval.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee has delegated to its chairperson the authority to grant <FONT STYLE="white-space:nowrap">pre-approvals</FONT> of audit or <FONT
STYLE="white-space:nowrap">non-audit</FONT> services to be provided by the independent auditor, provided, that such services are no more than $50,000 per calendar year. Any approval of services by the chairperson of the Audit Committee is reported
to the committee at its next regularly scheduled meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recommendation of the Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>OUR BOARD OF DIRECTORS RECOMMENDS VOTING &#147;FOR&#148; PROPOSAL NO. 2 TO RATIFY THE SELECTION BY OUR AUDIT COMMITTEE OF ERNST&nbsp;&amp; YOUNG LLP AS OUR
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER&nbsp;31, 2022. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc268305_10"></A>EXECUTIVE OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our executive officers as of the Record Date are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Position</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Ang, M.B.B.S., M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>President, Chief Executive Officer and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tirtha Chakraborty, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Scientific Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nathan Jorgensen, Ph.D., M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Slapak, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Medical Officer</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biographical information for Mr.&nbsp;Ang is included above with the director biographies under the caption
&#147;Directors Continuing in Office Until the 2024 Annual Meeting.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Tirtha Chakraborty, Ph.D</I></B><B>.</B>, age 49, has
served as our Chief Scientific Officer since November 2020 and previously as our Vice President, Head of Research starting in October 2019. From October 2018 to October 2019, Dr.&nbsp;Chakraborty served as Vice President of Cell Therapy Research at
Sana Biotechnology, Inc., a biotechnology company. Prior to that, Dr.&nbsp;Chakraborty served as an Executive Director and Head of Hematology at CRISPR Therapeutics AG, a biotechnology company (&#147;CRISPR Therapeutics&#148;), from 2015 to October
2018. From 2011 to 2015, Dr.&nbsp;Chakraborty was responsible for building the therapeutic mNRA platform at Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines. Dr.&nbsp;Chakraborty received a Ph.D. from Tata
Institute of Fundamental Research and completed his post-doctoral associateship at Harvard Medical School. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Nathan Jorgensen,
Ph.D.</I></B><I>,</I><B><I> M.B.A.</I></B>, age 45, has served as our Chief Financial Officer since May 2020. From August 2016 to April 2020, Dr.&nbsp;Jorgensen led global healthcare investments for Qatar Investment Authority, the sovereign wealth
fund for the State of Qatar. Dr.&nbsp;Jorgensen served as investment analyst at Calamos Investments, a global investment firm, from 2013 to August 2016. Dr.&nbsp;Jorgensen received a Ph.D. from the University of Minnesota and an M.B.A. from Cornell
University Johnson Graduate School of Management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Christopher Slapak, M.D.</I></B>, age 64, has served as our Chief Medical Officer
since July 2020 and previously served in a consulting role as our Chief Medical Officer from July 2019 to July 2020. In April 2022, Dr.&nbsp;Slapak resigned from his position, effective May&nbsp;6, 2022. From January 2018 to July 2020,
Dr.&nbsp;Slapak provided oncology consulting services to pharmaceutical companies, including Takeda Oncology and Translational Drug Development, Inc. From July 2018 to June 2019, Dr.&nbsp;Slapak served in a consulting role as Chief Medical Officer
for Prelude Therapeutics, Inc., a precision oncology company. Dr.&nbsp;Slapak served in roles of increasing responsibility at Eli Lilly and Company from 1996 to December 2017, including most recently as Vice President, Early Phase Development
Oncology. Dr.&nbsp;Slapak is also a clinical associate professor of medicine and clinical pharmacology at the Indiana University School of Medicine. Dr.&nbsp;Slapak received a B.S. in chemistry from The Ohio State University and an M.D. from the
University of Chicago Pritzker School of Medicine. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc268305_11"></A>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information with respect to the beneficial ownership of our Common Stock, as of April&nbsp;18, 2022:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Each person known by us to beneficially own more than 5% of our Common Stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our named executive officers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our executive officers and directors as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The column entitled &#147;Percentage of Shares Beneficially Owned&#148; is based on a total of 37,511,434 shares of our Common Stock
outstanding as of April&nbsp;18, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares beneficially owned by each stockholder is determined under rules issued by
the SEC and includes voting or investment power with respect to securities. Under these rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power. In computing the number
of shares beneficially owned by an individual or entity and the percentage ownership of that person, shares of common stock subject to options, warrants, or other rights held by such person that are currently exercisable or will become exercisable
within 60 days after April&nbsp;18, 2022 are considered outstanding, although these shares are not considered outstanding for purposes of computing the percentage ownership of any other person. Unless otherwise indicated, the address of all listed
stockholders is 100 Cambridgepark Dr.,&nbsp;Suite&nbsp;101, Cambridge, Massachusetts 02140. Each of the stockholders listed has sole voting and investment power with respect to the shares beneficially owned by the stockholder unless noted otherwise,
subject to community property laws where applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as indicated by the footnotes below, we believe, based on information
furnished to us, that each of the stockholders listed has sole voting and investment power with respect to the shares beneficially owned by the stockholder unless noted otherwise, subject to community property laws where applicable. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>Beneficially&nbsp;Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Greater than 5% stockholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with RA Capital Healthcare Fund, L.P.&nbsp;<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,120,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities&nbsp;affiliated&nbsp;with&nbsp;5AM&nbsp;Ventures&nbsp;VI, L.P.&nbsp;<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,361,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PureTech Health LLC <SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,207,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with FMR, LLC
<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,181,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Named Executive Officer and Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Ang, M.B.B.S. <SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">863,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tirtha Chakraborty, Ph.D. <SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Slapak, M.D. <SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">188,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew Patterson <SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniella Beckman <SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Lubner <SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sven (Bill) Ante Lundberg, M.D. <SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kush Parmar, M.D., Ph.D. <SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,369,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joshua Resnick, M.D. <SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current executive officers and directors as a group (10 persons) <SUP
STYLE="font-size:85%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,848,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than one 1%. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 9,295,647 shares of Common Stock held by RA Capital Healthcare Fund, L.P. (&#147;RA
Healthcare&#148;) and (ii) 1,825,326 shares of Common Stock by RA Capital Nexus Fund, L.P. (&#147;Nexus Fund&#148;). RA Capital Healthcare Fund GP, LLC is the general partner of RA Healthcare and RA Capital Nexus Fund GP, LLC is the general partner
of the Nexus Fund. The general partner of RA Capital Management, L.P. (&#147;RA Capital&#148;) is RA Capital Management GP, LLC, of which Dr.&nbsp;Peter Kolchinsky and Mr.&nbsp;Rajeev Shah are the controlling persons. RA Capital serves as investment
adviser for the RA Healthcare and the Nexus Fund and may be deemed a beneficial owner, for purposes of Section&nbsp;13(d) of the Exchange Act, of any securities of the Company held by the RA Healthcare or the Nexus Fund. RA Healthcare and the Nexus
Fund have delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in RA Healthcare&#146;s and the Nexus Fund&#146;s portfolio, including the shares of the Company&#146;s Common Stock. Because RA Healthcare
and the Nexus Fund have divested themselves of voting and investment power over the reported securities they hold and may not revoke that delegation on less than 61 days&#146; notice, RA Healthcare and the Nexus Fund disclaim beneficial ownership of
the securities they hold for purposes of Section&nbsp;13(d) of the Exchange Act and therefore disclaim any obligation to report ownership of the reported securities under Section&nbsp;13(d) of the Exchange Act. As managers of RA Capital,
Dr.&nbsp;Kolchinsky and Mr.&nbsp;Shah may be deemed beneficial owners for purposes of Section&nbsp;13(d) of the Exchange Act. RA Capital, Dr.&nbsp;Kolchinsky, and Mr.&nbsp;Shah disclaim beneficial ownership of the securities other than for the
purpose of determining their obligations under Section&nbsp;13(d) of the Exchange Act. The address of the entities listed above is 200 Berkeley Street, 18th Floor, Boston, Massachusetts 02116. For information regarding RA&nbsp;Capital Management,
L.P. and its affiliates, we have relied on a Schedule 13D filed by RA Capital Management, L.P. with the SEC on February&nbsp;19, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 4,595,089 shares of Common Stock held by 5AM Ventures VI, L.P.; and (ii) 1,766,634 shares of
Common Stock held by 5AM Opportunities I, L.P. (collectively, the &#147;5AM Holdings&#148;). 5AM&nbsp;Partners VI, LLC is the general partner of 5AM Ventures VI, L.P. and may be deemed to have sole investment and voting power over the shares held by
5AM Ventures VI, L.P. Andrew Schwab and Kush Parmar are the managing members of 5AM Partners VI, LLC, and may be deemed to share voting and dispositive power over the shares held by 5AM Ventures VI, L.P. 5AM Opportunities I (GP), LLC is the general
partner of 5AM Opportunities I, L.P. and may be deemed to have sole investment and voting power over the shares held by 5AM Opportunities I, L.P. Andrew Schwab and Kush Parmar are the managing members of 5AM Opportunities I (GP), LLC, and may be
deemed to share voting and dispositive power over the shares held by 5AM Opportunities I, L.P. Dr.&nbsp;Parmar is also a member of our Board. The address of the above persons and entities is 501 2nd Street, Suite 350, San Francisco, California
94107. For information regarding 5AM Ventures VI, L.P. and its affiliates, we have relied on a Schedule 13D and Form&nbsp;4 filed by 5AM Ventures VI, L.P. with the SEC on February&nbsp;19, 2021 and November&nbsp;18, 2021, respectively.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Voting and investment power over the shares held by PureTech Health LLC is exercised by its parent entity,
PureTech Health plc. The board of directors of PureTech Health plc consists of Ms.&nbsp;Sharon <FONT STYLE="white-space:nowrap">Barber-Lui,</FONT> Dr.&nbsp;Raju Kucherlapati, Dr.&nbsp;John LaMattina, Dr.&nbsp;Robert Langer, Dame Marjorie Scardino,
Ms.&nbsp;Kiran Mazumdar-Shaw, Mr.&nbsp;Christopher Viehbacher, Ms.&nbsp;Daphne Zohar and Dr.&nbsp;Bharatt Chowrira. None of the members of the board of directors of PureTech Health plc or PureTech Health LLC has individual voting or investment power
with respect to such shares. The address for PureTech Health LLC and the individuals listed above is c/o PureTech Health LLC, 6 Tide Street, Boston, Massachusetts 02210. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FMR LLC reports sole voting power with respect to 611,457 shares and sole dispositive power with respect to
3,181,463 shares. Abigail P. Johnson is a director, the chair, the chief executive officer and the president of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B
voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders of FMR LLC have entered into a shareholders&#146; voting agreement under which all Series B voting common
shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#146; voting agreement, members of the Johnson family may
be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. Neither FMR LLC nor Abigail P. Johnson has the sole power to vote or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
direct the voting of the shares owned directly by the various investment companies registered under the Investment Company Act of 1940 (the &#147;Fidelity Funds&#148;) advised by Fidelity
Management&nbsp;&amp; Research Company, a wholly owned subsidiary of FMR LLC, which power resides with the Fidelity Funds&#146; Boards of Trustees. Fidelity Management&nbsp;&amp; Research Company carries out the voting of the shares under written
guidelines established by the Fidelity Funds&#146; Boards of Trustees. The business address for each person and entity named in this footnote is 245 Summer Street, Boston, Massachusetts 02110. For information regarding FMR LLC, we have relied on a
Schedule 13G/A filed by FMR LLC with the SEC on February&nbsp;9, 2022. The Schedule 13G filed by FMR LLC provides information only as of December&nbsp;31, 2021 and, consequently, the beneficial ownership of FMR LLC may have changed between
December&nbsp;31, 2021 and April&nbsp;18, 2022. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 412,072 shares of Common Stock; and (ii) 451,739 shares of Common Stock issuable upon the
exercise of outstanding options exercisable within 60 days of April&nbsp;18, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 3,534 shares of Common Stock; and (ii) 119,952 shares of Common Stock issuable upon the
exercise of outstanding options exercisable within 60 days of April&nbsp;18, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 188,290 shares of Common Stock issuable upon the exercise of outstanding options exercisable within
60 days of April&nbsp;18, 2022. In April 2022, Dr.&nbsp;Slapak resigned from his position, effective May&nbsp;6, 2022, and the foregoing amount includes 8,795 shares of Common Stock that would vest under outstanding options held by Dr.&nbsp;Slapak
after his last day, but will not in light of his resignation. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 41,196 shares of Common Stock and (ii) 7,511 shares of Common Stock issuable upon the exercise
of outstanding options exercisable within 60 days of April&nbsp;18, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 25,533 shares of Common Stock issuable upon the exercise of outstanding options exercisable within
60 days of April&nbsp;18, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 29,432 shares of Common Stock and (ii) 16,681 shares of Common Stock issuable upon the exercise
of outstanding options exercisable within 60 days of April&nbsp;18, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i)&nbsp;the 5AM Holdings and (ii) 7,511 shares of Common Stock issuable upon the exercise of
outstanding options exercisable within 60 days of April&nbsp;18, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 7,511 shares of Common Stock issuable upon the exercise of outstanding options exercisable within
60 days of April&nbsp;18, 2022. Under Dr.&nbsp;Resnick&#146;s arrangement with RA Capital, Dr.&nbsp;Resnick holds the foregoing shares for the benefit of the RA Healthcare and the Nexus Fund. Dr.&nbsp;Resnick is obligated to turn over to RA Capital
any net cash or stock received from the foregoing shares underlying such option, which will offset advisory fees owed by the RA Healthcare and account to RA Capital. Dr.&nbsp;Resnick therefore disclaims beneficial ownership of the foregoing shares
of Common Stock underlying the outstanding options held by him. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 5AM Holdings, (ii) 515,503 shares of Common Stock and (iii) 971,365 shares of Common Stock
issuable upon the exercise of outstanding options exercisable within 60 days of April&nbsp;18, 2022. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc268305_12"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive officers for the year ended December&nbsp;31, 2021 consist of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Dr.&nbsp;Robert Ang, our principal executive officer, President and Chief Executive Officer;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Dr.&nbsp;Tirtha Chakraborty, our Chief Scientific Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Dr.&nbsp;Christopher Slapak, our Chief Medical Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
table provides information regarding the compensation provided to our named executive officers for the years ended December&nbsp;31, 2021 and 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive
Plan<BR>Compensation<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Ang, M.B.B.S.<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(3) </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">507,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">919,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">218,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,992</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,663,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">424,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,619,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">211,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500,015</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,754,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tirtha Chakraborty, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">384,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,915</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">540,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Scientific Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">298,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,600</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">718,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,059</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(8)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,177,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Slapak, M.D.<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">428,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150,593</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,043</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(10)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">590,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">176,846</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(11)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">627,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">283,344</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(12)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,224,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This column reflects the full grant date fair value of stock awards and option awards granted during the year
measured pursuant to Financial Accounting Standard Board Accounting Standards Codification Topic 718 (&#147;ASC 718&#148;), which is the basis for computing stock-based compensation in our financial statements. This calculation assumes that the
named executive officer will perform the requisite service for the award to vest in full as required by SEC rules. These amounts do not reflect the actual economic value that will be realized by the named executive officer upon vesting of the stock
options, the exercise of the stock options or the sale of the Common Stock underlying such stock options. See Note 9 to our consolidated financial statements in our 2021 Annual Report. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts disclosed represent performance bonuses earned in the applicable year listed in the row.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Ang is also a member of our Board but did not receive any additional compensation in his capacity as a
director. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of $10,150 in defined benefit plan contributions, $4,000 health savings account contributions, $1,970
in aggregate for life insurance and disability insurance premiums paid by us on Dr.&nbsp;Ang&#146;s behalf and $1,872 for commuting expenses. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of $497,920 resulting from our forgiveness of a loan to Dr.&nbsp;Ang, an aggregate of $1,645 in life
insurance and disability insurance premiums paid by us on Dr.&nbsp;Ang&#146;s behalf and reimbursement of $450 in commuting expenses. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of $10,150 in defined benefit plan contributions, $4,000 health savings account contributions, $1,893
in aggregate for life insurance and disability insurance premiums paid by us on Dr.&nbsp;Chakraborty&#146;s behalf and $1,872 for commuting expenses. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Chakraborty was awarded a <FONT STYLE="white-space:nowrap">one-time</FONT> bonus in connection with
his promotion to Chief Scientific Officer. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of an aggregate of $1,609 in life insurance and disability insurance premiums paid by us on
Dr.&nbsp;Chakraborty&#146;s behalf and reimbursement of $450 in commuting expenses in 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In April 2022, Dr.&nbsp;Slapak resigned from his position, effective May&nbsp;6, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of $10,150 in defined benefit plan contributions and $1,893 in aggregate for life insurance and
disability insurance premiums paid by us Dr.&nbsp;Slapak&#146;s behalf. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Slapak commenced employment with us as our Chief Medical Officer in July 2020. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of $282,592 paid to Christopher Slapak Consulting LLC for Dr.&nbsp;Slapak&#146;s consulting services
to us from January 2020 until his commencement of employment with us in July 2020 and an aggregate of $752 in life insurance and disability insurance premiums paid by us on Dr.&nbsp;Slapak&#146;s behalf in 2020. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative to the Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We review compensation annually for all employees, including our executive officers. In setting executive base salaries and bonuses and
granting equity incentive awards, we consider compensation for comparable positions at peer companies in the market, the historical compensation levels of our executives, individual performance as compared to our expectations and objectives, our
desire to motivate our employees to achieve short- and long-term results that are in the best interests of our stockholders and a long-term commitment to our company. We do not target a specific competitive position or a specific mix of compensation
among base salary, bonus or long-term incentives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board and Compensation Committee has historically determined our executive
officers&#146; compensation and our committee has typically reviewed and discussed management&#146;s proposed compensation with our Chief Executive Officer for all executives other than our Chief Executive Officer. Based on those discussions and its
discretion, our Compensation Committee approved the compensation of our executives other than our Chief Executive Officer and our Board, upon recommendation from our Compensation Committee, then approved the compensation of our Chief Executive
Officer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Annual Base Salary </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
entered into offer letters with each of our named executive officers that establish annual base salaries, which are generally determined, approved and reviewed periodically by our Board or Compensation Committee in order to compensate our named
executive officers for the satisfactory performance of duties to our company. Annual base salaries are intended to provide a fixed component of compensation to our named executive officers, reflecting their skill sets, experience, roles and
responsibilities. Base salaries for our named executive officers have generally been set at levels deemed necessary to attract and retain individuals with superior talent. See &#147;&#151;Offer Letters and Potential Payments Upon Termination or
Change in Control.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT> Incentive Plan Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the terms of their offer letters, our named executive officers are eligible to receive discretionary annual bonuses of up to
a percentage of each officer&#146;s gross base salary based on individual performance, company performance or as otherwise determined appropriate, as determined by our Board and our Compensation Committee. In 2021, our named executive officers were
eligible to earn an annual target performance bonus of each executive&#146;s 2021 base salary based on achievement of certain corporate objectives. Dr.&nbsp;Ang was eligible to earn 50% of his 2021 base salary and Drs. Slapak and Chakraborty were
each eligible to earn 40% of their 2021 base salaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity-Based Incentive Awards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our equity-based incentive awards are designed to align our interests with those of our employees and consultants, including our executive
officers. Our Board has historically been responsible for approving equity grants. Vesting of equity awards is generally tied to continuous service with us and serves as an additional retention measure. Our executives generally are awarded an
initial new hire grant upon commencement of employment. We have also made <FONT STYLE="white-space:nowrap">true-up</FONT> awards following certain financing events or promotions. Additional grants may occur periodically in order to specifically
incentivize executives with respect to achieving certain corporate goals or to reward executives for exceptional performance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides information regarding the outstanding equity awards held by our
named executive officers as of December&nbsp;31, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Outstanding Equity Awards at December&nbsp;31, 2021 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>(#)<BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>(#)<BR>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares or<BR>Units<BR>of Stock<BR>that<BR>Have Not<BR>Vested (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market<BR>Value of<BR>Shares or<BR>Units of<BR>Stock that<BR>Have
Not<BR>Vested&nbsp;($)<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Ang, <BR>M.B.B.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">08/05/19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">152,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,772,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">03/10/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">03/09/30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">08/21/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">230,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">421,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">08/20/30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">02/05/21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">02/04/31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Slapak, <BR>M.D.<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">08/21/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">08/20/30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">08/25/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">08/24/30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tirtha Chakraborty, <BR>Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">09/25/19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">09/24/29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">03/10/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">03/09/30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">08/21/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">08/20/30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/18/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/17/30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All equity awards were granted under our 2015 Stock Incentive Plan (the &#147;2015 Plan&#148;), the terms of
which are described below under the subsection titled &#147;&#151;Equity Incentive Plans&#151;2015 Stock Incentive Plan,&#148; and our 2021 Equity Incentive Plan (the &#147;2021 Plan&#148;), the terms of which are described below under the
subsection titled &#147;&#151;Equity Incentive Plans&#151;2021 Equity Incentive Plan.&#148; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This column represents the fair market value of a share of our Common Stock of $11.62 as of December&nbsp;31,
2021, which was the closing price of our Common Stock as reported on the Nasdaq Global Select Market on December&nbsp;31, 2021, multiplied by the amount shown in the column &#147;Stock Awards&#151;Number of Shares or Units of Stock That Have Not
Vested.&#148; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares were acquired pursuant to the exercise of unvested options granted to Dr.&nbsp;Ang on August&nbsp;5,
2019 and are subject to our right of repurchase upon Dr.&nbsp;Ang&#146;s termination of service. The shares will be released from our repurchase right in equal monthly installments on the fifth day of each month through August&nbsp;5, 2023, subject
to continuous service with us as of each such date. The restricted shares are subject to vesting acceleration, as described in more detail below under the subsection titled &#147;&#151;Offer Letters and Potential Payments Upon Termination or Change
in Control.&#148; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Twenty-five percent of the shares subject to the option vested on August 5, 2020, and thereafter the remaining
shares subject to the option vest in 36 equal monthly installments on each monthly anniversary thereafter, subject to continuous service with us as of each such vesting date. The option is exercisable immediately with respect to all shares subject
to the option granted on such date, subject to a repurchase right in favor of us which lapses as the option vests. As a result, this reflects the number of shares subject to the option that were exercisable and vested as of December 31, 2021. The
option is subject to vesting acceleration, as described in more detail below under the subsection titled &#147;&#151;Offer Letters and Potential Payments Upon Termination or Change in Control.&#148; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares subject to the option vest in 48 equal monthly installments beginning on July&nbsp;1, 2020 and
subject to continuous service as of each such vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In April 2022, Dr.&nbsp;Slapak resigned from his position, effective May&nbsp;6, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Twenty-five percent of the shares subject to the option vested on November&nbsp;16, 2021, and thereafter the
remaining shares subject to the option vest in 36 equal monthly installments on each monthly anniversary thereafter, subject to continuous service with us as of each such vesting date. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>401(k) Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a defined contribution retirement plan that provides eligible U.S. employees, including our named executive officers, with an
opportunity to save for retirement. The plan is intended to qualify as a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> 401(k) plan so that contributions to the 401(k) plan, and income earned on such contributions, are not taxable to
participants until withdrawn or distributed from the 401(k) plan (except in the case of contributions under the 401(k) plan designated as Roth contributions). For more information regarding our 401(k) plan see Note 13 to our consolidated financial
statements in our 2021 Annual Report. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Health and Welfare Benefits; Perquisites </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive officers are eligible to participate in our other benefit programs on the same basis as all employees of our company. We
generally do not provide perquisites or personal benefits except in limited circumstances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Severance and Change in Control Benefits Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2021, we adopted our Executive Severance and Change in Control Benefits Plan (the &#147;Severance Plan&#148;), for certain of our
employees, including each of our executive officers. Under the terms of the Severance Plan, if the employment of any of our officers or vice presidents is terminated by us without cause or by the officer for good reason prior to or more than 12
months following a change in control, each as defined in the Severance Plan, and subject to the employee&#146;s execution of a general release of potential claims against us and a <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, we
have agreed to continue to pay the employee&#146;s then-current base salary for a period of 12 months, in the case of our <FONT STYLE="white-space:nowrap">C-level</FONT> officers, and six months, in the case of our vice presidents, and to pay
premiums for continuation of health coverage under COBRA for up to 12 months, in the case of our <FONT STYLE="white-space:nowrap">C-level</FONT> officers, and up to six months, in the case of our vice presidents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Alternatively, if a covered employee&#146;s employment is terminated by us without cause or by the employee for good reason within one year
following a change in control, and subject to the employee&#146;s execution of a general release of potential claims against us and a <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, we have agreed, in the case of our Chief
Executive Officer, to pay a lump sum payment in an amount equal to 18 months of his then-current base salary, in the case of our other <FONT STYLE="white-space:nowrap">C-level</FONT> officers, to pay a lump sum payment in an amount equal to
12&nbsp;months of his or her then-current base salary and, in the case of our vice presidents, to pay a lump sum payment in an amount equal to six months of his or her then-current base salary; to pay premiums for continuation of health coverage
under COBRA for up to 18 months, in the case of our Chief Executive Officer, up to 12 months, in the case of our other <FONT STYLE="white-space:nowrap">C-level</FONT> officers, and up to six months, in the case of our vice presidents; to pay a lump
sum payment in an amount equal to 150%, in the case of our Chief Executive Officer, 100%, in the case of our <FONT STYLE="white-space:nowrap">C-level</FONT> officers, and 50%, in the case of our vice presidents, of the employee&#146;s target annual
bonus as then in effect; and to accelerate the vesting of any outstanding equity grants in full. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the event any of the
amounts provided for under the Severance Plan or otherwise would constitute a &#147;parachute payment&#148; within the meaning of Section&nbsp;280G of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;) and such payments would be
subject to the excise tax imposed by Section&nbsp;4999 of the Code, then such payments will either be (i)&nbsp;provided to the employee in full, or (ii)&nbsp;reduced to such lesser amount that would result in a smaller or no portion of such payments
being subject to the excise tax, whichever amount, after taking into account all applicable taxes, including the excise tax, would result in the employee&#146;s receipt, on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis, of the greatest
amount of such payments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Offer Letters and Potential Payments Upon Termination or Change in Control </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to offer letters with each of our named executive officers. The agreements generally provide for
<FONT STYLE="white-space:nowrap">at-will</FONT> employment without any specific term and set forth the named executive officer&#146;s initial base salary, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
eligibility for employee benefits and severance benefits upon a qualifying termination of employment or change in control of our company. Each of our named executive officers has executed our
standard confidentiality, intellectual property assignment and <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement. The key terms of the offer letters with our named executive officers, including potential payments upon termination or
change in control, are described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr.&nbsp;Robert Ang </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into an offer letter with Dr.&nbsp;Ang in June 2019 in connection with his appointment as our President and Chief Executive Officer.
The offer letter provided for a base salary of $395,000 per year, a <FONT STYLE="white-space:nowrap">one-time</FONT> signing bonus of $76,000 and a target annual bonus equal to 40% of Dr.&nbsp;Ang&#146;s annual base salary based on the achievement
of goals established by our Board. Our Board has increased Dr.&nbsp;Ang&#146;s annual base salary, including most recently in February 2022, to $570,000 for 2022 and subsequent years. Additionally, in January 2021, our Board of directors approved an
increase in Dr.&nbsp;Ang&#146;s target annual bonus to 50% of his annual salary. The offer letter further provided for the grant of stock options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to benefits pursuant to the Severance Plan, as described above, Dr.&nbsp;Ang is also entitled to severance benefits pursuant to
his offer letter. Pursuant to his offer letter, if we terminate Dr.&nbsp;Ang&#146;s employment without cause, or if Dr.&nbsp;Ang terminates his employment for good reason or due to death or disability, each as defined in Dr.&nbsp;Ang&#146;s offer
letter, he will be entitled to (i)&nbsp;cash severance equal to continued base salary payments commencing on Dr.&nbsp;Ang&#146;s termination date until the first anniversary of such termination date (the &#147;Ang Severance Period&#148;), paid in
equal monthly installments in accordance with our standard payroll policies and (ii)&nbsp;if he timely elects to continue health coverage through COBRA, direct payment of, or reimbursement for, COBRA premiums for Dr.&nbsp;Ang and his covered
dependents for the Ang Severance Period or, if earlier, until Dr.&nbsp;Ang is eligible for healthcare coverage under another employer&#146;s plan. These severance benefits are conditioned upon Dr.&nbsp;Ang&#146;s resignation from all positions with
us, execution of a release agreement, return of company property and compliance with his confidentiality, intellectual property assignment and <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, in the event we undergo a change in control, as defined in Dr.&nbsp;Ang&#146;s offer letter,
Dr.&nbsp;Ang&#146;s then-outstanding equity awards granted pursuant to the offer letter will vest in full, subject to Dr.&nbsp;Ang&#146;s continued service through the date of such change in control. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr.&nbsp;Tirtha Chakraborty </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered
into an offer letter with Dr.&nbsp;Chakraborty in August 2019 in connection with his hiring as our Vice President of Research. The offer letter provided for a base salary of $285,000 per year and a target annual bonus equal to 30% of
Dr.&nbsp;Chakraborty&#146;s annual base salary based on the achievement of goals established by our Board. Dr.&nbsp;Chakraborty&#146;s annual base salary was increased to $325,000 in connection with his appointment as our Chief Scientific Officer in
November 2020. Additionally, in January 2021, our Board approved an increase in Dr.&nbsp;Chakraborty&#146;s annual base salary for 2021 and subsequent years to $390,200 and an increase of his target annual bonus to 40% of his annual salary. In
January 2022, our Compensation Committee approved an increase in annual base salary for 2022 and subsequent years to $430,000. In addition, under the offer letter Dr.&nbsp;Chakraborty received a <FONT STYLE="white-space:nowrap">one-time</FONT>
signing bonus equal to $30,000, with an additional payment to cover all taxes resulting from the payment of the signing bonus. The offer letter further provided for the grant of stock options. Dr.&nbsp;Chakraborty is also eligible to receive
benefits pursuant to the Severance Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr.&nbsp;Christopher Slapak </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into an offer letter with Dr.&nbsp;Slapak in July 2020 in connection with his hiring as our full-time Chief Medical Officer. The
offer letter provided for a base salary of $380,000 per year and a target annual bonus equal to 30% of Dr.&nbsp;Slapak&#146;s annual base salary based on the achievement of goals established by our Board.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Additionally, in January 2021, our Board approved an increase in Dr.&nbsp;Slapak&#146;s annual base salary for 2021 and subsequent years to $432,600 and an increase of his target annual bonus to
40% of his annual salary. In January 2022, our Compensation Committee approved an increase in annual base salary for 2022 and subsequent years to $450,100. The offer letter further provided for the grant of stock options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to benefits pursuant to the Severance Plan, as described above, Dr.&nbsp;Slapak is also entitled to severance benefits pursuant to
his offer letter. Pursuant to his offer letter, if we terminate Dr.&nbsp;Slapak&#146;s employment without cause, or if Dr.&nbsp;Slapak terminates his employment for good reason, each as defined in Dr.&nbsp;Slapak&#146;s offer letter, he will be
entitled to (i)&nbsp;cash severance equal to continued base salary payments commencing on Dr.&nbsp;Slapak&#146;s termination date until the first anniversary of such termination date (the &#147;Slapak Severance Period&#148;), paid in equal monthly
installments in accordance with our standard payroll policies and (ii)&nbsp;if he timely elects to continue health coverage through COBRA, direct payment of, or reimbursement for, COBRA premiums for Dr.&nbsp;Slapak and his covered dependents for the
Slapak Severance Period or, if earlier, until Dr.&nbsp;Slapak is eligible for healthcare coverage under another employer&#146;s plan. These severance benefits are conditioned upon Dr.&nbsp;Slapak&#146;s resignation from all positions with us,
execution of a release agreement, return of all company property and compliance with his confidentiality, intellectual property assignment and <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Slapak provided consulting services to us prior to the commencement of his full-time employment as our Chief Medical Officer and
received consulting fees of $500 per hour. See &#147;Certain Relationships and Related Party Transactions&#151;Consulting Agreement with Christopher Slapak Consulting LLC.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2022, Dr.&nbsp;Slapak resigned from his position, effective May&nbsp;6, 2022. In recognition of Dr.&nbsp;Slapak&#146;s service to our
Company, we elected to provide Dr.&nbsp;Slapak with severance benefits that are consistent with those contemplated by our Severance Plan. We intend to enter into a separation agreement with Dr.&nbsp;Slapak memorializing these terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Incentive Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2021 Equity Incentive Plan
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board adopted and our stockholders approved our 2021 Plan in February 2021. The 2021 Plan became effective on February&nbsp;5,
2021, from which point no further grants were or will be made under our 2015 Plan, as described in &#147;&#151;Equity Incentive Plans&#151;2015 Stock Incentive Plan.&#148; Our 2021 Plan provides for the grant of stock options qualifying as incentive
stock options (&#147;ISOs&#148;) within the meaning of Section&nbsp;422 of the Code, to our employees and for the grant of nonstatutory stock options (&#147;NSOs&#148;), restricted stock awards, restricted stock unit awards, stock appreciation
rights, performance stock awards and other forms of stock compensation to our employees, consultants and directors. As of April&nbsp;18, 2022, there were options to purchase 2,419,993 shares of our Common Stock outstanding under the 2021 Plan, at a
weighted average exercise price of $11.45 per share, and 200 options to purchase shares of our Common Stock have been exercised. Our employees, officers, directors, consultants, and advisors are eligible to receive awards under the 2021 Plan;
however, incentive stock options may only be granted to our employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares</I>. As of April&nbsp;18, 2022, the number of
shares of our Common Stock reserved for issuance under our 2021 Plan is the sum of (i) 2,569,279 and (ii)&nbsp;the number of shares of our Common Stock subject to outstanding awards under our 2015 Plan that expire or are forfeited, canceled,
withheld to satisfy tax withholding or to purchase or exercise an award, repurchased by us or are otherwise terminated. The number of shares of our Common Stock reserved for issuance under our 2021 Plan automatically increases on January&nbsp;1 of
each year, for a period of ten years, from January&nbsp;1, 2022 continuing through January&nbsp;1, 2031, by 4% of the total number of shares of our Common Stock outstanding on December&nbsp;31 of the preceding calendar year, or a lesser number of
shares as may be determined by our Board. The maximum number of shares that may be issued pursuant to the exercise of ISOs under the 2021 Plan is 23,742,528. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Administration</I>. Our Board, or a duly authorized committee thereof (referred to herein
as the &#147;administrator&#148;), has the authority to administer our 2021 Plan. Our Board has delegated its authority to administer our 2021 Plan to our Compensation Committee under the terms of the Compensation Committee&#146;s charter. Our Board
may also delegate to one or more of our officers the authority to (i)&nbsp;designate employees other than officers to receive specified stock awards and (ii)&nbsp;determine the number of shares of our Common Stock to be subject to such stock awards.
Subject to the terms of our 2021 Plan, the administrator has the authority to determine the terms of awards, including recipients, the exercise price or strike price of stock awards, if any, the number of shares subject to each stock award, the fair
market value of a share of our Common Stock, the vesting schedule applicable to the awards, together with any vesting acceleration, the form of consideration, if any, payable upon exercise or settlement of the stock award and the terms and
conditions of the award agreements for use under our 2021 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The administrator has the power to modify outstanding awards under our
2021 Plan. Subject to the terms of our 2021 Plan, the administrator has the authority to reprice any outstanding option or stock award, cancel and <FONT STYLE="white-space:nowrap">re-grant</FONT> any outstanding option or stock award in exchange for
new stock awards, cash or other consideration, or take any other action that is treated as a repricing under generally accepted accounting principles, with the consent of any adversely affected participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions</I>. The following applies to stock awards under the 2021 Plan in the event of certain specified corporate
transactions, unless otherwise provided in a participant&#146;s stock award agreement or other written agreement with us or one of our affiliates or unless otherwise expressly provided by the plan administrator at the time of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a corporate transaction, any stock awards outstanding under the 2021 Plan may be assumed, continued or substituted for by any
surviving or acquiring corporation (or its parent company), and any reacquisition or repurchase rights held by us with respect to the stock award may be assigned to our successor (or its parent company). If the surviving or acquiring corporation (or
its parent company) does not assume, continue or substitute for such stock awards, then (i)&nbsp;with respect to any such stock awards that are held by participants whose continuous service has not terminated prior to the effective time of the
corporate transaction, or current participants, the vesting (and exercisability, if applicable) of such stock awards will be accelerated in full (or, in the case of performance awards with multiple vesting levels depending on the level of
performance, vesting will accelerate at 100% of the target level) to a date prior to the effective time of the corporate transaction (contingent upon the effectiveness of the corporate transaction), and such stock awards will terminate if not
exercised (if applicable) at or prior to the effective time of the corporate transaction, and any reacquisition or repurchase rights held by us with respect to such stock awards will lapse (contingent upon the effectiveness of the corporate
transaction), and (ii)&nbsp;any such stock awards that are held by persons other than current participants will terminate if not exercised (if applicable) prior to the effective time of the corporate transaction, except that any reacquisition or
repurchase rights held by us with respect to such stock awards will not terminate and may continue to be exercised notwithstanding the corporate transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event a stock award will terminate if not exercised prior to the effective time of a corporate transaction, the plan administrator may
provide, in its sole discretion, that the holder of such stock award may not exercise such stock award but instead will receive a payment equal in value to the excess (if any) of (i)&nbsp;the per share amount payable to holders of our Common Stock
in connection with the corporate transaction, over (ii)&nbsp;any per share exercise price payable by such holder, if applicable. In addition, any escrow, holdback, earn out or similar provisions in the definitive agreement for the corporate
transaction may apply to such payment to the same extent and in the same manner as such provisions apply to the holders of our Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the 2021 Plan, a significant corporate transaction is generally the consummation of (i)&nbsp;a sale or other disposition of all or
substantially all of our consolidated assets; (ii)&nbsp;a sale or other disposition of at least 50% of our outstanding securities; (iii)&nbsp;a merger, consolidation or similar transaction following which we are not the surviving corporation; or
(iv)&nbsp;a merger, consolidation or similar transaction following which we are the surviving </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
corporation but the shares of our Common Stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment or Termination</I>. Our Board has the authority to amend, suspend, or terminate our 2021 Plan, provided that such action does not
materially impair the existing rights of any participant without such participant&#146;s written consent. No ISOs may be granted after the tenth anniversary of the date our Board adopts our 2021 Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2015 Stock Incentive Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2015 Plan
was adopted by our Board and approved by our stockholders in December 2015. The 2015 Plan provides for the grant of ISOs, NSOs, restricted stock awards, restricted stock units, stock appreciation rights and other stock-based awards. Our employees,
officers, directors, consultants and advisors are eligible to receive awards under the 2015 Plan; however, ISOs may only be granted to our employees. As of April&nbsp;18, 2022, there were 3,140,062 shares of Common Stock issuable upon the exercise
of stock options outstanding under the 2015 Plan at a weighted-average exercise price of $2.39 per share, and options to purchase 1,149,714 shares of our Common Stock had been exercised, including 573,128 restricted shares of Common Stock that were
issued related to early exercise of unvested options. As of February&nbsp;5, 2021, we ceased making grants of stock options or other awards under the 2015 Plan. However, any shares of Common Stock subject to awards under our 2015 Plan that expire,
terminate, or otherwise are surrendered or canceled without being fully exercised, are forfeited (including as the result of shares of Common Stock subject to such award being repurchased by us at the original issuance price pursuant to a
contractual repurchase right) or results in any Common Stock not being issued will become available for issuance under our 2021 Plan. Further, shares of Common Stock tendered to us by a participant to exercise an award shall be added to shares of
Common Stock available for the grant of awards under the 2021 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Administration</I>. Our Board, or a committee appointed by our
Board, administers the 2015 Plan and, subject to any limitations set forth in the 2015 Plan, will select the recipients of awards, determine the number of shares of Common Stock to be subject to such stock awards and specify the other terms and
conditions, including the exercise price or purchase price and vesting schedule, applicable to such stock awards. Our Board has delegated its authority to administer our 2015 Plan to our Compensation Committee under the terms of the Compensation
Committee&#146;s charter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a stock award granted under the 2015 Plan expires, terminates or otherwise is surrendered or canceled
without being exercised in full, is forfeited in whole or in part (including as the result of shares of Common Stock subject to such award being repurchased by us at the original issuance price pursuant to a contractual repurchase right), or results
in any Common Stock not being issued, the shares of our Common Stock not acquired pursuant to the stock award again will become available for subsequent issuance under the 2021 Plan. Further, shares of Common Stock tendered to us by a participant to
exercise an award shall be added to shares of Common Stock available for the grant of awards under the 2021 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Changes to Capital
Structure. </I>Upon the occurrence of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of shares, spinoff, or other similar change in capitalization or event, or any dividend or
distribution to holders of our Common Stock other than an ordinary cash dividend, under the terms of the 2015 Plan, we are required to equitably adjust (or make substitute awards, if applicable), in the manner determined by our Board or Compensation
Committee: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and class of securities available under the 2015 Plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and class of securities and exercise price per share of each outstanding option;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the share and <FONT STYLE="white-space:nowrap">per-share</FONT> provisions and the measurement price of each
outstanding stock appreciation right; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares subject to and the repurchase price per share subject to each outstanding restricted stock
award; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the share and <FONT STYLE="white-space:nowrap">per-share-related</FONT> provisions and the purchase price, if
any, of each outstanding other stock-based award. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Reorganization Events</I>. Upon the occurrence of a merger or
consolidation of our company with or into another entity as a result of which all of our Common Stock is converted into or exchanged for the right to receive cash, securities, or other property or is cancelled; any transfer or disposition of all of
our Common Stock for cash, securities, or other property pursuant to a share exchange or other transaction; or a liquidation or dissolution of our company, our Board may, on such terms as our Board determines, take any one or more of the following
actions pursuant to the 2015 Plan, as to some or all outstanding awards, other than restricted stock awards: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that awards shall be assumed, or substantially equivalent awards shall be substituted, by the acquiring
or succeeding corporation (or an affiliate thereof); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon written notice to a plan participant, provide that the participant&#146;s unexercised awards will terminate
immediately prior to the consummation of such transaction unless exercised by the participant (to the extent then exercisable) within a specified period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that outstanding awards shall become exercisable, realizable or deliverable, or restrictions applicable
to an award shall lapse, in whole or in part, prior to or upon such transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the event of a transaction under the terms of which holders of Common Stock will receive upon consummation
thereof a cash payment for each share surrendered in the transaction, make or provide for a cash payment to a plan participant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that, in connection with a liquidation of dissolution of the company, awards shall convert into the right
to receive liquidation proceeds; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any combination of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board is not obligated under the 2015 Plan to treat all awards, all awards held by a participant, or all awards of the same type,
identically. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the occurrence of any corporate transaction described above, other than our liquidation or dissolution, our repurchase
and other rights under each outstanding restricted stock award will continue for the benefit of our successor and will, unless our Board or Compensation Committee determines otherwise, apply to the cash, securities, or other property which our
Common Stock was converted into or exchanged for in the transaction in the same manner and to the same extent as they applied to the Common Stock subject to the restricted stock award; provided, however, that our Board or the Compensation Committee
may provide termination or deemed satisfaction of such repurchase or other rights under the restricted stock award agreement, either initially or by amendment, or provide for forfeiture of such restricted stock if issued at no cost. Upon our
liquidation or dissolution, except to the extent specifically provided to the contrary in the restricted stock award agreement or any other agreement between the plan participant and us, all restrictions and conditions on all restricted stock awards
then outstanding will automatically be deemed terminated or satisfied. Our Board or our Compensation Committee, in their sole discretion, may accelerate the exercisability of any option or time at which any restrictions shall lapse or be removed
from any restricted stock award, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment and Termination</I>. Our Board and the Compensation Committee has the
authority to amend, suspend or terminate the 2015 Plan, provided that, if approval of our stockholders is required, our Board and Compensation Committee may not effect such modification or amendment without such approval. Unless otherwise specified,
any amendment to the 2015 Plan shall apply to all outstanding awards, and be binding on holders of such awards, at the time the amendment is adopted, provided that our Board determines such amendment does not materially and adversely affect the
rights of the holders. Unless terminated sooner by our Board or Compensation Committee, the 2015 Plan will automatically terminate on December&nbsp;30, 2025. No stock awards may be granted under the 2015 Plan while it is suspended or terminated.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2021 Employee Stock Purchase Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board adopted and our stockholders approved our 2021 Employee Stock Purchase Plan (the &#147;ESPP&#148;) in February 2021. The ESPP became
effective on February&nbsp;5, 2021. The purpose of the ESPP is to secure the services of new employees, to retain the services of existing employees and to provide incentives for such individuals to exert maximum efforts toward our success. The ESPP
includes two components. One component is designed to allow eligible U.S. employees to purchase Common Stock in a manner that may qualify for favorable tax treatment under Section&nbsp;423 of the Code. In addition, purchase rights may be granted
under a component that does not qualify for such favorable tax treatment when necessary or appropriate to permit participation by eligible employees who are foreign nationals or employed outside of the United States while complying with applicable
foreign laws. The ESPP is intended to qualify as an &#147;employee stock purchase plan&#148; within the meaning of Section&nbsp;423 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Share Reserve</I>. The ESPP authorizes the issuance of shares of our Common Stock pursuant to purchase rights granted to our employees or
to employees of any of our designated affiliates. The ESPP provides participating employees with the opportunity to purchase up to an aggregate of 745,754 shares of our Common Stock. The number of shares of our Common Stock reserved for issuance
automatically increases on January&nbsp;1 of each calendar year, from January&nbsp;1, 2022 through January&nbsp;1, 2031, by the lesser of (i) 1% of the total number of shares of our Common Stock outstanding on December&nbsp;31 of the preceding
calendar year, and (ii) 1,800,000 shares; provided, that prior to the date of any such increase, our Board may determine that such increase will be less than the amount set forth in clauses (i)&nbsp;and (ii). If purchase rights granted under the
ESPP terminate without having been exercised, the shares of our Common Stock not purchased under such purchase rights will again become available for issuance under the ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Administration</I>. Our Board has delegated concurrent authority to administer the ESPP to our Compensation Committee. The ESPP is
implemented through a series of offerings under which eligible employees are granted purchase rights to purchase shares of our Common Stock on specified dates during such offerings. Under the ESPP, we may specify offerings with durations of not more
than 27 months, and may specify shorter purchase periods within each offering. Each offering will have one or more purchase dates on which shares of our Common Stock will be purchased for employees participating in the offering. An offering under
the ESPP may be terminated under certain circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions</I>. In the event of certain significant corporate
transactions, including (i)&nbsp;a sale of all or substantially all of our assets, (ii)&nbsp;the sale or disposition of more than 50% of our outstanding securities, (iii)&nbsp;the consummation of a merger or consolidation where we do not survive the
transactions and (iv)&nbsp;the consummation of a merger or consolidation where we do survive the transaction but the shares of our Common Stock outstanding immediately prior to such transaction are converted or exchanged into other property by
virtue of the transaction, any then-outstanding rights to purchase our stock under the ESPP may be assumed, continued or substituted for by any surviving or acquiring entity (or its parent company). If the surviving or acquiring entity (or its
parent company) elects not to assume, continue or substitute for such purchase rights, then the participants&#146; accumulated payroll contributions will be used to purchase shares of our Common Stock within ten business days prior to such corporate
transaction, and such purchase rights will terminate immediately. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendments or Termination</I>. Our Board and Compensation Committee
has the authority to amend or terminate our ESPP, provided that except in certain circumstances such amendment or termination may not materially impair any outstanding purchase rights without the holder&#146;s consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of April&nbsp;18, 2022, we have not made any offerings under our ESPP. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Liability and Indemnification Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation (&#147;Certificate of Incorporation&#148;) contains provisions that limit the liability
of our current and former directors for monetary damages to the fullest extent permitted by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Delaware law. Delaware law provides that directors of a corporation will not be personally liable for monetary damages for any breach of fiduciary duties as directors, except liability for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of the director&#146;s duty of loyalty to the corporation or its stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section&nbsp;174 of
the Delaware General Corporation Law; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These limitations of liability do not apply to liabilities arising under federal securities laws and does not affect the availability of
equitable remedies such as injunctive relief or rescission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Certificate of Incorporation and Bylaws provide that we are required to
indemnify our directors to the fullest extent permitted by Delaware law. Our Bylaws will also provide that, upon satisfaction of certain conditions, we are required to advance expenses incurred by a director in advance of the final disposition of
any action or proceeding, and permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted to
indemnify him or her under the provisions of Delaware law. Our Bylaws also provide our Board with discretion to indemnify our officers and employees when determined appropriate by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors and executive officers. With certain exceptions, these agreements
provide for indemnification for related expenses including, among other things, attorneys&#146; fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding. We believe that these Bylaw provisions
and indemnification agreements are necessary to attract and retain qualified persons as directors and executive officers. We also maintain customary directors&#146; and officers&#146; liability insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitation of liability and indemnification provisions in our Certificate of Incorporation and Bylaws may discourage stockholders from
bringing a lawsuit against our directors for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and other
stockholders. Further, a stockholder&#146;s investment may be adversely affected to the extent that we pay the costs of settlement and damage awards against directors and officers as required by these indemnification provisions. At present, there is
no pending litigation or proceeding involving any of our directors, officers or employees for which indemnification is sought and we are not aware of any threatened litigation that may result in claims for indemnification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted for our directors, executive officers or persons
controlling us, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> Sales Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our directors and executive officers may adopt, and some have adopted, written plans, known as
<FONT STYLE="white-space:nowrap">Rule&nbsp;10b5-1</FONT> plans, in which they will contract with a broker to buy or sell shares of our Common Stock on a periodic basis. Under a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan, a broker
executes trades pursuant to parameters established by the director or officer when entering into the plan, without further direction from them. The director or officer may amend a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan in some
circumstances and may terminate a plan at any time. Our directors and executive officers also may buy or sell additional shares outside of a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan when they are not in possession of material
nonpublic information subject to compliance with the terms of our insider trading policy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc268305_13"></A>DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2021 Director Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table sets forth information regarding the compensation earned for service on our Board in 2021 by our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, including the outstanding equity awards held by our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors as of December&nbsp;31, 2021. Dr.&nbsp;Ang, our President and Chief Executive Officer, is also a member of our Board but did not receive any additional compensation for service as a director.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees<BR>Earned&nbsp;or&nbsp;Paid<BR>in Cash&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(1)(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew Patterson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">304,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">366,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniella Beckman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">304,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">356,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Lubner</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">304,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">345,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sven (Bill) Ante Lundberg, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">304,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">343,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kush Parmar, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">304,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">342,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joshua Resnick, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">304,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">348,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This column reflects the full grant date fair value of options granted during the year measured pursuant to ASC
718, which is the basis for computing stock-based compensation in our financial statements. See Note&nbsp;9 to our consolidated financial statements in our 2021 Annual Report for information concerning certain of the specific assumptions we used in
valuing options. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The table below shows the aggregate number equity awards outstanding for each of our directors who is not a
named executive officer, as of December&nbsp;31, 2021. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Outstanding&nbsp;Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Outstanding<BR>Unvested&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew Patterson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniella Beckman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Lubner</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sven (Bill) Ante Lundberg, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kush Parmar, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joshua Resnick, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board adopted a <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy in January 2021 that became effective on
February&nbsp;5, 2021 and is applicable to all of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. This compensation policy provides that each such non-employee director will receive the following compensation for service on our
Board: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an annual cash retainer of $35,000; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an additional annual cash retainer for service as Chairperson of the Board in an amount to be determined by the
Board each year and which has been set at $30,000 for 2021 and subsequent years; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an additional annual cash retainer of $7,500, $5,000 and $4,000 for service as a member of the Audit Committee,
Compensation Committee and the Nominating and Corporate Governance Committee, respectively; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an additional annual cash retainer of $15,000, $10,000 and $8,000 for service as chair of the Audit Committee,
Compensation Committee and the Nominating and Corporate Governance Committee, respectively; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an initial option grant to purchase 33,823 shares of our Common Stock on the date of each such <FONT
STYLE="white-space:nowrap">non-employee</FONT> director&#146;s appointment to our Board, with the shares vesting in 36 equal monthly installments, subject to continued service as a director through the vesting date; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an annual option grant to purchase 16,911 shares of our Common Stock on the date of each of our annual
stockholder meetings, beginning with our Annual Meeting, with the shares vesting on the earlier of the first anniversary of the date of grant or the next annual stockholders meeting, subject to continued service as a director though the applicable
vesting date. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also will continue to reimburse our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for
reasonable travel and other expenses incurred in connection with attending our Board and committee meetings. We do not pay any compensation to our President and Chief Executive Officer in connection with his service on our Board. The compensation
that we pay to our President and Chief Executive Officer is discussed earlier in the &#147;Executive Compensation&#148; section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of
the option grants described above will be granted under our 2021 Plan, the terms of which are described in more detail above under the section titled &#147;Executive Compensation&#151;Equity Incentive Plans&#151;2021 Equity Incentive Plan.&#148;
Each option awarded to directors under the <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy will be subject to accelerated vesting upon a &#147;change in control&#148; (as defined in the 2021 Plan). The term of each
option will be ten years, subject to earlier termination as provided in the 2021 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board approved a grant to each of our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors of an option to purchase 16,900 shares of our Common Stock effective on February&nbsp;5, 2021 with an exercise price per share equal $18.00 per share, with the shares vesting in 36 equal
monthly installments, subject to continued service through the vesting date. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc268305_14"></A>DELINQUENT SECTION&nbsp;16(A)
REPORTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;16(a) of the Exchange Act requires our directors, executive officers and beneficial owners of more than 10% of
our Common Stock to file reports of holdings and transactions in our Common Stock and other securities of our company with the SEC. Based solely on our review of copies of such forms that we have received, or written representations from reporting
persons, we believe that during the fiscal year ended December&nbsp;31, 2021, all executive officers, directors and greater than 10% stockholders complied with all applicable filing requirements under Section&nbsp;16(a) of the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc268305_15"></A>EQUITY COMPENSATION PLANS AT DECEMBER&nbsp;31, 2021 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table contains information about our equity compensation plans as of December&nbsp;31, 2021. As of December&nbsp;31, 2021, we
had three equity compensation plans. See &#147;Executive Compensation&#151;Equity Incentive Plans&#148; for a description of the material terms of each of our equity compensation plans. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Plan category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;securities<BR>to&nbsp;be&nbsp;issued upon<BR>exercise of<BR>outstanding options,<BR>warrants and rights<BR>(a)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-average</FONT><BR>exercise price of<BR>outstanding&nbsp;options,<BR>warrants and rights<BR>(b)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;securities<BR>remaining available<BR>for future issuance<BR>under equity<BR>compensation plans<BR>(excluding
securities<BR>reflected&nbsp;in&nbsp;column(a))<BR>(c)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans approved by security holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,886,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,643,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by security holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,086,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,643,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table above does not include any amounts issuable under the ESPP because we have not made any offerings
under such plan as of December&nbsp;31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we granted an option to purchase shares of our Common Stock to an advisor
outside of any equity compensation plan approved by our stockholders, but subject to the terms and conditions of the 2015 Plan. The stock option award to purchase 294,117 shares of our Common Stock had an exercise price of $28.29 per share, which
was four times greater than the fair market value of our Common Stock on the date of grant, as determined contemporaneously by our Board, and is scheduled to vest over four years, with 25% of the shares scheduled to vest on October&nbsp;21, 2021,
and the remainder scheduled to vest ratably at the end of each subsequent month thereafter through October&nbsp;21, 2024, subject to such advisor&#146;s continued service relationship with our company through the applicable vesting dates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc268305_16"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a description of transactions since January&nbsp;1, 2020 to which we have been a participant in which the amount involved
exceeded or will exceed $120,000, and in which any of our directors, executive officers or holders of more than 5% of our voting stock, or any members of their immediate family, had or will have a direct or indirect material interest, other than
equity and other compensation, termination, change in control and other arrangements which are described under &#147;Executive Compensation.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Series B Preferred Stock Financing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
June 2020, we entered into a preferred stock purchase agreement with certain investors, including beneficial owners of greater than 5% of our voting stock and affiliates of members of our Board, pursuant to which we issued and sold to such investors
an aggregate of 124,519,220 shares of our Series B preferred stock in June 2020 at a purchase price of $0.52 per share for aggregate gross proceeds of $64.7&nbsp;million, and an aggregate of 87,259,605 additional shares of our Series B preferred
stock in January 2021 at a purchase price of $0.52 per shares for aggregate gross proceeds of $45.4&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below sets
forth the aggregate number of shares of Series B preferred stock issued to our related parties: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B<BR>Preferred<BR>Stock<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Purchase<BR>Price<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with RA Capital Healthcare Fund, L.P.&nbsp;<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76,923,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with FMR, LLC
<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,259,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,375,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with 5AM Ventures VI, L.P.
<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,461,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PureTech Health LLC <SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,923,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Joshua Resnick, a member of our Board, is a managing director at RA Capital Management. RA Capital Healthcare
Fund, L.P. and its affiliates hold more than 5% of our voting stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Entities affiliated with FMR, LLC collectively hold more than 5% of our voting stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Kush Parmar, a member of our Board, is one of the managing members of 5AM Partners VI, LLC, the general partner
of 5AM Ventures VI, L.P. and, as a result, may be deemed to share voting and investment power with respect to the shares held by 5AM Ventures VI, L.P. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Bharatt Chowrira, a former member of our Board, is the president and chief of business and strategy of PureTech
Health LLC. PureTech Health LLC holds more than 5% of our voting stock. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of our initial
public offering (&#147;IPO&#148;), all outstanding shares of our Series B preferred stock were converted into shares of our Common Stock at a ratio of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">13.6-for-1</FONT></FONT> and the
foregoing amounts are listed on a <FONT STYLE="white-space:nowrap">pre-conversion</FONT> basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Affiliations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of our directors are affiliated with and serve on our Board as representatives of entities which beneficially own or owned 5% or more of
our Common Stock, as indicated in the table below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Director</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Principal Stockholder</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kush Parmar, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5AM Ventures VI, L.P. and affiliates</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joshua Resnick, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>RA Capital Healthcare Fund, L.P. and its affiliates</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Participation in Initial Public Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our IPO, funds affiliated with RA Capital Healthcare Fund, L.P., 5AM Ventures VI, L.P. and FMR, LLC, each of whom was one of our 5%
stockholders at the time of our IPO, purchased 3,222,222, 555,555 and 1,195,566 shares of our Common Stock, respectively. Such purchases were made through the underwriters at the IPO offering price of $18.00 per share for an aggregate purchase price
of $89.5&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Promissory Note with Robert Ang </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2019, we entered into a limited recourse promissory note with Dr.&nbsp;Ang, our President and Chief Executive Officer, pursuant to
which we loaned him the principal amount of $497,920.10 to early exercise stock options. The note accrued interest at 1.5% compounding semi-annually and could be prepaid at any time without penalty. We forgave the principal amount and accrued
interest under this promissory note in full in October 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Consulting Agreement with Christopher Slapak Consulting LLC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2019, we entered into a consulting agreement with Christopher Slapak Consulting LLC, an entity wholly owned by Christopher Slapak,
M.D., who is now our Chief Medical Officer. Pursuant to the consulting agreement, Dr.&nbsp;Slapak agreed to provide services related to the customary job functions of a chief medical officer. In July 2020, Dr.&nbsp;Slapak joined us as our full-time
Chief Medical Officer, at which point the consulting agreement was terminated. During the length of the consulting agreement, we paid Christopher Slapak Consulting LLC an aggregate of $0.44&nbsp;million for consulting services and reimbursement of
certain expenses. In April 2022, Dr.&nbsp;Slapak resigned from his position, effective May&nbsp;6, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Investors&#146; Rights
Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a party to an amended and restated investors&#146; rights agreement (the &#147;Investors&#146; Rights
Agreement&#148;), dated as of June&nbsp;30, 2020, with holders of our previously-outstanding preferred stock, including certain of our 5% stockholders and their affiliates and entities affiliated with certain of our officers and directors. This
agreement provides these holders the right to demand that we file a registration statement or request that their shares be covered by a registration statement that we are otherwise filing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Employment Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into offer letter agreements with each of our executive officers. For more information regarding our employment agreements with
our named executive officers, see &#147;Executive Compensation&#151;Offer Letters and Potential Payments and Benefits Upon Termination or Change in Control.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Certificate of Incorporation contains provisions limiting the liability of directors, and our Bylaws provide that we will indemnify each of
our directors to the fullest extent permitted under Delaware law. Our Certificate of Incorporation and Bylaws also provide our Board with discretion to indemnify our officers and employees when determined appropriate by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we have entered into indemnification agreements with each of our directors and executive officers. For more information regarding
these agreements, see &#147;Executive Compensation&#151;Limitations on Liability and Indemnification Matters.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Related Person
Transaction Policy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have adopted a related person transaction policy that sets forth our procedures for the identification, review, consideration
and approval or ratification of related person transactions, which policy became effective on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
February 4, 2021. For purposes of our policy only, a related person transaction will be a transaction, arrangement or relationship, or any series of similar transactions, arrangements or
relationships, in which we and any related person are, were or will be participants in which the amount involved exceeds $120,000. Transactions involving compensation for services provided to us as an employee or director will not be covered by this
policy. A related person will be any executive officer, director or beneficial owner of more than 5% of any class of our voting securities, including any of their immediate family members and any entity owned or controlled by such persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the policy, if a transaction has been identified as a related person transaction, including any transaction that was not a related
person transaction when originally consummated or any transaction that was not initially identified as a related person transaction prior to consummation, our management must present information regarding the related person transaction to our Audit
Committee, or, if Audit Committee approval would be inappropriate, to another independent body of our Board, for review, consideration and approval or ratification. The presentation must include a description of, among other things, the material
facts, the interests, direct and indirect, of the related persons, the benefits to us of the transaction and whether the transaction is on terms that are comparable to the terms available to or from, as the case may be, an unrelated third party or
to or from employees generally. Under the policy, we will collect information that we deem reasonably necessary from each director, executive officer and, to the extent feasible, significant stockholder to enable us to identify any existing or
potential related-person transactions and to effectuate the terms of the policy. In addition, under our Code of Conduct, our employees and directors have an affirmative responsibility to disclose any transaction or relationship that reasonably could
be expected to give rise to a conflict of interest. In considering related person transactions, our Audit Committee, or other independent body of our Board, will take into account the relevant available facts and circumstances including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risks, costs and benefits to us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact on a director&#146;s independence in the event that the related person is a director, immediate family
member of a director or an entity with which a director is affiliated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of other sources for comparable services or products; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms available to or from, as the case may be, unrelated third parties or to or from employees generally.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The policy requires that, in determining whether to approve, ratify or reject a related person transaction, our Audit
Committee, or other independent body of our Board, must consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best interests and those of our stockholders, as our Audit Committee, or other
independent body of our Board, determines in the good faith exercise of its discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the transactions described in this section
were entered into prior to the adoption of this policy. Although we have not had a written policy for the review and approval of transactions with related persons, our Board has historically reviewed and approved any transaction where a director or
officer had a financial interest, including the transactions described above. Prior to approving such a transaction, the material facts as to a director&#146;s or officer&#146;s relationship or interest in the agreement or transaction were disclosed
to our Board. Our Board took this information into account when evaluating the transaction and in determining whether such transaction was fair to us and in the best interest of all our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc268305_17"></A>Householding of Proxy Materials </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC has adopted rules that permit companies and banks, brokers and other nominee record holders to satisfy the delivery requirements for
Notices of Internet Availability of Proxy Materials or other Annual Meeting materials with respect to two or more stockholders sharing the same address by delivering a single Notice of Internet Availability of Proxy Materials or other Annual Meeting
materials addressed to those stockholders. This process, which is commonly referred to as &#147;householding,&#148; potentially means extra convenience for stockholders and cost savings for companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This year, a number of brokers with account holders who are our stockholders will be &#147;householding&#148; our proxy materials. A single
Notice of Internet Availability of Proxy Materials will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they
will be &#147;householding&#148; communications to your address, &#147;householding&#148; will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in &#147;householding&#148;
and would prefer to receive a separate Notice of Internet Availability of Proxy Materials, please notify your broker or notify us by sending a written request to: Vor Biopharma Inc., 100 Cambridgepark Drive, Suite 101, Cambridge, Massachusetts
02140, Attn: Investor Relations, telephone: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-655-6580.You</FONT></FONT> will be removed from the householding program, after which you will receive an individual copy of the proxy
materials promptly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholders who currently receive multiple copies of the Notices of Internet Availability of Proxy Materials at
their addresses and would like to request &#147;householding&#148; of their communications should contact their brokers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc268305_18"></A>OTHER MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly brought
before the meeting, it is the intention of the persons named in the accompanying proxy to vote on such matters in accordance with their best judgment. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By Order of the Board of Directors</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">


<IMG SRC="g268305g01a04.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Ang</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>President and Chief Executive Officer</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">April&nbsp;28, 2022</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A copy of our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended
December&nbsp;31, 2021 is available free of charge at the SEC&#146;s web site at www.sec.gov. Stockholders can also access this proxy statement and our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> at the investors section of
our website at www.vorbio.com. A copy of our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> to the SEC on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021 is available without charge
upon written request to: Corporate Secretary, Vor Biopharma Inc. 100 Cambridgepark Drive, Suite 101, Cambridge, Massachusetts 02140. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g268305dsp050.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">VOR BIOPHARMA INC. 100 CAMBRIDGEPARK DRIVE SUITE 101 CAMBRIDGE, MA 02140 SCAN TO VIEW MATERIALS &amp; VOTE w VOTE BY INTERNET Before The
Meeting - Go to www.proxyvote.com or scan the QR Barcode above Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time on June 13, 2022. Have your proxy card in hand when you
access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form. During The Meeting - Go to www.virtualshareholdermeeting.com/VOR2022 You may attend the meeting via the Internet and vote
during the meeting. Have the information that is printed in the box marked by the arrow available and follow the instructions. VOTE BY PHONE - 1-800-690-6903 Use any touch-tone telephone to transmit your voting instructions up until 11:59 p.m.
Eastern Time on June 13, 2022. Have your proxy card in hand when you call and then follow the instructions. VOTE BY MAIL Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing,
c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: D82551-P68177 KEEP THIS PORTION FOR YOUR RECORDS THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. DETACH AND RETURN THIS PORTION
ONLY VOR BIOPHARMA INC. For Withhold For All To withhold authority to vote for any individual All All Except nominee(s), mark &#147;For All Except&#148; and write the The Board of Directors recommends you vote FOR the number(s) of the nominee(s) on
the line below. following: 1. Election of three Class I Directors, each to serve until the 2025 Annual Meeting of Stockholders Nominees: 01) Matthew Patterson 02) Daniella Beckman 03) Kush Parmar, M.D., Ph.D. The Board of Directors recommends you
vote FOR the following proposal: For Against Abstain 2. Ratification of the appointment of Ernst &amp; Young LLP as the Company&#146;s independent registered public accounting firm for fiscal year ending December 31, 2022. Note: Such other business
as may properly come before the meeting or any adjournment thereof. NOTE: Please sign as name(s) appear(s) hereon. Joint owners should each sign. When signing as attorney, executor, administrator, trustee or guardian, please give full title as such.
Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g268305dsp051.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting: The Notice and Proxy Statement and Annual Report
on Form 10-K are available at www.proxyvote.com. D82552-P68177 VOR BIOPHARMA INC. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS OF VOR BIOPHARMA INC. IN CONNECTION WITH THE ANNUAL MEETING OF STOCKHOLDERS June 14, 2022 12:00 P.M.
Eastern Time The stockholder(s) hereby appoint(s) Robert Ang and Nathan Jorgensen, and each of them, with power to act without the other and with power of substitution, as proxies and attorneys-in-fact and hereby authorize(s) them to represent and
vote, as provided on the other side, all the shares of Vor Biopharma Inc.&#146;s Common Stock which the stockholder(s) is/are entitled to vote and, in their discretion, to vote upon such other business as may properly come before the Annual Meeting
of Stockholders of Vor Biopharma Inc. to be held at 12:00 P.M. Eastern Time on June 14, 2022, virtually at www.virtualshareholdermeeting.com/VOR2022, or any adjournment thereof, with all powers which the stockholder(s) would possess if present at
the meeting. In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting or any adjournment or postponement thereof. THIS PROXY, WHEN PROPERLY EXECUTED, WILL BE VOTED AS DIRECTED HEREIN BY
THE STOCKHOLDER(S). IF NO SUCH DIRECTIONS ARE MADE, THIS PROXY WILL BE VOTED IN ACCORDANCE WITH THE BOARD OF DIRECTORS&#146; RECOMMENDATIONS. (Continued and to be marked, dated and signed on the other side) </FONT></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g268305dsp050.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g268305dsp050.jpg
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M/"]X.GAM<&UE=&$^(#P_>'!A8VME="!E;F0](G(B/S[_[@ .061O8F4 9,
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M P& P.%OM"?_ &H_>[_S,3_ZH.>8Y.\^&/@[I8<*3\E?_LY=_P#_ *)]5_\
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M#*SX:2D^ P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M9+5Y>GMH<VPU%=##UO-^N2XRPZ(B);8<S/V*TT.LV&UB4!#Y4?\ 53A[<6=
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MJ*M)^:CTS6TZ'MXLQSBU>8=JL?.!MH&5(16XAXR0Z?;P$BA&QY*KZ'Q)50!
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MK1@DFRDST(7J)61I%F0PWI$HO]6EYQ#_ ,&U:)Q\5(CN6UZD.<8I<'R$C4L
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M[U8)*FC") QMB,YMM;^T"."K;'SWMP41,."/+ 3+EU\9>B(D UTTFXW=K'7
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M088FWUVI6FUDDDV9)&KDPPJ5*TA&T_&(-L(;9?<,\UIX@E:Q/,6@2W>:'0#
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M2XDIEN1%E1G6WXTF.\C3C+[#[2EM/,NMJTI*D[VE6M_'6_A@?? 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M\M,LL!761,%L9%;9?U&^RTZC.-.-I3I)=TLG=_$'F-NK(^NQI%B$(!\K#<F
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M9$CP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M/CQI^PGPQVQ<T,BF8,O3:!A!I;OS9,%AB3"4Z<S$1$-Z\.3 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MDMH)<=%CE.$66[<[[GR:W=, =(D7>N1MCA-R+N6UJFV@G;>D3QQ%<&= ?F!
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MOL3%2(R(\E'J6-T='\WXN]A''J+<F>B";-(Y_8)UP <^-F^F;JH8FP!N J
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M+B*U\G:1<3'>EK=K-=C.%>!=CX8&OAX#60]XN%AYTF4]3V^AC;#&IH(/5[0
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M5N+#$FWB$:2^V\(>BPI\*,3AC94"1-9DZ+%<ZMF2H3MJ>3^48$+#ZB4)2+=
M+46[F)5R@W6S0RMOW-M%<%U6/>H<V,*I-:81$B2JY)KL<T/?0U&9CRV'GW":
M7"H103R;#*7--#>QSYHSFW,]U]^'(Z#,(S&0_=[@4MZ(T)/0S%=#EB?*M#]N
M"C>R]DW%<9@K)RY#+KBRZ+*M=9[U?+19=5O7;:A<+-;+$7!75^QDP7- 7%9G
M*IR*<!75%'FA@NWP+_\ 0HDQ=C$GTEFWY3CWV8O>EDTA,/'T5Y(D.C&3G58=
M\KU1L5?8[H+"F[3'(LU.Z=1 Q*K*\?7&(1::VJ#QR/49!%;3>E#MS["VZPZX
MXVK:!-<D!X%7?+2LW3DZ.@_G*.5"SWC1F]NV*T12;E <K7BQ]V$PIB733\N=
M1K[?9#4C<9K4A,.U#')>T?\ O#;K99V\F XU'\E:3?HU@O0KM!>E_G>GH.PF
MDVDMK<::+\E(?U#E>,W>XSS8-N07I[CA08@6 VE,)+ QIV%)DK$UR>8[ \F"
MHCEL(E7^Q-PZ$,YE2^K?5D+?+:MEE%M="3;+,,9YM>0MON014A(E]1*/*;1(
M5(B_-0ZEF8PR-%]]I#==F=.?D5H?U24J2#Y0CBQ:GV6:)H-2LH^Y&)/3Y'5P
M[9^! (0I5>>@*DZ+PR#<T6VY$'I3.VXETD52GJQ1_)H%XW]O!V/?0'K\87S<
M_4T0+'=;+*T%G.5W=QCPI,GH/WX9N7K'E/M\8*+"X#B5,J$_3;E+])?;<="G
MK\HAO.[]S>16>O%+M>H5)#TZR$3<\(+K-0*E"(NYV&#=RARWSN?6<-2'')@Z
M%,E%S42>F$Q)DSI*'I:AI=I_RZ'VE1^HI[S5.N.EPE0"4ZFS:I<S!*FL7"FF
M[J#L-SOSE<-!F#4V_@F@9=L@;@/P=M/KC-M,2&Y33Q)KD\?*P'DO \;I03H"
M>@3?()HAP^6;LB;$IP.>#MF:*X3:IC"C+WW<:"U>%/AV*"^M4R221,D.R"")
M;,EX:7V45#HWGG!@\^IXXITF9NNTSD<LO;C-WA:)VP(;J?<2?4*-/,SB4Q@9
MV"MD)<$##/3HDR'\]8(@ZIQQN2[%+>.K9WN3OD/.>XY-X52;IJM\X"!NGV 2
M5OK54.VR<Q.#B8O)+"P3^WYEREN\\W9-3XLV6TRD^\'E*EN+:VM!(KFC$2K=
MRG\7[52@T;H4DW)ZM2U4V^W4[=*[;+G7R5^J4NZ?:XJ+>$F*T'K=>;EPI$BO
M3 D(J/2MR!$B*WM*A<6@G1:CY)C]7P?4X78'^AC_ +Y*$V:NW$XOELWC<7AQ
M$76*S4A9>WR6]= 5T5,349<AA5F^V4.37IRH"_4X6*\EF6L_UBTRNGQH%5[H
MQ4BW3.57'Z"%#,U4],XI"J5 $WZLTDGHF.G@+"Y:XDZ3-%Q7H167!1,W%WM^
M2UM8T[6J=^M^7 Q48D A]?F5<2Q8>Z5JMD[RTJSS8_(KM<FJ!XX6>5.L<F5*
M*=KY[; GS]3)#K:' 3B24GZOUN.0]JX^-UWLM)Z&J%:IW3[@V5J5%EVVYV!1
MR>/JMN>D4!)NC5.$0LTJHV:F'I4TQ+<(PA,4I6TQI#;\N6V_$0S4FIX-]<.3
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# T&[#Y2WCEUFZ@^B1RV35Z/<&J,/JY>/8H-Q
MDOR."">NKN<@T.-ED3 ($B35HG#8!(<8#,.RDRMNM_*<.HB)8#G7E3V*]:I
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M_A86L>OX6SP^P^2IY%EWY$\LX_S-R*X*U4D\G[+:NNI,M/(G[-+.KLW&^1[
M+@K;C:CI9U/U)TZYM6V?EITX2:Y*'D="]RA,F2F+XL^(+T1,F0F(\]YD]38?
M>B)>6F,\^PCPY?0P^ZQI*EMZ<<TA6]ITI6M>K9:QZSZ?\K_YT?\ (PGS:SE.
MJ\QY+4.LQ5GM5"FTGK]GO-&--QQ##U:4>OACD-&,U]90XIV/,TP!(:AQD)>1
MN0M6V4DFKTX->4]$]S'TI]7BIX>:5\->K2?,_JN]:5\/PZUO?AGK>]:W_O\
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M'KSLIM!4D#KD_P 3ZU!.E8</:EL1'B,%I]S6D*?:UOUZ+6/6?3_E8?:K1Y;
MK )C>/O&>%=)K#P;;YLMU/O=SY.9@'OK9#>APT)6^"]7B$QGV>EIWZIR;&<^
M:M3?R/2G3BB1MYSJC?+[EYQ%KP'@=BX#XW4CG;R".SMFH'DS?^AVP>XV.DN"
MTC*B;\:.>C"B991#++^W"\7;#"U.ITZI&FE"8QY3J^O5;CYN"+N2@<7X)XY7
MKGC48:H39>A^2M]YQ:YDMV$TLLS.J0+QLZ,,@,0R&UML.(+/J?:3IQ2&M[VC
M18C&M9U9KB]J\O#EE(Q>_P#%N#<XJ+01U\6:Y=Y 77JQZ78=383;(V: L? >
M50H(IP>N0ZJ6@@^ZEUM#>F-I7MQ!)KE*#7.\^X%!MMDAT'QO\6K'1XIF:Q4S
M]H\K^D52R&0+;N]#R)RLCO%.U#P).2S_  G8K).>VTK\"7W-?APM8]9]%L<0
ML/DL>19=^1'*^/\ ,UQ5B]5)/)^S6KKJ3+;R9VS*CJK-QKDFP*H*VXVH^F=3
M]2-.N;5MGY:=.$FN2B)70O<G1*E(A^+7B$_#1*D(AOO^9'4H\A^&EY:8KTB.
MCPYD(CR'H^DJ6VEQQ*%;VG2U:UZMEK'K/HO_ )R?\C"?.+,3ZMS'DM/ZO%<.
MZJ%.H_7[/>Z.::CB6'JXH]>S'(:*8KZRAM3D>6E@$0U#C)2\C<A:MLI)I>G!
MKPGHGN8^E/J\5/#S2OAKU:3YG]5VG2OA^'6M[\,T[WK6_P#?\-86L>L^C85D
M_P"1V^(N'G^8<D;\A]0GEM<T:[!:'>4+().JCQXR^N*Y U9D17*YK4I3NJDI
M2)>]Q](4C7U&R:7V:][Z)[F'PW\/%7P\WOX;^&M^9_5=:WO_ '?'?]#/?PUA
M:QZSZ-A;V?\ (T?RRMEN;\PY):.RRDUW[V4>W=@M%.Y\&5)'..VG0/HHOD%P
M.'M""NDLPMO5V!]<QO;KGTRM?*V2*O7@U];Z'[EFW&].^*_A^AK;C>G5H\S.
MJ+6AK:]:<6A&_#9&G%I1\=Z3M2=*WKX?'7^W"UCUGT7]VVP>2(&'6E^/7+N1
M=+GRI!!-MC]5[':>2Q@T5MB*H8Z"E5KCO67#[TN2MY+R'FH&F$(0I*G-KVE!
M(KFIZIWOW")EIKD2[>-?BL!ILDV-8M9RN^6?2K+8 ]>=EM(+D@E=G^)U;@G2
ML*%M;C$1XC!:D.)TA3[6M^O1:QZRL3M5H\M01\1'\?>-<+Z367@ZGCA7J?>[
MGR8R/._6OH2/&A:WP;J\0F,V/2VYN4Y-C.:=4IOY/P3IQ1(KFC7+[EYQ%KP'
M@=BX!XW4CG;Z2&SUFH'DU?\ H5L'+;'2G1:1E1-^,_/AA1,LJAEE[;A>+\AA
M:W4Z<4C32RSMK29M]NK7'S;$7<C XMP7QSO?/&HHU8JR]#\E;[SBUS)CL-M9
M9B=4@7C;T89!CPY^U-L.(+/J?:UI:D-;WZ-$C;SG5F>+VKR\.68A%[_Q;@W.
M*@V$>?%FN7>0%UZL>EV%,V$VP-F5^Q\!Y5"A"G![DAU4M!!YU+K2&],*2YMQ
ML3MY3J@]TO/N P;=9(5 \;_%JR4>*8F,U,_:/*[I%4LAD"ASX0"!VLC?%.U#
MP).0U^%V*R3GMM;_  :?7_MPM8]?PM?A]B\ESVK+_2)Y7Q[F>XJA6JEKD_9[
M5UW1E+R9_P!M;.[LW&N2?8&X*FXVH^F?K_J=.N>KY/RT_,)-<E$RNA>Y.B5*
M1#\6O$)^&B5)1"?D>9'4X\A^&E]Q,1^1&1X=2$1I#T?25+;2XXEM>]ITM6M>
MK9:QZSZ?\K^YN?\ (TISFSD^L<PY+3NJQ'3FJ?3Z/V"T7RD&V6!$=ZNK/WHS
MR"B&*\X3.J=CRTL R&HD9"7D;?6K;*237+@UY3T3W,=I3M?BIX=Z7Z=>K2?,
M_JJDZ5\/X6M*WX9IWO6M_P"_X:PM8]9]&PK%@\CE<1=/2>8<D:\A]0Y*V>:,
M]@M#W*%STG5QXD=SK:^0,69N*]7-)E..ZJ2E-R][CZ0I&OJ-DTOG37O?1/<P
M^&_AXJ^'F]_#?PUOS/ZKK6]_[OCO^AGOX:PM8]9]&PMZ/^1H_E=;+\YYAR2S
M]GE(KF[91K;V"T5#GH=R2/4Y:D@^C#.06\Z>2'*:TS!V]78'US.]N.:C*U\O
M9-+[-?$=#]RW:V].>*_A\EO;B-.*3YF=46M+>U:TXI"-^&R=+6E'QWK6]ZUO
M?X/CK_;A:QZSZ-@.VV#R1 PJTYX]<NY%THA*DSTVV-U7L5HY+%#1&X\90UX%
M+K7'NLN'GY4I3J'FWF8"64(2I*G-JVE)(KFIRJWOW"IEGKL2Z>-7BJ"I\DV,
M8M1NO>6G2K&?$5YV6T@N2"5Z?XFUR"<*PH.UN,1'B$%J0XG2%/M:WM>BUCUG
MT9_M<'R"!WV/8O'WQL\9.E*-UA4"XWGJG7#O)[NJ2E]<1NNHU6_'SK#Q^N[$
M,L[VY((L?!7Q:^GVE.E[$56LRK[DE7\CW.@4U'4/#/PLYU1@D0M!U<.:]H.W
MBZ5&&Y%,3HD*IU<IXJ<[@*B$CQ!:9*$F(*&T3'W]:=7O;;@FJTF;93HH?R6J
M%Y'1. >(_A_9Z!3(>M\_M%S[78>56T%,.1OFVR,*JE8\7^A#JO&D$'7$;<AE
MU*G(WZW4(4K:-#2>,S:=\:)>4YXV1">0' /'3G7/_L^46@S>8=SMG5R<VWJ.
MPRC;,ZJV3Q[Y6+BQ9#STF<Y/3.>D)FMHW\E6W%.MDFN4S:K^CM^8TJ\WQ56\
M/?"^]50QMVMP[9>_(NX ;?=:/$?T\+BW4#'\2+A%B(VO^'L;]J$HK"_PI<5O
M\.%]O65P\,C]P-0;",\A.#>/_+QL$.)KE.'\DZ>:ZU"*UUQ$U)@$:B63B/(X
M]>##],Q=1HK"9[$C3B_4EGY:?F$FN4S:H9-U]QI@N3F#?%#PZ=^>Y]"V5>\P
M.FPRA$./ESUAM$=->'$E3>VFYSKNH_SGFX[LAW2%*]6U*+6/6?3_ );#<V/^
M1A3GEG)=:YCR6F]2BNFM5"HT7K]HOM*-,,"([U?</W@SR&AEZ^X2.*=CRDL
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M:B3C&Z(Y2UMC^Z+YT ?(7B7&>B<IY_4TWJT<R%-,VGA'8J&1Z;2>G^6UGX0
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MP>_KE>*?[0_(OROPYVY=)/Z=_@]_7*\4_P!H?D7Y7X-N723^G?X/?URO%/\
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M)WCJP?D=;,E^+\>*5FNF[)RZL=7KY>XVJE='ME=%!Y8NZ"A4UEF3)+ [!.1
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MXM_HM!?BL&_/K+2RX>)7L(\\[O>^"]!\%_%VADN:U6FVJX] NM(Y)5.<CD=
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M'>*6[B4KQ_J\DISXK(& 7(R@-UJ%YCPCSS:&";LP<B1!DPE?PE%RG+'IKJZ
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MNKM2&VWC=U[#?*]?[-"^\VXO2+%'/]=<?'_;S$Y 60.8>A?+<WO:1OFJ;?\
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MS%5VHG)7":/8O&F!7K0,DU8"1E\^YKU;Q-,M6@=>XM^U=[!>[3!&=!;O 0A
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M0@VIS3#B6IVA-.JP\?&^:E?R(\5&D?#?JWL7,\5DX0P& P& P& P& P& P&
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M  9'>V/Y1^7X_ID]H_PV?-S_ +S\-?\ U;X-L?RC\G],GM'^&SYN?]Y^&O\
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M %;X-L?RC\G],GM'^&SYN?\ >?AK_P"K?!MC^4?D_ID]H_PV?-S_ +S\-?\
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MK4YK2MBDI;CE6WTE8K#$4'$BLMMO);8A,)BMZ3'^+6Q<L^!X5R&KNL.UV@@
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M./MZ1)5%CZD):2287WA# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M]7ITI.]_#X?'7^W Y .>T\6TKE)41Y"%J=>.7^._BAX\B^B4L"8!6N "\?\
MF'D'SB\%*^ZQ<?HH#G3-]JAS6F9#4I(]P&A*U2=N(6R=[^VB51O;:O(WPE@^
M+D'N?U5R$=XYGW$;?"C?28X:-+YMT>BWU->#QJITRKWRC0+"]2UK6Y7SXU\>
M0)2)49>G=J6L;HW76E*HJWM)=4I D>*J_E</A31/*E46%;%\EGJ.O-/<*A\6
ME\OG!-],7S^1X[.DV7[D@(L.X<U;I2I[Q:1(^8\\6<XGD _:&MXL$\V4\B8]
MQ/C'^50JK MU;Z 2Y\BB<_[+W/IY?EEEK,/KHTF3I%C&=1 P$MQ9\)YIVDC%
MN*?BH3";&_LLNT^V1="_C=XD<#">0;0B1XU\4(\:EV9^I6SZ207)"*,+&>0'
M.P]?ZC6Y50[OS'=-?74YQ.:=@C]&INGF']J]>R;XN93M[V]RU3X+#Y;Q^\42
MJVP%YR&_-((>/<])D*I,(SO(*P=F&T^RUP!<*Z2FJA BL8([/C3XOS?HTO)9
M;3OY*1NUN>E*<'^TJ7^NJN[#Y$$"01-K5T3HP"MU0M0P5BOIWK'E=V6X3J?7
MP5[<%TRN+N'DA!V,&NZ)Z98K#"9SL_;Z]I&^.G]://S7VF[+3:SSBK7+O4?L
M 6LR>LP+E7^DURWGZQ8(O4Z5S:ER.FU8 KHS(RI]J%QZ!-?3*DM%Q#CMK,N*
MB?5R79CQ9S[(8$]GSHP>A/T2!Y-#*K'1XUS>!C"M"H]YK)$;&WX_"^"# <-+
M?7Y L=R6,6#_ )Q]AHT5DLWT&?*EM%4,;2W@WQ=US;.PO;Q,5^J^>=&H_7$T
MBH>6_.G*-SL2,#V,F2XF2W1K)2V[5%N)BYR;B18CQ2\+<0)"FC18I0Y3L!,=
MR8]Z";N%\E*6OVE+!*N?6CU,\AB8NHW.7SZ54^6V>!<SG/V*O1CG+3'YD.CA
MA?0P$J^<<EL\W?CL-?51"45HY+3MUU#LU! N_LRD_P!JNT6.['3=L[W'(5*P
M=-"7>TUD;7+V.F=2K;?D'5.WR*-ULB]UB<./"N?5FNO4*D_9L$2@749SL>:W
M.^.T*AOZ0JT=[+9Z.(!!2'DT;(P@%&I@Z$E43HK3S741(3Q5#WCK34Q/6-ST
M6&^:\?C3CV]NJ<95:W-Z<4ME:I%/]D=&;,^SY=I!J]20/EC< =>/\X\B><<^
MK,6/;HH[C5?ZW+\A&J76Z?\ 0WZ/(FTJH@NUCV98Q]U#<B75XDEA3"D0]#QO
MZPD9?VE3CG2:+8P/<Q\;G= [T Z[3N;6"K7D_%YN&KW;.2]L<!<MG:ZP/B5X
M];27/B TP1G1";;D(FA4:/'>96M\;])\$@N_@EWVF^#=;\=N0]3(FNVUKO\
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M)6(]S"WLY6"E@(SW(D&&.+Q^<DVD*0XZXE]+25H2EU*L+$3*T UYI=B,%Z^
MME=-G #<-XV(%&1\\B*9(-)?@O3XD60Z_&:E-*TI"E:UI6MZ^&$J5<"/(3GA
M(29M<^1/JG/!DO4$;TRYZ%UJD6V1]I21"ONI.(E4$R+"B$52&'G8C#,Y&TNQ
M%OLK2YLM2S3/=^)R+!'JD?KG-G[++E0H44$S=JXZ5DRR,=B5 C,0FR*GW7IC
M$MA3:4IWM?U#.M?A>:TL5+Z"NX\9.P!10+U7GI<6<,IKP<F-MX*<.)''(T28
MP)ASHTYV*]/E12$9QEO2_4\B2RI'JT\WZA4@SM_(#PN08K?2J19X3"&]IW6[
M.%-O2G)$T:,@QH+(^:^N9**$S4*-$0CX[DOSHZ&_5M]KU"I9NL=&J-P'$)P$
MM'E/!8<"58@[CK$8W5Y!$4V88$6<:^ZAT ;:A.ZV]%E;:<85K>G-)^&\$Q2+
M0_('BDJ 0G+ZE0(GV+$"2K#%?N=8=D5U5A<C1Q40PJ"6F16)<N;+:CH2AUQ+
MCSB$MJ7ZT;4*EB@/DQPL[41ETWTVF@Q1*M5*UJCV&S !9(8*O,.#.J^BL11-
MW42689)1],-:6O;JWVM(]7S&_4)B82&?W7BHQB=*(=:YQ$C#!X,K.D/W.O(8
MC#K-N'JNS%O;(?+VP=V2B_2;UO?U'U3'H]7SFO6*E@BODEQ(/;8=,E=%J:RL
MBL%;A->BV$'(' J^+9JLA! ]*02]0]HNS=1JH.]H5J4F4UM._P#BM?,%3Q?8
M_P"2'!:S')22W7*$A ?[H[*-0+&/,3(#5[)UP14I4F '>GSFX1N;;Q7RG]M_
M*TT0CNJ4EIU"U"I32V=,YW0Y,*%=;S4ZI-)0"A0="L!\8)FD!H3<-!>?!B39
M+,B7$&ND8S;SC:5);<DLHWO2W6]*%3*-R.]<;:*, 8_3:$2/R(X.>T"@72J*
M*K$6":!B0C:(TDS&^:+0U9H,A2T;4M4>6QMM+BI$=#HJ6-:\D^"NS2,%/6:.
ME8JMUJWS93IV(P*16[@8/@:V5:-/+;$2F"I6KSFF]-/K7KY'J5K2%(4H5*0M
M]JX^Z3<"M=2Y\X69)EPKPYNW@5RV2X"*W-.#'F4S]K9G"(KJ5R6U:TMG6_X>
MM8*EC:IWCD]SK=ZNH6ZU]5'YT;D@[+=Y)@2Q48[L*LUVUS2+=@W/4.T(A#;,
MPEU]U;6FWD.)5K6DZ4H5/F'>]<C!4@[T#=\K!BO@*V3M+Z@)X*2ESAPH3:#3
MK(QA!!M$HA(ATHM\EG:T;4L=(3O:?D.[0*G@QD;R-Y%..0!(^X!9P^?795I1
M;V#E>33&14!5O04V\>DF6&URPZJ1/^L9:0XY%0UMQW26T/+:%2GK_2*!%I\?
MH,JXUR+1I3,>3'MLDM#CU]R/+>TQ'D:*/.HB:8<=W\/7M6DZ^&][WK6M[P5-
MUS8I_LO)8Q-\*_TJD-%X]@@5-X:JS"/K46<FVX]"K_T^I6W-F'F65KW'UK;J
M$(4I2=:UO>A4OV'[#R>PQG)@+I=#,1&GI<=R2,M@.:PAZ#-!#I:%.1YSB-?)
MFV@8WO?Q^&U$8OPWO4AK:R5*&D/)W@L+8UJ-U&F&Y9J;9A0:*!L(@DDB7J-4
MFW8X+^TVYJ 8R3%K0]R3ZYTJ)']&M;VYK7X<+4LQ,\A.#CQIDS.[+S"&)KI;
M[!.DI-YK;,$09TV1=6-(R5DM,Q);30::IQ"]ZVVF#)VKX:CO>@5/1\^A]WY_
MS0O001V<J23Z4U9YE79@S 3$>0*I]=79CQJ02.&0HQH7$@;91I:7EK4Y);WI
M/R_F.-B(M^)WD=X_#''&2';>50G6GBD=;4F^UAIS4@).FBR\?T+)Z4I\<4&2
MHKR-?%2),5YK>OF,N)2*ED+UVKG_ #PES0783$=#_5S1(14Y#4T2T.7'"U$S
M>#=@FDR)*!!9KXFN W7W7FW'7-^MO2&UZ5O:1$3+*UGK?+;G.'BZCT2EV8F5
M%SC@X:#L@DF0EAAI!0@B49A0Y3LE4""53N,Z[Z?0W(UMM6]+U\,%3""53R8Y
M';BIH7"LL =L1>S_ #9B69,5N"@_<*R<U6BPH -T=>L$U;)UM^,G:X36E[BN
MKU\6O0M8J69->07' H(F?WT&KE8PU%K2W%"'!1&>7(TH4Z9L(,&RB8AHF<AP
MVM_\LA?JVO>D_@W\?@*E-W+Y3XL<5()V,,%4:%03(^*:)P!DMX>1(!A$5_3$
MJ0A6T*,V&!#WM/J3]7,9:^/K=1I1*1U/;>.J'P"^NI4#[)*?;^QY3=L")&R]
M5:$LE8]LSU3=15:"C6U29'\/_A1];=W_  /X6%J6:(=*YZ)KH2W%+O5!M6LB
MQR*_8IYX9$#&U%V=R1NA9&1);BSM38J5/(VVI6MLI4Y_["5*T2I06S^27":E
M6;C:R?5:$X,HDDF.L:(5MKLB7$.B81>=*K>F-DVT_>#Y5?G)U%4I"]+AOZ5Z
M?D/;06IE[Q'?>0%'&8;W0:>$,NC"YM5=.6NL0ST4*#<,:)%IP]HS)7!AQ6 $
MYYW;NT+8:AR/FI;5'?2T*E-Z=>:9T,-]X:):J_<07UDL<HM6BT$R/01'N_)G
MCW9,!Y]IF?!>_@/,JWIUI?X%)UO\&$J8XI5@:!WV_P#E1TGR<Z9PO@/0>*<@
MKG&.3\9O5BL/3.-6[M)RZ'NTG>OP(< 5# ]HXX/JH:JCN3^I:G%$GYSY#?\
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M.G[=FSYGSB#S;SS6ITQ^9J&TIMEE*84'3WR8Z-ZVI#*$IVI6];5LCW8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M7EY.\N&9@,!@,#@EU'_4D>+7^5?VG]?3.&D?5/B[VX9F P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P.#7GK_ 'U_L>?Q'S[_ %$A\-,?
MKR\G>7#,P& P&!P2ZC_J2/%K_*O[3^OIG#2/JGQ=[<,S 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M&9@,!@,#@EU'_4D>+7^5?VG]?3.&D?5/B[VX9F P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M!@,!@,!@,!@,!@,!@,!@,!@,#@UYZ_WU_L>?Q'S[_42'PTQ^O+R=Y<,S 8#
M8'!+J/\ J2/%K_*O[3^OIG#2/JGQ=[<,S 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8'!KSU_OK_ &//XCY]_J)#X:8_7EY.\N&9@,!@
M,#@EU'_4D>+7^5?VG]?3.&D?5/B[VX9F P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P.#7GK_ 'U_L>?Q'S[_ %$A\-,?KR\G>7#,P& P
M&!P2ZC_J2/%K_*O[3^OIG#2/JGQ=[<,S 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M_4D>+7^5?VG]?3.&D?5/B[VX9F P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M^5?VG]?3.&D?5/B[VX9F P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M(C7_ +E5*3?>@PY<RK)O4,=;I-6%7L>-8V(8%R?I-M%'=O2%NJ46)T?&L^W
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M?U],X:1]4^+O;AF8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MZUK0E:.$,!@,!@,!@,!@,!@<&O/7^^O]CS^(^??ZB0^&F/UY>3O+AF8# 8#
MX)=1_P!21XM?Y5_:?U],X:1]4^+O;AF@'2/_ - "O_W_ .6_K*JF!/\  8#
M8# 8# 8# 8# 8# 8# 8# 8# K;GO_P"D.G?_ %)(?_+%3PLK)PA@,# 6O_\
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M -F",,KX2W3YTI*^?45:%)6A=.K"D+3O2DJ2H)!VE2=Z_!M*M;^.MX<SQ3'
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MK8857PT/YOT@D(.ABAD7Y[SDA[Z:! 9CQ6/G2'5+5Z4:]2U;5O\ #O>\(RN
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MKO5LB^J&]+EM)^3$4I'S'T_3ZBUS.6-;<.#M7AP8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
F8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g268305dsp051.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g268305dsp051.jpg
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M/"]X.GAM<&UE=&$^(#P_>'!A8VME="!E;F0](G(B/S[_[@ .061O8F4 9,
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MRCIG$ZKU2#HG955<0: V7+)"^2R)V2.O'H2J$V*V'$&(G1<I/7"$A&$"DL0
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M*EBIB?ZHR$(_5S."O4'-[<3**FNK3W_N^N&"4V-!M0^7R.:P%[KYD316%/\
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M(@Z5W<;'5J7Z7.+NA,OKN7R)]ECNTI%2&;/I2YKFSEIB9ERERE5#(QC# RB
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M94[00G5_!)&4(3DE*.V/8="+$2]*2GA# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MQ4C36#4]<)FU$2ET1M.8F-5&&&"'H8 :"'8JD\>EH2>)!Y50/#N!@J;Q^J&
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M7I=KO963 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MIZB?(1672,8OCGR/+G#54CF5$0E'/839T6C2Q6K1QJ4?$5_)'_*!**VEV8$
M0_'-]T;N<_XYY;Q3^E_*Y& P& P."5H_\DCEK_:ONG]O1.'2/M3ZN]N',P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&!P:[U_P!:_P '
MG]A[[_82SX=,?MY>QWEPYF P& P."5H_\DCEK_:ONG]O1.'2/M3ZN]N',P&
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M#I0J)&G3EOX!@VB)T,PS7Q-&"<[BIB-F+Y^\9+7RG.FD?/'6'45<<X-,[?;
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M=2]!-J!,:2<>VRMM<8X)N^9,]=K&C24[0?8:'>XN.$1,1.MY?!:2:VST_5E
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M82G5FE(6LH9_TS:E8/:0_?P?P@]2U$87I=SN_K=U_P#]_P#YY7 P& P& P&
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M8I5$+AMM1IW<'1,2]%&)UNB%*8T&_@Y6(F\...D_F_IVPY& P& P& P& P&
MP& P& P& P& P& P& P.#7>O^M?X//[#WW^PEGPZ8_;R]CO+AS,!@,!@<$K1
M_P"21RU_M7W3^WHG#I'VI]7>W#F8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M]9U;G+*<(UWF5>J&[A[4F5!\>5U0%E41RZR.OAVNON&0D5YS5 U,?036G+3
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M:,.@'#1':#O>RQ>@9? _.A@V(0-"#L8/;[PZ%K8@^[6]A]P=;]0^[6OP>O\
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MM0WQKY1&H";I4,6]$#&NJKCI:%U[#?DHA\\Z-52F'6'Y!FZ8B>VIS+I>)TW
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MSK;A"=0Y-4K1Q94VU8V#E+@8X3AU844,0RY/ RAO:YF^?VN2-Y1IXBOA%&B
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M?E^V"0L:Q M,:E*PI*K3B*-$$?IK9FJ1_*NI:0@JJ7HIK*7>)J83IG,=BY#
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MJ=E&];3%F[V$1H"M#V$.]^FC,S:H!O!)KA#6RNGRY7%RA=>U++J5I)$5!FQ
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M+()_?UT?:XK&Z\3F:T>O<E*U:J4&&'A!LHHH3.E=$C<_5]/*GB2*K7]SCKM
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MACU<$UI'K>4I6D'/-?T@:M<("U*U@G:I+&D=EUU-TI#<^LK:B1I'F6+2'1F
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M23: T?W\=MKW%U2Q0](LCJ8 2A:&4:0L*%H8-CC$[;Z++<@7E-+F;KE;)V!
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M.^7I=N<2:./M-N6XS(C:AG\@+^ZI&T$@:BOH&H(_.JHHC9HB2%VT1"49@R3
M&"**T(.Q!PM2EEZCL'.<&B42)BBAKK'=[2,,B>FQH&X,6W8PIOVE:'=<1M2V
M;<S3@$>PDP'QA#"#TWO>M8+EADSA4U7LYC:C75W7<?0KU)9J!,IC429T;HH$
MB4*P&)2AMZ).O/&[)AF:V'1@MJ2Q"]?B!WL:R^AB*JV^6+VXU)7Z&<V$UF"=
M$)A$<32R<,K<F,3G"7I1  \25K0I-#+%LP)Y11?J'?H'UU@UKPSS#*(G(=KD
MD7D4=?!,@DJ5R3,+NVN6V@:E,%2A3KB6]0=M )0CWHPH!F@;&7Z"#K8?PX1K
M+V14.TBBMI&36^T!J V0JX"]EQCY0QK&[[4G/BB*KM?!&@&_F[,$I$1LO:P7
MNV+XF_7"ZLNN>Z_AB9U>')WAT41MPFEG>W1<O9&),A$6G*VQ-;JM/-2E)A 2
M. /E"#A!]"SP_##[1Z]2:HR@$QI&W9@]25H9(F;9L#D,X@8EKTV145C(T4"E
MKQ"W5R:E!)RZ1)X:N>"E'RAWO*+.+/\ Q@ $8(.%FX]&^R-OJIN5Q'<N15\A
M7$R4TZ![D::.)E94P=5(UIQL1VY@ <"2N2PP1HA(_14<:+8M^HM[W@U56BE@
M<>UQ*I1'HZ^P^1/LUN^VH':4H4GQ-PW#9E(HW,>B)E$+!DB[3::W0X"!,I+2
MI3!*B"U!A:87J,LX11J8RG7Q_A:M\1U:\F-K%)4L =3IL!(<T,SX1'5QDN*C
M -.R$UM;UX31/X(\6?\ ,E"* ;I)H?Q ^S6_7#.KWLI4 ?DBPR.EP]Z0E*FY
M"X#90,KBD+7,.TSFTHU@D.CB0*F;:@E0F+'Z#3^\!@-!]0[V35'55V;3=SP*
M/6#&-1G3=(FUCE![2[:C(9!'5MF-9/R225-Z-8X 9Y)(T;KI.84,S9BOXNR]
M",T+TV68F)IN[:LJ^"$ML995$#B!*QT&PLT<:3H['P+7Q*E)-&QM;0E&C H=
MB$8BQ;3% V:$O8=[#H.]8-98MG?JM=B&%*85#V=XGK >H20]W'%"9*XM\F3#
ME3VTJ&A(L6:=-JMKS5;@60-2G.,&8<(1FA;,V-7P=046>JELJ>P5,<M8$J>+
M3N2.H8>8J94)9Z-8DCLM>%>MFMJ4M2%.:6D6& !HS18@@]?;O!JSJ3=8/,W$
MYH-P-UL=JCZ70W!)]WETW;8J[[^91:$K)^*_(X^YB-^(5ZB"F.V+W!]?7UP:
M^Q]Y,*NI*I#7$Q%"G]6^(A.(8')ML3JI>&Y";H8UX8NZ?'-<$2,\KUV;\ 99
M8P^OKK>L)KN\#,SU-+D$;7QYKKN3M<%7&I8@L9D4:>D$.<FW120]/&U"$I2G
MCRY!H@!0P)=DF%>P(=ZUZ:UA=7R*DM/J#2DQ$@K8\\;LJC1!!3K%S#1/DUU]
M:6Q\HH!XAB=I:'7S9J36OC+]:^*((_\ YL&KWI7*LP.BQE0KX*!ZCSHSGKVE
M*JCX71C>G1O!'& Y8@),TK;'1Q:M!0(Q#  TY/Z$%^H/0.$U?7[M5TL-;'?Z
M!"E1\$4.1;,Y_2F(\V&J_3U> -BWX AQU1Z:_P#9T4(D7I_\^#5X$TIJ8M"H
M?D<CKLMLB[B[)U;TF=XT!#'G9R )W?2%#B4HTG:7%>6=M4K"(99AH1[,,UO6
M_=A=7Q7#IYXE@GAR%6KI.J_1D&B=5PHNMED);W@/Q$I@ERC9KQ&T;H!1[B]^
MXD!^A^NO=Z_A&K%N1-"/,8<Y*[E5"ZPQZD:5T>']R!#%T8=I:A.)8$;BYNJK
M1K4OD:-0F+1%'&F#4EC+"2'>MAT'0U]K6;8G5&1.5P$$]:8B_3&0R0%=,QQ[
M?$W60Q9))F%Y<7%:ZF.IY3HQ0TYI1F%KC0>I8@JBPC (!N]X(M-3>3'27!R&
MU%,I3JM3M2]W$WEH0."M+L@Y R+'(2;6E*A/M,WF$I3#?4/PR! +WZ WK1&L
M.#I52=SD;<ZN-?$O+:%LGDN0."R.%N: #(%M^C3.1I5)@524+0!L2?*N*H(=
M)])R?AF!^&#T+J^9SS4AR9C^8=:Z-1RE2>KC7QET9&FD:R6 6)%*EC]YNRG=
M3)2EJ@H8T_Q!K G&!WL>ABUL:L6H%1:TI)8BK=3*R%!9,*0SI1N'GE'D@=-)
M4\2228SW -+"])OA@0 /WK2HOVZ+^('TT-=F2L2=16H8X?-7U"84WNDTKN-.
M2AJ3("U)SS8DTB-6L;LZG*5" D2)M5OR+:Q0:;L9#<F%L.A_# 7L1J)W*HTY
M*.?I'"N"$\N>4(D$U3JHR43)Y"J1F1ML$CDA9@0/3RH;RQ("-@.-/&2'9 /4
M.MAP:[(EC]I\^2.PK,;26N H%'+;BQPQ[L1V4UFE;(9(94P-L@4Q9D5Z>S9/
M%](FQ_1E*S5"1N1'+#S$A)AYZ94 D5/O3!(3ZK='&.&2PZOG%V:M&2R(F2$R
M.*W%M"E1G+CI+'!.6S%*/2=O0F'"6)O;["21#V/00;WH:OD=&JCEK Y/BA@K
MF31>4C12MW>#FJ,O+!(S&M&46W21R<!D*6YW&W-Z0 25AHS-DDE!T$>@AUZ#
M6$%,%_<HV]-(9]'7UW-C9%7S@]0:RE:2)JV->RN,I/KUPA+#('8T+KIZ='0P
MTDQK**UH\D0M"T+W>W9:F%C$FH$9*G-&AU$!S=$0E='E*D^C"E21*N1$M2)Q
M<R"?5W((6-R M,4<;K03"20EAWL(-:T9U11<E@431FZKDUCLC.A4KYM'JJKE
MU10Y,[N$57RO0T(#4JI(A,4P^&MK>F$-T7A$0A0(P>X\00>F%BY;TO;*;62&
M/1ET;ZS52MH)<?NI'UZ2+'R%L3B3I5[O]WFI06)R1$B2B(.4_+%A#LO8!C_!
M[=X-7R;@TJXNLK=6D-7+WQ8HCR6<.3=J)JG56J4G)_NHGE:Q-[U9Z@]0$GZ<
M!8+8A#T#X.M[]N#5X9(QT89(-OTQ2UL<_O+Y&&$L^4G,!YBV6QCZ@HBB1&C>
M#1I]S)K*DAWRHR2]..B5 0:%LO1>@C7H4Q(X-(&*7)X S+F1LBUJVC$7HAP+
M"$]?-&6:.P9J^!.^><3UQ+Y)3U*H*@XS1QWQ?<( -_BZ$^4OX1P:[U_UK_!Y
M_8>^_P!A+/ATQ^WE['>7#F8# 8# X)6C_P DCEK_ &K[I_;T3ATC[4^KO;AS
M0UT5 'JUJ!NRL8V-N+D-AU38$)8S'<XU.U =I/%G1E;A.2@A,L.(0A5K0;-&
M HT00>N]!%O\&RQ-3:FJ#EJW5%ROR(#?#8GS+)+K8[@ET9/DY4LFLBE,6ELJ
MM0+@QKP0-F<6R&3>T1,+BX,#LZ.H$0TZTM"-.E,T2<:Y17_TB9FXAZ E\Q<)
M+=HJODA+X\\Y'3=J+6LID8ERRGNDC[@DSVU0]@J:'(&R-N# J&%K;W@]\=3%
M(S2EZTSWF*5 Y1$5"=N;>39=4]XRV>3!0J<RT;O?:R'RQKEL4*;I P7C:B.P
M2V.1PEIJ.,RO:^)-;8@;B1NDG?$J33:':$)92C1*4DS$P_RP^39G+^NRKB7K
MU;[7KFMHM^0_3Y;%XV]5T]T<[O[X2W:2NM42N4N\5DSBY@--3LTD8PK-+%Z9
M:5L@WXAHC+Y:0YOQ_2MLI-HKR.1VHVYU)XA9Z2DB(C0D;+*KDCDIB<K;'%W4
MEQ<\QP:!+&]UT4[J4YRQ*:Y&&A3BV:;K9>6M^6WK>1[44/#=+01BM1.:VSNG
MGU2UFOPM'P^-= 5PA8&58TN_W1,"O711]:P%*DA(4@3DYOQBCM[+^$,7'Y(J
M1>/&UEQTV9I#)M)39'7[B7#;"CTR8$A,(E3QR$U<SG1AY805$FLB1QAF6E+5
M24LF7D-IB8:91M(2M3Z"(<H_'JN!R[24WKRT;PL645;4%.-%CQ&B(PP0BI'U
M2^I"E54M]A-KRZ/!OW-A380%67)D9#<%.F$/Z<E*"?L!@=EA),W$0C*6<NV*
M5:,RG3+7U632.D]/(>A&R%/;Z4QMUFH'GFM/2;@UR4H4)>$3-,:XEZ/;^TJ%
M1;DC7?,C_&1JMZ/*$3%5X3_5'/&FGEURY]LDEB$AF#=;S=((]$C%1T4B4>MR
M6S20E5]#%#@C;U1D:KIBEQ;(U&B2I/\ U6\H8$Z</M)+$S\UPJVQ<K7FVD5Y
M9]D0VEK^MD8[C#<$$EDB6H8(\/,Z8JJKV"3F-O;O I(28Z1*M:;2-2LE6T:'
MM))'?Y<W>][)6%N-HTA'*S@:ZF>*D19D<H8[*FN.\<NZ^5)'AO9G*PG[F] J
M8I3 GDF65Q/T(&ER+$E=F-P=$SR5M6W)2%B<L0=K-1>4?FOU7-22VL>7#:KK
MT]''[!3PNP=Q$R>.:.=,,<GDR5R:1M9+X?'XK#FQTA[#)W\)843>T(4I#62%
M*F("46#6ZQ,W-RIS3O$EBH[(CLUMUI@CY&TUU*K2411[=(W+5+=HWE8ZC#5'
MR$8J6LZ^$ZJ9*+9A9*)I3DDM8@;V9LX&B@&IRBJAI['PQ<S"S0&,JHC2LQ5%
M//"KXXV3()*[!DU3-_*4NKE9*89 DNX0L6.[6Z,\/5K&(1:YL)"O>5Y:LH)>
MPB4%Y1^?Q=.XX\R*T*C&ZN\*=JY?IA'9"25#I6>0)Y92UNW- R_7_DP#+0K5
MS=\NJ4)M:&8C$=LD?N&6+>S&TJ"5UPU+8JS-BUT::T,G[7->!G5%*TQAI[LW
MQOFF)T_&[(;6Y\.8"G)#I>3%Y 0WD%; 6M3.&P'[)"H."$U.7ZKCWC6C[,YC
MSC-8['HM(U%/W.?+WE%(E938L+C$@JVR:W<7".N)C*]:^KL#A-D;H%(+2<"L
M*#8='%FZ*WAF)W]'/]Q\?-BME55)$($77L5<X/05#Q.=HH\L0,Z:QY[4%QU]
M9KLUN:]WKR6M+DUOR5C> IG%W:'((%ZW6ST8B3U&&^47[6V(N$I(>D9FQ:S1
MQ3$UBOG9ZDT4F\D;)<:)7!>R[!Z6L=E/VP5Y$(BL8/ITQ"!I0)6I&W%CU\EH
MH"8L)HR<O?\ X7'Z9J-\LZ PQJA[5&'HVOK1KBR/T=RA2)HAT^:8$[:6CA3H
MJ(:GE.W #K9:YM$:B4)2W5O2?% $K0C &8FE#FWARSD[&_*7J!U^4>M<+8DL
M:A%;V-J.DPN2S'L!\Z#@:QDD$FJU\C2S419'(DQ:F7L"EH6N 3B/DC$H@:V:
MG*/QZ-EDG(]ZR"!W[!9C$*+L.5=$5=%VIYN!,XJHN=#)&V41$*NDM>-,840Q
MQ<":L62>-KW)GTA7)M)BI&M":C*,"(:H7&E=&Y(N*GA+TQ*ILL1H5%8N,RU/
MX)MD>82Q-L-(*YZ248"LWN!AI\V4O<0+U]04EHDTM3LAI;GLPQ"!00+YH<OE
MKJCZ+\:W(QL]..KA"JC>5%.P'E6,.51JY0I'"[+7T P=10U[.4.VX/\ )M_J
MHN9FE\?$K;3P!>V[12D! P 6!4<H\OD'@*9+XG;P7:.5"7)IGS]<$,K1M3GJ
M'!FI^9V;>EJW"Q1:(N:F*(SVJ+04J6,Q!#FB2I3=+&[9J9(F*+3E '+\W3Z!
MRE[ER*0K7N%/$("US:8Q=F2OIZ<:Z1,47?%;$AFA24@.A-[1+!(3%;>4;O9H
MT!A)PO3XN@A,2YYE\JV5&WM"[IJ:HJS6.+SOL;3?74ND9+3%)*R].VDT6;%[
M*&4.LI A9I7"F=.HB3DA.1+##6E8J,1K-EB^34&[CNL(KYZER7CB&T4FD;=(
M[4J^NJR^YDP>3%J9H56_3&HY)((]K%1A3D[HV$<XB:3XP]A4*]-XAZ%\4>Q:
M$2_FOHJK+.)[551:0,I,9J"?R.XN>"ZTELRF#VO2+*0N:3SRUK.LRWZ]#N&.
MZQ^1OLWMK;F26E.9'/2Z+M6MGA#\,YO+RBV,L;A^VWIY>#FELB:R,([XN6PM
ML33(X<Q*;*CEX0%!'3'EV*F=*V-%V6:P%<6L1; <WJ=JV]T5GIER8S>DIHC*
M%V;4H][>N8&NF8,I)5OT,:Z;'&-SJ0+5P7M93$L@TN;FR3RXEH4+S%,CW"@I
M5+MI 88$U1M5M,+>ME;)$_-:@LFI.[0]$0282^AZ:L=ZG]@=466"N7R4NKG"
MHY'I%2?,E7-"=ZFZ^N'-H#+S%$25!4EF-(TZAO.5!2C,&#01FKBM)GHV^(<.
M6S#6V-P%0GK*8&_>/DJ5&='N#NXIK/KA-SC&:B8Y!"HBRJXJY."]K?SZS<=L
MQ@'E"247+7+YXHS830N,2<HE//+O*3M0;Q2ZTEF@<?21+DECINPBH=H28<AL
MEJD4;>@O!OL:&\3^W)Q%NXRERP6E035YF]%Z^.;O*F65^]I71'*UJV995LN5
M9M\+BT?M&MAMDW>9=)=/)4]ET=8&XFM]-S(3!E<FK52V.[.F1.JU$\GMBQE!
ML8VI2OV4<G+$Q$:L4=SS?KK:SG?TJJ^G94H6VQ(I<70SQ/UKDT$,TBY[HVHF
MR8!ESA7AC*;:,.=ZM<R2@#;-H]L$C5@)5!4:]IXN*I(-=\G/,+L2#V$2R0%K
M>D74W2MPS5Y:=BT_NT"MV+68T19C$Z:94ZMS4HUCW'_FD1IA:0H#: 8!#$G)
MUMJDSI7A_G4_-T^M.9RV0QF'5;9""PN=GB@DR2T'A>T?H>>W-\?G4=EQH":,
M2?;HE>@/:;;NF2";7,9T<:_@'[UL1B81,1[VK1KCB1)+59E4LCM=2R"1[I?=
MZ'2-X$F6ODV)<./':B#ULABID:TA#,6ZPQ_41&&JE))Q+@8I 8!0#96R\M/-
M?JBN(\(6DTR^FU$L6IW>*1B#T-%UA$0F\<CZBMW.@[;G5D-!L?-D--2>3N$8
M>T[^UE#2LCS&S!Z;S$:C1B4TLPD3E'1?WE>G":"YYJ&I]LT897B'0"*-$L!$
M4X"F9RF*)B;T<F>BU'R:!0YG.KJG,-&K4%!4*/70C/QOP:,S-S;G+7O#%WQF
M!5RT?<>AX=)Z/JZNXFG%"Y2]?3>@I3!>B*0OLATF#D9 &]QBI"<FH%B-&I5%
M/*DAUE*\_0=$ W\V:Y1[TE-O,/07Z0&JU/NW6\;L=WZ"F<\<'DB<CD\7BE,S
M1UJ,^30)[C+U6PCYC+'UAKT>TCFTGL*IH?BDYA:T:#:@D\7%5T?FO^&);&XT
MVC>&JMSYZS,WCD:6>3DG&JG-H(Y0>(2LLM.U/*B/EKF\A6A;'8MKT3H&EVE>
MP*-$ -'H(G*/S^*.(5P%8$5KZ2-<D:%LXL5D1PUCB4J06[!XTVRMQBU@OD\:
MK66M'[NQB;4M;WER&L4II<7,PJ!NC@E$8I+%LY5"<M=-EJ^<J.N6L[=?Y3)T
MD":X[+*_;#K2.CSB0ZD3V^=,]<MBZ=UPT*(8UR2KH0>FC3H4M8ECVZ(31";C
M$25&,E88IJ3,4TV\N;[[M;HV,S$2J$JJIB$XA,F9$^G=KC3F*&M\"D\9G<,?
M=(:P<YV\R61OLG5B2K 2A(SI695LO2/2DL[:T1,1%=4]<B5A8%0UDOA,V2,K
M0T-LF,+K*,M[JVR9ZB=<)(W&FMKCTPF;1#X*AF3XC>FY>).O$W[6?2#$1*U4
MM6$GJSB95,Z*/M_CH>6NLB(^AB5/(IFDXN:J41O*4KX(DUS)9N?+U,M(= QK
MYPL/SH@*2GC0/J(%>O>$ =_C;-<OS>.Y^>;G12*Y[VM!YB:=KC4&OS<%<(V8
MC/5+9@ZW'4%H\I'L4'B%4,LG&\1)UJYK1.XG1\D#BY/8Q;1;"0?K01$QM'X[
MKHPVOI+!^,Y PRQ&#])DEJVS)U9I#05M5\>W+1;Y)/+$(;-$@">N3D362JTR
M'7ILSY4HDO7_ ,NM:)?S>%'Z:XLFLTBG/TBEE6TY XK'X=Q4W/\ 6S4M6N;5
M,4=%HIS)7.;O[0OA3,62\E+)LC1M38N I5%@(4_.*?\ Z(-%G*-=[U:5T5Q[
M:K-1$X:QPBLG'4#;.A%8[#:ECX\3KH\%[RE8-GB=B1QLB29T;F$ W],X2?8G
M!UV-Q8D8V\KX/_\ 3EC*+M,,[XNN&7+ET];X_"(:F<[R<+ 7<]Q"513[LC8%
M?/:"BQO8)!-*3F$&-G*Q<C,7G%CC0"OIBC98%85@1"-)RB/<W1IX=!$5@7(;
M7#U+2AN2C9"]/DJ=C9),'>C*EY'B=&O,;E<F.C:-1(7 R0,RXX1(@$I%A)XU
M0]%&FB*".7X]J3/'W7LAC54O<VF*WZT]S5_U&H?(#D3L@7.M TP495= .*Q*
M^$)70@^80:/_ 'M4 ,+!_P#<).J$'7M%K"93<Z(R=.5+6^ER.+AKZHY/]+Z/
M<^B2IN\24Q*MZ"9'&X5UCI*GMA#N"K7)H6QMH=4Z5 K&I>6KYF+,^_@%IM[3
MHRW'P1N]>/F:S%GO)6_Q.G4+A:=27FP0:&$K%+I'J@D-LV P2I+'(ZZ&Q1()
M&@-U'0N[JXH$J;>I"N4[2D[*"6<.'+\VRW?PQ.93-)*]PMOC&JY<+,F[R15+
M$[P^')%4;L3F^CJA<) FU+:@M"'L\G8Y!73T#X9386>:V/IYY*XH_8TJBD9>
M];'H"AGR=<PM=*0M)'94Y1QUYY5HVNW'QT6,<L::9M>LIP[-$SD2-D=')P4R
M1@A"A.8J$@-"H5GZ&<5\,0PX2)J;4CF_"=KS$.WX]AB3(R2Z7]"+Y'0L'FL7
M9V.$,EY1*FH>2YQB53*D)['CI(D+JYU7N8T+(T*0+)DX#1+1;+,TX%Y)H?\
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MCH7#GJN&-JGCA?#I*F6,KZY9YL*J88A>)%.W=,TML3C=EO(V=D ("4"!P$:
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M4-K7.:!6J1"3I]E##M,FV4+FJ?F/P6D:SEE719B0-S!+F>!65'ZO:!.;RI7
M@:N00!_LI.A+6K51:U,%^2,!IYJC9AY0MEA*&$ S B&LZCI4%,6#,[!D#\V
MFDD<(2YTG-&]ZDLB?&AFADP:6![D<,0Q-:\'QR)%S-I$U*G03>D2J'0!20:@
M9OPBMA%S#3ZGHKG%$N63&NT"J0O;+:*YR=I<]3VP)Q(-VC6T4E5"K1/+],I*
M].KFY16)NCDP?"4&FD%E:UZ!V,HH81,SM(NI[G*J%L<F7N55TJAAD<CZ98QV
M//XT6O2S>S')1$8]-&QCE"4B;L3I:,U6_34CV2N2%*W%242$!1R@ A<RL%*X
MNQ3B+26%2E %UC,O8'F+R-K&<I3 <F*0-REI=T U",Y.L("L;U9A>QE&%F!T
M+U"((M:WHB/IUS_2]F10B$SZMHK*XVE;6)G3)'EM+5JD[7&ER)Q94)+N+>G@
MM,B6MY0_;I1K1GIO0_=H8]"+$S$W#.5[%?NJ*< %-GN9&/L]=Y!M.[+DZA)!
MTRMN9DC5 8XW)?1.P1Z/LJ!,(I+H(1&''FJAZV8I&+8E$I//M"U%JV[)5[E#
M5&Y7^DBP+@;Y/:5FR.M7@,I;C55@O\CKZ12MWA9Y(V1'LK6OI^P(T! $R8)1
M!9901<SHC];RYR&4RPNN%"5]3?I"E\5G<'.U<%PAF<C?:=CI[Q! -LV%-QR\
M^/UI'PB5M#0-=]*;1%A4$)PGAT9A>66Z27?DZI7N0PR7KUEN[E\!B3E!HY+$
MU_WDADA47>7]+)GAL<WA'81"U]VZNZ!,)2>M$H4GDI$Y S!$$%%@)<LO"Y;!
M(I"IO;;C<2R7P28V"YR$B42!P$;'HF4J<VBN&Z#Q4@HD(&N/-#TR@3!*"#U.
M<SU*@S>S#QBP;Z,DY\Z4N\2&R)6XP=&HD-NGUHIL1S^IOI1LD/I]<0Y5T8<6
M2Z%IT HZL2E#_P#4 G^:^$#2GXP0AUH7+R?HII-]"DKY$B]JJK;(W="9"PRB
M3M3S$;#G+W,Y:J?1N[0\)7-.;*5,M>Q*6\Q0)*H;7(U.:GVC/ 6(7*,(UR-R
M;)6Q7)(Q$C'9JDC.I8&Q>CL*QSDT89TMCLUD?1:]*,EOI5Y<;M:')'5*G8P-
M@V=V0AV0$@17L"6<LMF]$<F4 0T',FX&)4B5:G6UYKE*9FZ.;HHLR:0NQ)ZO
M=GEQD*IW='.432O6=P4J3SS#]G)/0(P@,."83E+VTS2":LI;>UC.(H^IG-^V
M0DFTJ51II6M#80VQB'1VO(2S@)7NCJH4JTD:C!:M>I]Q0%+LO5F@*+ ,(<$S
M<1'9B'.E^=I+>:I^<&L*RX6@V"W&XLY4MF21OTZ-25Z@$"LUTA*-\3PQPD21
MLCZQH2N9Z(U9\HCT0(>RRBM!%S7AO%+L=51F-/T>I]3H<79Y_.T;DVE/S\^H
M8[--2)8;-8^VA?U[@)B1-\C-4>C:CV4WHS!C"G*+!OTP3?5+V$<&N]?]:_P>
M?V'OO]A+/ATQ^WE['>7#F8# 8# X)6C_ ,DCEK_:ONG]O1.'2/M3ZN]N'-%-
MYQJ72^H+$8*_?7*-3Y5%G)3!7MJ<#VM4BF;47IVBVS5:<99GTU0^H4Y2PK>_
M8H1F&E#UL Q:V6-W,5/%>T;9.5M@U-VU8EOE@D?4B->[2=6S"H*8,,<D4+K;
MFA:H:W#9K.6:O7020NC,3ZH%RMHD>CO<%29HPU\L,E'(UU]<+\F;Y(9>=21?
MIAHD5Z/:E1)5;.KYH7Q6*RJNXA228]I<-*H\Z/2AY@<F.;D@OEEK@RR(9OKL
M\?O'RQVN'M@;EUZ]RV$32>QRZHU'[P<VB>6;%4QR]450R'E8*CX\+96- N-&
MA%U.Z($!ORB'1GU1(8I ;K7OV 0GC6E?]LS>K9U([/UVQ^N"[H30PZNY1T76
M\C:'1Z:W4R<2ZK$=61WGU!L3@G=V]9&9@F=IH:V;T A*I5(=:UK8-! (XZ73
M]N-(2I4_T[:-@MU]3%]C_D-N*6+R!3>SW<B'52H5=*0:GW%D@D?DJ=H;JZ1I
M9#&MB$0A,!IK6&'+?>B^8T$7&T=O^&AHY=U0FBT.85U8= R%S@7-Y]96ZLD!
MUAM3,ZV@ZW;3<;?9TQ.4%?D,ZM%?#J\2OTA3J8V?I4\-GO2(U85*@\LF'R^-
MVCHJ\Z//BZ^12P-UL#XWP%]8V=\;XI;[X_RIACG8-S/E<5M(T4.G[S>;5&I1
M41['I2H!)#GUN;S4QB]2?L*M.=5T\?B$QUK7U[,4J_3,3!K>B,RF/5$=>I16
M"BQ7=ZBB&KG7CB%M4C8'--]6W"I&D36HPE(C9.K3'. GE)H[2@).MEY$F8V\
M?JT&GXOT_9%CQ-/.FJ_:[J:26%4TTFD>0RJ[HL%B<MTQUDLLN#*YC.K'?;%=
MHFW6&G@2-P5MPF)@=U@$IB!'HHX\TZDU$:;_ /35XS3O55@Z8TUP/]L*7@J^
M*C76S%6]HMEE1)G%DODQ]56+7MD/4W=H:W1)) 4![>(N"$-9061<F&H"F7)@
M:!%O&-NR4)+'+T:T>V.8MO53S7D?;NL(S5)53RN=FV"1/T]X/.J#=IC(6V1$
MR5]:=U(!$5&722*U<>*T6>8]CV88F-%4T\7HAN7UGTBG@MM-]EPZ^'@Z:0KI
M80&SGY3(FH4CZ;D]9TPV1B3K$\7=&I*MB+R>WR%,Q'O(1Q1.ITHTXEAV8BPM
MQTIL7W'[))_32G32.UHA(6&G+&1U?'HQ&+36M$EB.^54T?K",1>1%S$=*P^=
MQNXCBW#1GT<F6">F\\GWC;U8#-B\4SS&B;?+FDB11^5].?=M@D?$T?B"Y+<E
MD':4Q5\LYS)ZD=E"@^2&_7'%TA+X>%[7+-'*&M,40:V"1')B3 &;CQU1Q(H5
MUY]\H=$TDLMZ%UXQR&Z&*M9=]+N*SG5D?$'34@W7SC/=1&>-3C*(V;2&V<AI
M637;NPG-85P5@PJ#-"/+>/M: _4STS9M3= HKC56U(W\!9[I+*F9&J[VU+)Y
M$P="LDNC<GJZ:#L4V'N:)GJUD6IF]DA2= !P2JT85R<+@E**T6XB8K9-LBKO
MH2;/%HC,<.C&F,M$)[#?ZH2LT[GL/,-EFOW>3N==&A0/;<[N"]L+3/XF9N<!
M&)MF[7:5$&"V(.35+CQT:])7:YFB\J?63U1T*U3N:=7THB9%3)(Y8T4DLHY7
MSZ2ND\*>XZA>2J[5+P6 SOZIU;C$(Y%]1)+6>OT@HL9=72M-J39,UMP2>S+1
M?V]DO)"_R2H65?QB?I+/V2J(A,%==RC;DBNN+L:E,Q,\T3V(H*,7_?=&<AVV
M"0$HM_&)6%Z,Z5XO5"[%!+HETQKABC!7847I%>]T@FN,JR)[8S/.UDV0QJZE
M5H')9$MDILJ00QPT*/I9$I9%2>-KW$Q)MF%K859N%T\6QS;5?3GW1@=>J5%^
MO(^@Z\L*K;N?YM+)#*2(6A4WM#VM%*56GQU4-L,?&[FDZ3I&Q2WE)CG58)$8
MMVI5ZTHR%QOIHDPGG:T#I]/J"BS0O@5,54DN*X>?9R0E1H(H@L#H6&O<7A<6
MCX$&Q*$XZ/ETHGSB8G*) !O1N4>$1^,'6BZ7&_5HLCBDML>J*"K"&\PV)6\G
MYZJ:UVZ;!>HHC8X_'DQ_+EF4[NH*[E19XT%HEV'84E:%:<QC,5MAJ-G"M5FD
M*RT9(R[3,S.[PP KH;ER$S;:^N['M>Z;)C/,D6A5MHJK5O\ &X+%B*R?F$9$
M_K^LFP:S1_/#XWR)0M(1$C7R+3\T(Q*"0GF'HR34^C$O=&OL2@TKIZKZPMB2
ML%N<U\K5#0LQ>8,O:E4#>:CFD\/?7.U]NB-H6U4MB;G)TLS"):E1%*CQ&DMX
M!*R"DNRW>L]Y3LALYZ=K<NGH>34%?1Z^D*SM"M:+I]NI*8(WN=Q@R9Q9RG<G
M!*'%E31)_D=RR^%LHHZTIUQVF^/-WU [_P!A<L(1$K2(N-4G\N25@A#"F%/!
MRAMNCJ*[YC*92U.E83^!(55F;K=(]N35$F.71QF>2Z[@-85XA9R9 M)(*=E+
M=HX\0%Z[:?"3KZ1#3NOFVWE<VD8V%!T"Y-"B@%J+GS=$O3\TH&;IT3])?B.=
MEZCKHV(PHS&XZ-;:E,ITHB)"9.[@5AUL[0#AC7C=-W*4.L1A:+0DEMNDX<9]
M++ALG9I4HDTA<HXW1)FFC^EAB:N8TY+SF>+PM0TG[4H_E4Y*A40>7M0,S19(
M2AE7390".-W7%AS"0&.L9O2L(;.I5S6ZRZ+L\FM]"=#'4GHEXU<D7:)Y,9\[
M.+H@!4XR2'IUB"1AC*EL&#Z=HS90#28ND-Q+1]#1:R:NI\M^M9/&;FMVV*ZT
MK?IH^+GF"U#S]>;]<T6EJ1Z='9;*5:.S*67+(28["-.6G%G,FE1XQ  /*:5:
M8?(&OOT]A;8Y1T*GRQ\% ;-E$5GD#5V6K5H+98DC(37L).8*^G,#8R#) :X*
M5I;M,%"N,I@MPTYJ-4-3\$0PKJJ'T,TW4TO$NG#@W]*IK!KF0=WSYYL4+[(B
MZ+B56F<T=#H.='>$#,=_NDR.[4TO; C)$R)D[RE?-N(G,6AG%F'1<:\=/S37
M(V/H][G,@(CVKZ*M5XMPHZ'2XB1RA%STFY>7UFF2[1K0!=@U^ED(#!J0;"8D
M^^(9KLI<6/Z4$!H:FD>C&(RNB[A=*S85K-U%!H<C8.*XE9ZU6Y2RMW1T>X^/
MH\_H72=U;GI)(/DE!@XRC?7Q":4%S).2B1JS@ +4 &D=KU+!KKI]JC5CRZ$.
MW0ZBP)9->]8T2D*G,I<4#378J[NM1SB*(Q1:ZG1N.B(F;+&3(ZY)4I;E\RM^
M&(\12@1>A$Q>M5HSCI470T+E\V=JUD-^NBV/7!1[?5A4TLZ=2Z'"B4KK=H)N
M%Q?6Q\>UZ231Q3-W%0I=#'$M7]*5$>YN"D"7H&X7$]FETI5_2<I8ZB;+(G'0
M!30^6E6Y-VQ(L5WUT]L2IDH*_CK.7N5CR>PGUY>8=.[+719.J+B2U'%RER D
MQM]NE9GMJS,1M23>8JRL%@Z&A5A6O';>529RYQD]9$S22O$W>V[0H!?$\^A-
M\Y]'E5'$T@=*S6LJM*N<DP5+P8(X\)QBKYC>R3,5IW86^* ?9#T7;K@RQ6VP
M"M!V\>KJ"9Q9]G/T,#!5G32ERM338Y >3XW"WZ+QOY-8/28I$X%(#5"I'OWB
M5&Z+$Q$>]'LW@_78).V0EFE=Q0VM&637_'JRFOT^Y[4?HW(CK,C*RHY#*]0V
M?-$BF44;(6J5E,YLO-=HX-&0J3.7MV),(9+QJ]+>NTZWZB)((=$,JOE"SS:\
M.O13AS2.%U3=WB*=)9$A1\FKXG!*KGD9DC-6S5#!+52<EO"8UJ5AS:8[DG%
M),3PB8^$?Y;WJ(]#K[+)8)4??3W9"R[HBB<)TSNTNBG/+MRB. ,35/O<U-$@
M)A$9D#L2%WV6E*!J:HYH>G5)C]-A11X*:5TI93BO;+7%(T1S@M22=GLRO^:J
MBE<TBLB'*WI=%BI B6, $CQ(Y I=BTR]1)XP[$)VW:W8TY*$P))1:<H&M$G6
M;\JW6E^]S";+LF0PAGN&<Q7G^8+K@KV/('4U0V="-W0!*!B75'\L<X@T](J%
M6&2AQ(2*-A);BSF39&M?"#H!8XUKO+6'RC+23.58'6.ENJU#:@Z<-1LTH+D-
MANYZN/O_ (_FJ"J)F)H9'TH3E"'KHE<J L,4ISDR(U:M^-HM&:MV*=2XZ5^)
M3QQ=6=F5$.OXB]AL[4/'QQSJ9(R9_)'V2HVR\64N0LDT;VXM[<5R6*.Q3&4@
M*7-C66C;  3I]ED $'>Q5,IB=?*L/0+5U%95A7XULM9V6VP]ZK/I> .,73G6
M4_QJ5$M<>C9%'RI"XR6;&U:8Z3M6D4*T#?$V A4U!//3NJWYD9I1IJ*B/*TS
MXEG5:</]E.18)!"IDWC\@L\B3@E/"T/R$+O8EXS*"2ID7"'H"(U8WK43B@4[
M%K00F%F;],,QKE'L5U;6NXCUR%R0M/8>N6C9341EH1R0R&RU%\.#V"LKB*L5
MRB6R)$;;AE;'6(X0$;N1'5($RU6F<#FPHQMVM^8-:>+8M)%.WA(TL>0K;Y2-
M3VW/'0,6>W^3?-R:/IJ$G,^W4W/UA+P.ZHTR2WE"EM<!?T(C#-.0&V1:7C,5
M&J!FCY?#(J([V%)YY3SX[2&UJT9Y^Q1VSF@/T&TYT&LK(F5[RN;2RL+'8H%.
MF2.-J.+4NYQB+!U*DB^.)R$CH)-LI3LW9Y/EIL4<AUZ0U=0$R6CZ*GTR>;AL
M8Z>5;)Y)<*F*ZCTEO4#6QS53,F24(H/ BZ?J@@I0V,3XF4,4A90'D 3?55&E
M8QIKM2?.KH7>DIG<-B=52&SF&)7Q$W2G[ F,%?5+6&C1Q]Y1V$W6PWGE*R#6
M!X?(BFD<< M2ZT>:Z+6< A>TL.P$B8K7HKDQU=?E[2VLK/N9DN:!N+E&>H#'
M&-QR8R:#+("O:HU0=;0ACTZQ)Z0.+0W3^4UZ\S)N3(U)92PQ84-1H82_A86X
MC2".D](JSX0Z=!M/2#G5ZU;'%=B,];*INAF0)NJY$Y? R*E3963DWSP-9H;9
M3V"6[(V'82"Y::G.6$B3@,, 7Y=:J_\ ,I/I:I[0@-IQ27(RK92()QU7V ?8
MS0\260*H4DJ60*K5D]:.8H4J<!QEG(<Y0@9E:-T*2!=3U#D<$T\1:D8-&9GI
MX_X:KU/1#[++QMQUCD5MLYQM&KN+&9NF$1=YF:QHPU?UZX2"S2$(].RF(0^2
MQJ$NK6ZI#-I$ZK9>EBE$(1H5XMQ8G2/6?R1W:L$ZL02%Q@L5DEU1FH&R<7PR
MP"8E%W;:\HC+Z]1BA'>F90K%"+!9[ F,.C3VX3D+?]X5+K&RU!.DCD5\$"$1
M98K?2UT^QT-A@IV-KH<KGK_,HM)$+X.'UZSV06FN!P;HG)$Y4$E+G4KZQS.O
MXW('M22I(> +]-S6Z)D8W M6AT>F.K..ZGJ*M9Y")S99JR!=%,U9R_JXZR[O
M:J_E%M/<E?XA+>;(^F@YT1D,9DRB0O\ %XY;Z10CD22(J"UX#DR+YHG;47L&
MRZ>+IA Q/H-Y@5H1N]8YTE*7V1\ZS!EYH1H'.8.[,C*<VFXT**.7X37KR",.
M%W*(XX,!#LKE6E+:K&(@M&>)8!PV(NEZ5NW6"TK;LW<N8X[=[7< 95 K LQ3
M>$NCLKE41A3N!WH!Q8HBMJQ]BKJRO$&J5;M2C3)V1">C<FYW2#(<S5JD2A>X
MDN(NFML#?UDJ:X69,D71IMXG1WD@-3.Z!UD:.K&-&V(H>#H0-XH&ET2PHV1J
MGE-(3I']Y$QZMQ:5" IBWM:#VE">/39%LAJ:Z@5\="'^O.CEVU1]0F4['($I
MDJ>',NDO84SEETG64SMSLGA^U:V%'M2]09(2#Q*F )9;+OYX"D.%B8OI^(2*
MR0'L"0)[,)E4[NACE#M8\98)LP1%NMUA"M8'?LJNU14WK6S'F;.L 9F..\ZH
MWA((B&(VTT3(X>YS 6N1A#@O'V?X;-(X[9<"D3NBB*&V)K,H7T^]OYU7LJ^U
M/I-P0.8-%6(ZO?)?;,8D;<LC)\"KYE^EM[G*U3E'5RQF=4SBF//^$J3$TZ[4
MM/6D+D\WIWJ%NC+^[PE);-I7JNIF0MB]8VN483/20AB)FK,J1F%*DJ5YM-M=
MI*C&7O05*9P =KW!._"2=)A4YKWW5-5J20HF6SX*\="M+O:AC!)W7Y>+\ZRZ
M@H[(F*$5BX)/GE!#*T7M+!Q!S7)"=#3N*5,]_,!WHP01S5?ECV$9#?$;?(/,
M8E'^N057#A4,Y7?';(7SF66'(;!+/GC/9BR(QUV>7=\EC*B1OK<HDI$?";&G
M 9"4YE(/&F5:W33Q;!)XUTB\F26P'R&7RSMTA50TJ;D)#W=#;JJCD?=W4TJ=
M(7&UD:>!R5(\(*9D<;/&WM"L+H7&CA)$&_F1$EY#3\>B[?#<8D$7JJ=DO\<L
M*, >NB.A)1&D%J#5FSI1"9#:<B<H:Z/)SDI6NYI;E'CDYJ7:\T;EI&(H*S?S
M03LJ9;^Q<O#+@UWK_K7^#S^P]]_L)9\.F/V\O8[RX<S 8# 8'!*T?^21RU_M
M7W3^WHG#I'VI]7>W#FTVQ9]%JJ@$ULZ<. VJ&5Y%'^:RQT*1K' QNCD8:U3R
M]+@(&\E2O6B2-R,P>BB2S#3/;[0!$+>M;&^B" ]C4Z,A4G"18_WP(E;?#4M7
MF5=.$]IN[L\1ETFS0I:(,I9B7A8PN,,8USF%R]H4)2=$H <:4H(-("7C+SI>
MU^?7!OE#ZW2)_<(M!:ZW9T[EB:$RSZ#!V#Y1V6@;96<<TDK6:7"+85I8F<TC
M3@2I2F)S2BU ?A8.,LZMZMJEH<XHS2$J<QMTDQ$75+DKW 90E# D\\F"VOZ_
M.LQ84WJ&^#%3V:-YS>T"6F@"L,+$9K>B #-"*ECF/L&H),7!#8\38#SJT7QZ
M:JX BKR4B.FC1&RVXY_G+&2:@*,-@C.4[)]GN!FB_;\76O9O>A:T.,M2ZTZE
M<.>V:0!C3,"6S$J"M;_'XNDB\IDCEI9(+/A]9(I$X)&<YL1KXNR.$M+,5(BE
MZ5Q4CT !0RP#$<67&+]$HV+T1"J>W7S).")H\S.P(_(GMBCD"K282A\=D\%0
M1];.%Y<;CR>1K69.S$2(@T1"A089Z#^"6,\_VA&2(MIP.V*!5FO@61\E$G3,
MB&NCP.<:@4Q>&B0.EO,<.DM71.).:=G^3D\PF\?G3>N2MR,1IY*,9AZK2<DH
MP81QE[F'L:BI(8_#:GU^&U0V#+K L21*HA)&]AK)G;!2@M>W6&O7-R?<7DR-
M3"7<@YM/!\V2H;S2A@"9[ C'&6 6=R4<A^61&IK5'*CCI24IKU/3MC*+$:"H
M;'X?,'U<^0\J/"=VAO)AL]:G4DT\  JDZO19/O5!&G"7C+=JRZ3C5KVW.ZQB
M\9EHVJ'UQ5-FM=FJ&P14#F[#;),@6,8HNY"]!*=%H631@1BUKX_N-"'0=IQ^
MXDQ46T2Z.U('3;;8OS,%M61RRO4S*Z;A2"#/;<ZR^..LX:H JE<+5.B0A#(8
MXRO[N26J4$"%[-'$BT'9:@DP98QF?1(EG7^FK>6T+#QU_/GY5?4F>HPW.;4R
M#-;80H:*^DD\VIF@]C]Z#1A,?$2(K6]"+!H\[8O:G%H1(B[\(8IONZLIW3D,
MGDP*DD=E[S5U-SA;%T]>SI,*7.=N@;F1E3U"WN+88Z3MK<Y^I,:D8DVSAAWH
MLXX04QI:@99QF)J-DZ+^DJG;::,OE8[O!=?)W1/'UPRXI)E,G;Y.=/2:N411
M;"TK4=*BI0V6$=MH5H-)-J"%I8P;#^+O>$J;KJCUC[?H!X4.9*MWE\3(8B)\
M"0NDWKN;1-E87^K&15*+%A;F[.[(G0@F,2BB(UT4(BQF;,0%C-($=HLS0"\9
M?XL[=HAM:E2]S4S]N<VE4^:D\-5U=/2Y]"V6,QV.S&0S&8PS3")]C\+9XA+V
MIQ.<CB=$?"<2"0[$J'M/H<98A/VA"U,AG[>M9I!$([6EMJ*Y6RV3Q]Y4,EA-
MB/FMSZ/5OU<KF,A:0H 5%D!BD U6PD'MY(3 #V:M2%;'&6 ;NB>2')__ $R(
M:_=1VRX[@K)&E9M"25'=LY:K+CLB<8$NAJ5;%D\M>X[)8G"7DP*H(P$I4#(M
M"LVG D,"$5.W1:BI+7AEW0%GLNOU3FLBSXKD*!&8],+U%W8I?%9*\1!_0N4?
MD2%L>VI8VR%A5)S"E)!1FA%;WZ>F];V28K24D80P& P& P&!\Q$E#,+-&46(
MTGWZ*-$ (C"M&:UHS18]ZV('Q-:UH7IO7KK7X<#Z8# 8&!W%8R*3@FHH\R"F
M)3$.,%2H36B%(BHV:O"Z&L!+R(G;B4S'.985 TP3-$C. $8@[$$.]#PSV!@9
M/%8Q-F)?&)E'F25QITTG"YQ^1M:)Z9'("160N3%KVMQ(4H5A1*Q*6:$)@!!T
M,&M^GKK SNM:UK6M:UK6M>FM:_!K6M?]-:U_VUK _P!P& P& P& P& P/GHH
MH)@S@EEA.- 6 PW0 Z,, 5LS90!CUKW# 5LT6PZWOT#[M^G_ %W@?3 8# 8&
M/=FEK?FIS8GQM0/+(]-ZQI>&AU2)W!L=6MQ3&(W!M<4"LLU*M0+DAPRCB30"
M+,+%L(M;UO>L#VEE@*+ 44 )918 EEE@#H "P UH(  "'6@A"$.O36M?@UK
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M>\W=/<<%Q*UW6=ZKS[H739#=.HKTTUDDU _*&NT!MY&V:4QD*485S6D3%II
M#6A%Z-SG$SUWMT^L[A*3RCQSUER&P68F<KMH"O.?U-+7I-4:TT"+H/F(4.D%
M966^D)1.3NG;'&8PHD+F62-0JVTK5).A&B'OW&8R^;ETE0QZ\3=]1&.TV[Q0
MCEOHRPA<O=-4K?T>Z.!*FNN#+PZZLU#=5L],5VH:X#/7)>O53M0X-JQK6(&]
M:YQD*-,!P2;)V 1KG&N\1?Y,3/?#E?"N%615$1LFJ'YFL+A_@JAEEMS ^2,5
MDJ[;X2FZB3C#(VQMA\I3NM<=%MJ@M$^+Q.9CBU%I0:&A=@A"#8C.-YO>?BZ.
M<<<?/5*<\WE6\J:TL*E5^SNR9Q*$S=<#S>Z%&\SR%Q^&*G\,F=ZHH]*4O<2V
M$"M4@0Q]&BT?O9GQ#3SCS1&,LKF)CHX<="^,WL^&\5V2DL%CI2>N$$\=7*'C
M[KR 4<3:=H/L\U3G5T%E)UE2AA<H'&%0(_)XQK:MP9$&E1C6G)/#M2>#U.+.
ML9X\O;?P6O3^+/IM!>2SK@J$<:*I5^\D\6@FXDT^3%)RP9%57*D?YD1S$F8[
MIL]0WW?\RP"?!*]PDY)I&L-0_$T?O:S9GG%<=:K?VVU<OP;6,=24EKE_EU!2
MR4+/&1;O'L)=WB.2 ;+6ER6MT-8=Z)7"#IUK"\KXY3]<(YDC8F0Y.+3T2B9T
M_M3%:#H(8?V:^VW13R(\;67T]SW4D+JU%$C;VI^3-LPJZTI+:LBK@FHK'0US
M)H0AL]&D25-<33:*)(*1'$N$8>FDI([-BD\/S*<_18]5G#*,9UV5)F/C5[#D
M5W/#I]_.>G*M["ZC\=_6-FV :9-(K9&I;Q]7M80&PXO":X98<Y0UL)FCA6A3
MVR+1O)13=I0)O&ET#0%198SQKS4_%\*E\6%TLM#\M\R6-&.5#X9REV54M[K;
M)85,H=)#U+!(*KN=R=7RVH.[5HC2,UNKET];%1P#WJ0(%[G\^?M40#9(#"SG
M%S,7K'N6E@_CTFC'XX.E^%SK%C\(>;L<NUB8;,JZ2N@&&O8WTK:]JSF#($K2
M8GCZDDF*,,[2HW!$D^ 1ZE'E)C/A[ 9LSR^>,O12F3>)KH>TZPZO^OL/(-%3
MJU^>N4Z0K2I:3%+G"CE\BY7LQTLM/:EBNRVMH>ZMCW. ..XVA A8UZE@CH0E
MC4KQ:^&&+SB*WI+2SQ861*+2DMX/ :"B%C2[R'<G=?[71?Z^ZO,'JZD:#@%6
M3:J8Q-5$#8G4UQ,?6-W&SZ"F1-JA$LT)0%.,TXD-.<56NTPJ?#O!M<K?SK;]
M$2)YK5?+':AF'G:)W$YW).GY@L*#H>DJ^NQS4RVETE&QH$ <'-LAAPSC12.8
M+ /;BJT0I+2J3C!&I_DB[\NO_D XV<^F.,'7EZD$%10414SH:01B.S2/*DE/
MIV"H+JK^S5\0=(O#FT8]1U[98@<W_)IB"RAZ4: +98-B%HYXY5E<N;L1\9/9
M<&LIKZ7B:3D..VLY]/=.VNZ4*RR2QFFAJ\@_0O,5<<Y)SX;*VZKB'Y]F#6XU
MBFD[VGW'VA(]J'%00 Y*8 *D9OGC5:U7ZL77?B+Z6K$_FQJ@TGIR(JX5Q7$N
M6.GK,33F621LOYE@]&6C742B372<AITTF &1:=SPEP03%JE2!R^CZ5)5+8I$
M:$.Q.>,WOO;.@\,]AFUW,VIS>J"<[)6<\^(RH*^FZQJ?U*Z&/GC]F;5)K=7M
MKV=$QOC"SS].W: R;0^T\XP(/G@$!#K>H?V1=Z[S\6)9/#=-2I1T$BM..PZ]
MX9,2.X#(4[NO3UC5HLG3)V/+ETH=J[L"&17GYR6Q1464X%D.$D!*9)H*IG0+
M4C66+8R":?V;5X^#(UQXR^W8K/\ D:SET_J1-;-/2U6QSBXQSU9*5Y'(@[N6
M6.DY:?*T/YRC4-O26I(O\ A-903(&_)GPP:L91X4Y7QH3GC4QK7XU6X\H'%_
M2W9")AA]23"M$-:.5+="5G,XM.'QVA"M+.;28&!I@MC#D\:K*PY/+H=%DS:O
M(<X>G5QLAW-6)E!ZXP*0).JSAE&.^[4N,>!^@N:.LWJT O-=Q*E934Z%NN*-
M,T\?[4=[VZ 1PNHH6@NAG;IC4L3=Z$$G9Z\5$.[>@DSXWOVS$ANTB4PD0M%R
MRB<:ZM9MWQ0.]K=,V/>SP"BWE'-_(1QUU44&3Q]<Z2;5/\YT(R5?*Z[<%*B,
MJR1O3Y*F\]<@2!/&UF)C?508 P0@8(SJ*\2J1:_AP[+DW/J7FF)V;0/Z.C()
MTNR-+?MYE<$:JYF]N=;V'?<2E7HP5"_2FQHZWUW)&EE+CFG..M+$\MPUQ1;B
M'9>@QJ/Y,;O6_P#"?:#YH>)3Y@.@[!9R7<WE>F7@'0Z9M=(#+8I'2/(I;M5M
M_.MJJHFZ2YE9VZ=HV>F(()X4N+-I6@)=9CL>E/QAC &I,_)77]$:>03A^^.O
M>Y>JX=7%4T^LC=P^-^B:)'>5ZL<P3M]6+'J^;Y=9!*J8D++"I*VR*S8(V_*.
M)C%\VT'_ #1C2J$N(++]IPQRC'&+[I6D/B8L)M8)M+(KJ@9S;)WDZ/[M(9K$
M2/*6*7I6;;'%,8BE.79,4T,?7YO>8^-V4/[:<6V/C.V29*F5!3&[&:8")SCV
M52E4D\:_3\6OBL(8TTMS+:3_ &)1GE0G+W'YNSSPOD#GMUZXN2BE#)6-;S-)
M63^H1N,1:E"M<0G/8VH<D+^M_+%-P3=#*K7.*Z]%E*[\-5J5S>51/[]-6RZZ
M\B[7P.J<I8XW)+*JFT(FG$U?Q&$:=F^(M]/6&.RF>0K8C]6:D6Y7%BR#W5>E
M7Z4D'C--E)_9$QYU^+?JG\4J2AJLXP06:93ZJ!\RUKW>5UT3"HU*UJRY473$
M%<6%6YLK<V1(;_,EZ*-[,3+0+2?GAI@ 3(RSM!+*RI.=W76J2!X/.>+*K#G6
M2VY>!CRY63:3C&:S@CW*8R^0Z5*>2>6V4VEN5S'V+2E&WR:/.4NAK4LEZE.O
M(3*]J90,PXDLT0@Z'\DQ=1L@MA\6O3D/JB"U0DC7(\U+YP[06]:0R4RA]F2)
M1VDA?)S=DE4Q/JMJ!4SV;$IM$T5NE+6M^*63-*.1,J11M$03K7PR\XF;UVKT
M>9-X9K0?XR@#-W+G7;BO@'E?-_1TWM,@<ZNIBQO(0X5^NK:-TX2Y1$H>H!4H
M8JN^H. D+6L.5.1YR- 6$[90!_9'2^GP8F7^%FW4[/HVMI=4<<-C:#QK/31!
M(NXO==,<]F/%]<7- ;-*DLF2UM+2(THEIMGI'.-O@V%_4$N#.0)<BUH(! $?
MR1UOK\5Y5' $H,\45R<&Q(<;KR;VS4_0$5;PO5C2FV(5#95=[_-9&8(V<**_
M@;^[L"-SEHCC0)8XW$IQ",)2)@$ *UAGE\_)0)[\/O4$P*LF=K%G,U1S =H<
M12>%4KS^_3*'5'-V#CB*VA%5;[+I:YU0XJ838=AAM#YIL-+BTC3Q\4=:B3A.
M'P]GEFN<;:]?BFQK\0LL/BL,CK>^PZGTQ'$7D&YP=U#9,Y%<,W@-D]H6?%I]
M'YE"+ =:[J\U[9H/I&[&&@"A8-HCW$:5M(+2BV,*DYQ\8^"*Q>'N\K/VD56;
M&^.ZE9VQD\>M5N]-TMJ7N]4VM ^.NB2KCGU@3TESK6';%+)K%]GQ^.L9K>N)
M;VX\U.M=#RS?_'%YQ'?K\4[1'Q:3>)=Y/=ZJC([**>5=0(>I($Z(+AD->R6J
MG)#1R"GTU>!I]FI=Y:YRSM*!"8VMX]S=G:P1Q8),:V[-3%[.J<XXUUI-W</#
M=LW_ 'RTVS50Z<"D?^*.N^/YH;8BI^9I'%5=^-T.706SXBK8(=*OO$?&'J'F
M(%:!0:V&%('0TY.H$+0TYI,<HB->\2IS.O#+92B!RZ,UC*:=@FEG/?C'A:".
M1@#U#6&:6EP=9<WGDVU-UK;"'0M)&+*0R)&E;7D3<\.*14D+/5(#RR D&FHS
MUU[S\75'@GFURY>H]TA#XRD1R0RZU+)M>1LB.VGJZ4"-^L-^$\.AZ6:O-:U#
MH9CNIUM<K2HXZW("%ZH_9(1Z%LP9C*;E=;#+@UWK_K7^#S^P]]_L)9\.F/V\
MO8[RX<S 8# 8'!*T?^21RU_M7W3^WHG#I'VI]7>W#FA+I:X=\\\YWW?FF'4J
MW25,V=;6HQMQVT:D7Z.H6]2_Z'MVTB<MMFG;Z1\#YCY<_P"#\3W_  Q^GMV6
M(N:<EHUY?;>/GJ6,SOC5FA\<;+5X?@T\DC9T<CE;A'(_Y  -J2E7=DCY=2-'
MWHDD7>7'VRINVJ1)428&C$"UQ$/80&^$5OW^#2VSSQM2B"65;BSE2Q3*H;XC
M)9)4$K9SK%4IY2[M=Y1&AHG"K3>G:DF6"5Y([&>YHE>&T,>>IP$MI3+BS-;<
M$ND9Y?Z^EZMJ2^2WK:R;+XNBT"YY@]>(;2[ LOG:Y4UF/5OLB67,<)YZ?;N0
MS*BW:;4- 90Y0=PCJ8Y1]3<(\A4Z?V0QD&G 0>8[$$X1$3<]$0Q;S VG7]0*
MG*/\^/\ ?".O^=>L>P+-E]G]"1N-S!LJZA>S+:I)^C+1N/T>E9Y5)!1Z):/C
MJ3Y5M)"G*+1+5@C"MKE4M9PN=^WY+2R7RNR@BWS(_"N<&V14:W]L\\\'O=J/
M=TH8S.DEMW?'(#,G1]0TZ"!O)CA"8<Q6(C( >)\(6.*X!HBTX$18U8:SPTUG
M6K2SUWY"YCS[:-D5A57/R2ZUU \KK.S+_<'VVF^J"X_3)#[,&1&TUR0LA\MU
M/K)=2Z]?%8$BLQD:$Y2(HL]Q+-5EA",<;BYG>:;IR!W!).O[7OMDBU,E1NBZ
M8=8I'VJXG:>@-D$\D,]J*FKLC#:DJ[46(6,*=+";7]7-2I=-Z3K"22" *?BG
MC2DRQXQ'=3*W?-.15<@Z$2HZ3CEDQ"M*:ZSM:JIS7MF3E='[(<.0'V-LD^@K
M[(I+0\4@+:^.)LCT'9D5?9LG9UR4Y$X"*.]@A&H_CNN\_JWL?E;FT-=)BTW9
MS0U5L9473W*-+WB[-5V)II%*XJOL>(IW:L+G/DFZ\C1:P<6E[VULDF:S"$R5
M%M2-6G<E)  ^\<(Z3O'Y+ L7?)CKPDD[7>8+$Z_2S=W.!3\,L&P) V(YI&I5
M;!M?TBYK'J,UC,967(;=C:EN>D#&S1Q\<3#7(E F I.%\3#/'YN+GS,?,);5
MN5):<%I/FI0R7O#Z![FGMO'O-P.%>(J@:.6G\BJ%$JK1=-J?9Y=,Y>^2V2I'
M)K:GUBB)C>2F&6XF)3=@T(WPB)N9TN'@H7R5V;$U<$K/;!..@[WM^KO&/ *T
M:+$M>/0ZLW:S[TY.L^[+$GCP_(ZL<9)7Z +'6+DYOAA@I4M?'+28EO1H]B,T
M(3A'I$7^:SD4\M1LA5EL+G0FXU+XW5GD4D5L,:BRT;JWPNT_'A,*]ALR@K#(
MT43*13&(SM7/ *4,@^&A,2IBPZ.0?'$:423AYTT^*-%/F3L 55=+7(U<DI'"
M"\Q<J<[]&2UQ.N],A7/TFZ0HZOKCAU31QH%7)YQRENW*EZ->\'F$)22D:4X)
M)@U9A*0<-8B]9EOSYY3;AC3V\U4]\CL*?H1F[0HKD8V!).A2%T"-!T;0KM?=
M>S[=GAJ@E42%C940$;\W!8C1$'%G#1'K=?! :.$;WI2'&7SENC56:FVK@Y+5
MP>*NG.-]7/7Z>*70@L%^E4PYOZ&A7,4^@;LWEUY'B8NQO]F6 @&PO03G T]I
M+.4*D"4[VI=C^O6HG6TALOE?O:6/54UE$>+B5ES6A;UP50V(I?:%CU14SDDK
M'G]!?J:RHA.K1YNB<YDL*7(E*AB7:%$4BI"^(#B@!/)V _8X1K-Z,QR;Y%K^
MZUZVH-EC595U$.7KI\?,<ZU4-SY,7==<$8?Y#.MPQ8G-,00S<;>?HDJ2C:2D
M1:E*0J;A"==J@': UZ)EC&,3WNF_3#R?O$;N&=-B#G[3QS74_8=1\*65=9MJ
M-[9/FV]KA%62%I<HU20H@K,D=:1N16\PM[@O,?T3F;M2>I1H%"=*(1HX:>:M
M,W)/9]A=*4);/0TDHAOJV%0Q]N)@KPC]*!$Q>+('1\VL>!3%Z7H4D/9P0AG5
M2"!_#;M&FKE2@LPPT91( E?&)EC4U>KGU&O.',00^H'>R>.PQ:7=34)0-V<H
M1.-= ,DN1V IORWJ[H]DAMG2=37L=14^H;)=9[2X&K_A/B83*<9O6MN! T(I
M;<_QQK4[3JWR7>8::UY)-U[9/,C#7<IKSH5PH+I2S)'<4G7\LTHXFP&K;-KU
MX5W=$**DSF7JXXM:J4#(&0QZ,H4;FB5)7%:EWHDP^I_7VGHP@_)KUS +(Z4C
MTRH&G[&;V3R54_P;0C%%+?>H6O+4VS5$-F[8XSA]?:N<D)J) DD:5T6+"0B4
M!/<5+<0C-"@3JG&'#&HJ>EMRC7EHM.Q7$JIJQY'9Y!TW"P=;+KUK>1]"MT1K
M>$-/'-F1FJYR=![;'63P?8B^?228-_W?)&PM)9!)I@W0U#\'>C*<(C69T_Y:
MU&?-.Y3YY:I7 >7SG?G0;MX[TDALQ[MU%'I^T(?(HW10F [;*JU!'5(^NE>2
M68)2GLK;^D(,0Z$>D./'OX01_76DSKK\&(??."H0-724U8^5)E(ZPIN&==/\
M,F:-SL-*G?GWD-Z=F%Y8[/=G*DD-9ULEMI;''3[KG-LGE"G0D/P'%*C4FZ)!
M+/Z]M=9KXM[:O+);S9= :NM7C]E@[(P].T-S18DOC_1"6<J(^\]05,BM^GWN
M.1TNJ& R5EM;$Y)TTI)&J0!;U1NOIQKJ#0Q I.$5<3T1)'_.J^RBGI9<['QK
M-'&,JHO4<YIA1J3S=F8)LSVOT;7%!-L*G4]EU(1B!0FUQ([+0R-*A9'&7LZE
M#H\G;D6-*:/9?Z]:MNTD\E'7<EGW/M?P&AZ9@\M,\D$YX=Z*CLJM^0RMI4F1
M/GATOYH75C,VJIT!XF9_A2@M<H<%K00L1.3;ILTC&2M&Y(Q&&-3,STM.?<?4
M/4=5=44?1=5,]9$5):O,78-E3*6.LE?V^RVIYI2.PHT#K%TJ2(NK4B'$M39&
MI0D#4[T^*5)I9QS:!"6)<9QB)BY[PIAS_P"7ZS:CY!A"_IRCGJ06/'N"^'^A
MH7*D%L$S1ZO[]Y2:L?/#(Y61]-KTA56DN=K5.*=7,E 1*/A-2_8B?CK2MHC)
M;4X1.6D]96 CWEPL=^D5-P@7'[VURR=/_3"6=*Y#,IO!X='8#S U4O,Y9<->
M*K(H^%SRS(7)8#:QPFH@R.LJX<A;OIA@0%"-7D5.$;VT>N_-XY3BM3)Z/D::
MI3[#1\W&\U%%2":M4)L>0=2VFVU77M<V!:-@4M HA IS'U+^VO#Z)C',F8IF
M5B,0KEQI/PC!/\=35_B&D7YV_P!97?8W,W/D+BB#GN<1[R0I.8.LFJ&= +-"
M>AL?-#OU!$FFN+514BYK%U:3R!FD.;D8:T-#T4O;0,1Z8"=<>X$%C'&+GI7^
M']%(1!%KW!%H0=^OIL.];UOTWZ;_  Z_!^#>L.3_ ' 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8'!KO7_ %K_  >?V'OO]A+/
MATQ^WE['>7#F8# 8# X)6C_R2.6O]J^Z?V]$X=(^U/J[VX<VISR#1&SX/,:V
MG["AE,%L&+/\)F<9<PF#;9%%)2U*V.0L;@ HPHT2)U:5QQ!N@B"+8#-^F];_
M  X(TUA"9_&_,"E:X.)],0\Q<ZOE"21Q5;(7:-5/O+IR=1S\YF;"MU_[55'I
M"Q->]>F@;!KWZ'A>4M-1^/KCI 5:R BD60R/76TRMDL2#K9!-7*M7)OG,E23
M.7A8ZP<)*JKV#JY!+T)+JI4L38VJ1N)85/Q/C:]^%Y9/<7PAROJ)06%JZU7O
M+36EM(KT@CA);(M64S&-VL@;-L1$M0V'(YPZ3X1PV 0FXY*:YF(%#:,20T@:
M<8BMCE+[D\(\@IV22QLB@X(4Q3&JK&I"3-8$J\*5YJ:VY](+2LB"JP:7^NV.
M7V#*7!U5@#L(]JE8]A$$/H'0Y9=U/K4\4T4M3L:O>D3W2F89$*]M*F+C T0F
MAU+7><PD]#QM.SP".S.[5=HKXZXQ)$ZHR%)J@B'IY >W)B6@;CM"#T$7G\M:
MKE] \0<J=3OK#)[\IJ/6&_1UB71-*YK'"1LJATA;FY)'AR@,N^[#TR%SNO'!
MV0E*3X^]A<&4T\.QC3;$(6]F8RF-DR0*H:SJYRL!WKV&,D1<;3EB:=6"H9DX
MTWWHEB.*1N#)'I>5\01 %*:(0]L;RPE!++ F1%!T'7IZ[$S,[JM"\9?"1J^9
MN*CG"&*S9\SVO')$E7.$K7M&HU>B\IVN",Q]B62$]DAL:L1Y*TN=&YF3H$2A
M>(:K97S QF"+SR[M?[$\?L)Z7ICH*I(2."U,KZY3P*(=*SQ= %D\D,RK.#L(
MXNVH8ZG%,8PWQZP8ZQ%)RH^]GA7IFDTG1HT*H>@;",<JF/"RLVYEHVQZ49>=
MYK7[:]U#&VZ"MT<BH%CLS&1O59'LZNOG&,/T><&B1QA^ARY@1GMK@W*TJU&>
MG ,HT M>N$B9B;C=6^1^*?Q[2U@88Q(.8(.O9(Z]V._H4NG*8HSEB^X1MAUK
M$R->@DR5QE[/8ZMF2J7MN=C5K>Y*R J#R!GZ^)A>>7=I48\7-('S'HUQMUOC
M-B5W;BWF9!5-8LL??( 10$0Y+@KI#*@##YLS313-R[!:M2)>/<A;5C,>6F&4
MF** '1PCBSG.E?BTK2/QI<+2V UE5[]SE#%4%J F?)8&Q)ULI; H4=K[T.U$
M#XXM4@1.TU;K.4ZTHD:=\/<2'Q4$)ZT)YP0F:)SRN[2"'B;E($'LNM@T="@P
M6XX?74 L^,Z3KOILTAM21%M@5;QYX#\]\4Q!$(>SI6])H @""02'0MBWZ[V3
MEE=WJV)UY2YV>YTLLQVJ6*KIXX6E7UUK9.>2KVYJ+6JF"*:QKN<&#"K"5MZB
M4!6&M:06@Z %,/>A!$+\;!<U71J.N%.0?N\AB1G/U>*8PVU_<-5HF%:UG+FH
MFO+_ )DBL*Y(I\FL5'DFM<_F[<G=%NAZ$/2LD RQ%[#K"\LN[W5_Q?S762J"
MN$6KHTYWK.1S*6P.02^;V'8\FC#_ &!!TE:R]8W2:Q)9*7_13O D!+5M.-2-
M,0C+T DLO_K@G*9?Y#N*N7*\DU*3""4]'X?(^=H \553KE&U\A9]Q&MGT?QW
M&#C2H7DE#(XSM7_[)"1V*7%)%?\ [!&BSM_$PDY3.[P/W"W)4FOA)TP^TC%W
M"Z4<@CLPU*S%3^6@6S>'M>V2(3]YA1#P5 W^PHFS["F:W]<V*'AO(++ G4EZ
M++T$<IJNB3&*AJY@M.2&D*MC[;6\)>D%C$I6UB3&FHVEVM%UD<CECV0E4JMC
M/5.4JE2UQ.#LT(1GGB]-AUO7H+F[G=2/GCQ"\4T;02"DGNI(K::UUH^KZ0M*
M=2=*_P"EUA,]8:;W1N7-+.NE+ZGJHE5/$6Y,!%&CT!*5_'I< 6U8 *-&ISRF
M;C1*YOC.X?/A++7"FBD*J#L\O>YZMCBN<6:K03J7R-='')Z?;A^9FII]XJUZ
MR(-8A:F0WTL(4!  A" L(=$Y97?5HG3OBZYRZ2E**:&LQ$'D;_T-1U\W:M:0
M2!61=0J,9W5A8&%W;$\L9FJ*OZII6I2?O.V$%O1(&U+K8S?@$_"+&<QIX;J]
M^,7A*05Q JG<^>(WN%5F=/#X@0@D,[9I&EW:JX;G:A+Q.V>5()W+4=H.(OCR
M5.[N2XA_-"$2\"@0 ;"3GE=I5,XPY7&G?T8*,@*5#*'6B'I[;V]K&VMJMRYA
M&RCY_.*;F\],B0EU/N.(=,Y*<LHE.%*6'8!!UZ83E+4UOC\X_<76W'-;3#<H
M)O=JGS1:\8%*9[JO9<GM42<RRUAU8@E0:Z:GV>GI0FNSF@:TKBO.V,PX\8S#
M!"+RR2 X\E<WNTF7S)QJ&)JY0Z6A5ETN#T:0LVL5VI24600FJ)L:+2S0-O,'
MBC8G0HA:#HL)!6M#"+?KO"<IV1NQ>/#C6-MTL8FBD6HB+S-S8'AVA*B43UQK
M]O71>R6JX6(4.K]RE2R%UXE06<QI'K2=@0-B<Q:G (8!:U[<+RR;7,.)N69X
M0ZDR:G8^K&]7RV]/N"] X2)@>1W\U1UNAZ2T$[['WIK>4$C%$FHAK/VG/*(5
M-VAICRS"330#)RGX-PM[F6B[YD5<RZV:];9?)JE4R=17KX<X/K4XQXN;-!3%
M,&P*EA=6H;FP2EJ3DE.#:M^8;U?P"1&DB&24( B9C9H[APUR.[1H<.<J%@2Z
M,"H2'\OZ9U2%4<E)H6OG<R0P6MTWO6;-2-,0?S/GFTXH0%J-:$!Y1P32P""7
MEEWZLO >/N=*T<8.]QBN_CR&N"[)*ADHF$NG5CRQG)M]/%TEE$[E=B2>4R)R
M(EJ.%-)*@"M2>$)* HLO0 !]-DY2CMH\<G%K) [ JU#1K296EEM[2U2.OG.5
M6 ^0MO;(_(#I9'4$!C#W+'!FJA)&Y0?]1;2XL2S!;UH"SD^BS"BA +RRN[U;
ME7W$?*U6M4!:(13,<:B:RM5\O*'N"M9()!(TEQR6+O4)?K.=Y9(WAVE$KFSK
M$9"K;3G%V6+E(D1NBO=["R] ).4SNFFKJKKZEH2V5S5L700V$,RQ_<&N/-@U
M9B)&LE,B=I9(%!0EJA6IV-SD;XK5F>XS>M&'B]NM!]-:$S,ZRD#"& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&!P:[U_P!:_P '
MG]A[[_82SX=,?MY>QWEPYF P& P."5H_\DCEK_:ONG]O1.'2/M3ZN]N',P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M.42%XDLS>?O'.9Q.9U)76:SR>SF0?+HPO$NF4L?5;@M. 203HT_V$E%$@+*
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M!,"( PA& 8=@& >M"",(M;T((@[UO0@BUOTWK?\ UP/UK7I^#7X-:_!K6O\
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MO8[RX<S 8# 8'!*T?^21RU_M7W3^WHG#I'VI]7>W#F8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M!@,!@,!@,!@,!@,!@,!@,!@,!@,#@UWK_K7^#S^P]]_L)9\.F/V\O8[RX<S
M8# 8'!*T?^21RU_M7W3^WHG#I'VI]7>W#F8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# X-=Z_ZU_@\_L/??["6?#IC]O+V.\N',P& P
M&!P2M'_DD<M?[5]T_MZ)PZ1]J?5WMPYF P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M^*O)0JOR!R6H'" Q.N^D7MZK$R&5#RY-W.JB(6$<O98D#Z 4AW)VQ0C;T2L
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M/Y-U/]CC4^CY/E?ZE3\Y^('\FZG^QQJ?2\M\Y(\?/6;GUXA\@7DKO*K;9OZ
M5](:MYXJ7GZ.2".430D8F>P??=^;%,LT5*)7.I8E]R,Y6K*#\%((0/B'A^7T
MEK,Y8UQPV=J\,& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
3P& P& P& P& P& P& P& P/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g268305g01a04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g268305g01a04.jpg
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M!@<(  D1$A,4%2$*%A<B,1@C)#09,F&7UO_$ !<! 0$! 0
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ME2[V2NWLN[(^SCODR+Y@I]BD;'9G.L=%;%,(7KI/?YUJDA9=8T,[842@W1*
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M[7;-)JYX!O*1U&?62>=%?1SOOOD5PD[)-J$G=QNW-GLDEQ41/I4\&!X \ >
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M84R!FH&R(M+5$-SP,2",*YFV91E4(UT=NZ>*-'ATQAIK,WW)7^"#P!X \ >
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MV%1$&MHUQX("4/\ 9RB63]Q,/L7V^[?-O\_L?W[>WL/O[?KW8'@JX:Z[?/\
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D"VVVKNY^2*4TS:FX*J2 ##B[=4O2$W/-N(2Z\BVGP9'@'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g268305g02a02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g268305g02a02.jpg
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M$YOY7#<US55JHJ]8:9,E[IFGW1"MZS8VLYW ')E@C=LY'7)(.>\<ZGJ<@'Q
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ML+?4[&YL+I=T%U$T3],J3S21,]'B<+)&>YU4]U>, P(/0_M]U79;&[PXGO\
M;38-N]A1_5H,VHX]H*.\C"R:FP:Y\6YH9[A]F)8T-O'FU$]&)Z;I4,CPJ\+Q
MO=RWJFG7&DW]UI]R,2VLK1E@,+(GVHY4SSV2QE9$SSVL <'(J"P*D@]0?V/Q
MK67UJ>(_[Q/%J9N/B]9[O<WCREGG-3[</G-M\#+'"NXF/L\45Y5#6P8F61!H
MA#/DXRZ!$8A;4GGG'HSXA^AM>2SGDVV.L;+27<<)'=9/J<W@,R,T#'D-LVYC
MA!B/<1[TR/M+D^\=X_7\*B*UU#5NJ[+I#\1_W6>)V/3<CK/8[I[U>QW*S[W
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MN'ZS\/"L?.I'UIV[+9+D.Q'%)E)D.XE">349ONO: #<XUA=R!S@S*#$JDGE
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MGFDV:G>1IOEEA>1MB*J+N8[455&  !;YW<2L [ #;@!B!]D=P-:Y?WT^8_\
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MH11P":G9H@A8T8AM3]&L8UK43^Q$US@S%F9F)+,2S$]22<DGS).:WH % 4#
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MH]Q^6?\ J_W5KN[I?]+_ &RYW;9;D9UG.Y&=X5.PK.XN)PH6)Q<?/$F13X_
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M]&"!&CA:\QS%>Y&#$)CGO>J-:U55$U]LRHK.[*B*"S.Q"JJ@9+,Q(  ',DD
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M16.151S5=V5%5%14U]W.I:C>#;=W][=+D';<W4\XR.AQ+(PR.XT"J.84 ^(
M%=D:A5[32E>*6!!,]Q30XA2.[>1"QPD>[Q1&IY/<Q7+V:B-3NOPB(B?")KZ#
M,!@,P'@"0*5R!CQX[5;' $#7+Y.:$3!-<[MV[JC&M15[?'=?GM\:\))ZDGWD
MG]-*Y51%145$5%145%3NBHOPJ*B_"HJ?"HOWUY2O"^F5O^CH/^R1_P#=Z^M[
M_G-_:/XTI],K?]'0?]DC_P"[TWO^<W]H_C2O.U\TII2FE*:4K0)U/.CU2[[)
MD&_?&&JK<;WI<DFVS';L'MJO&]U3(CC2K*I5RA@X]G\I4<\Y2*"ERJ4[UK-]
M=<&EW$_;? OI&ETGL=)UR1Y]+]F.VO#NDGT\=%23J\UFO( #,MNO*,/&%B2+
M- &]I  W>.@;W>?Z??4E<7;O/9V="VPB89DY]QS9"N)CP0='8KEJY.V6L!]
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E4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
